>MA049172.1 JP 2018019694-A/1607: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGAAGCGGC
>MA049171.1 JP 2018019694-A/1606: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGGAGTGTC
>MA049170.1 JP 2018019694-A/1605: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATT
>MA049169.1 JP 2018019694-A/1604: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
ACCAGCTTC
>MA049168.1 JP 2018019694-A/1603: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACATC
>MA049167.1 JP 2018019694-A/1602: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACATC
>MA049166.1 JP 2018019694-A/1601: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGAGTC
>MA049165.1 JP 2018019694-A/1600: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATG
>MA049164.1 JP 2018019694-A/1599: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTGC
>MA049163.1 JP 2018019694-A/1598: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TGCAGCGAC
>MA049162.1 JP 2018019694-A/1597: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGTAGAGTC
>MA049161.1 JP 2018019694-A/1596: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGAGTC
>MA049160.1 JP 2018019694-A/1595: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGGC
>MA049159.1 JP 2018019694-A/1594: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGAC
>MA049158.1 JP 2018019694-A/1593: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGGGTC
>MA049157.1 JP 2018019694-A/1592: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGTTC
>MA049156.1 JP 2018019694-A/1591: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAAAGTC
>MA049155.1 JP 2018019694-A/1590: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCCGCATC
>MA049154.1 JP 2018019694-A/1589: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCGGCGGC
>MA049153.1 JP 2018019694-A/1588: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GACAGCGTC
>MA049152.1 JP 2018019694-A/1587: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAAAGTC
>MA049151.1 JP 2018019694-A/1586: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTG
>MA049150.1 JP 2018019694-A/1585: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAGCGCC
>MA049149.1 JP 2018019694-A/1584: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACATC
>MA049148.1 JP 2018019694-A/1583: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATAGTC
>MA049147.1 JP 2018019694-A/1582: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACATC
>MA049146.1 JP 2018019694-A/1581: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGCTTC
>MA049145.1 JP 2018019694-A/1580: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGGAGTGTC
>MA049144.1 JP 2018019694-A/1579: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCGGCGTT
>MA049143.1 JP 2018019694-A/1578: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACGTG
>MA049142.1 JP 2018019694-A/1577: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGGAGGGTC
>MA049141.1 JP 2018019694-A/1576: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGATTC
>MA049140.1 JP 2018019694-A/1575: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCACAGTC
>MA049139.1 JP 2018019694-A/1574: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCACCTTC
>MA049138.1 JP 2018019694-A/1573: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
CACAGCGTC
>MA049137.1 JP 2018019694-A/1572: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAGTGTC
>MA049136.1 JP 2018019694-A/1571: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCACTGTC
>MA049135.1 JP 2018019694-A/1570: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATG
>MA049134.1 JP 2018019694-A/1569: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTG
>MA049133.1 JP 2018019694-A/1568: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTG
>MA049132.1 JP 2018019694-A/1567: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTG
>MA049131.1 JP 2018019694-A/1566: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTG
>MA049130.1 JP 2018019694-A/1565: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTG
>MA049129.1 JP 2018019694-A/1564: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAAGGTC
>MA049128.1 JP 2018019694-A/1563: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTG
>MA049127.1 JP 2018019694-A/1562: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAGTGTC
>MA049126.1 JP 2018019694-A/1561: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACAGAGTC
>MA049125.1 JP 2018019694-A/1560: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTG
>MA049124.1 JP 2018019694-A/1559: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTGC
>MA049123.1 JP 2018019694-A/1558: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTT
>MA049122.1 JP 2018019694-A/1557: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACATC
>MA049121.1 JP 2018019694-A/1556: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCACGGTC
>MA049120.1 JP 2018019694-A/1555: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCACCGCC
>MA049119.1 JP 2018019694-A/1554: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATTGTC
>MA049118.1 JP 2018019694-A/1553: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAATGTC
>MA049117.1 JP 2018019694-A/1552: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTACGTC
>MA049116.1 JP 2018019694-A/1551: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAATC
>MA049115.1 JP 2018019694-A/1550: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
ATCAGCGGC
>MA049114.1 JP 2018019694-A/1549: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGAAGCTTC
>MA049113.1 JP 2018019694-A/1548: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATCGTT
>MA049112.1 JP 2018019694-A/1547: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTA
>MA049111.1 JP 2018019694-A/1546: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACATC
>MA049110.1 JP 2018019694-A/1545: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGGC
>MA049109.1 JP 2018019694-A/1544: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTT
>MA049108.1 JP 2018019694-A/1543: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTA
>MA049107.1 JP 2018019694-A/1542: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGAAGCATC
>MA049106.1 JP 2018019694-A/1541: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTT
>MA049104.1 JP 2018019694-A/1539: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTA
>MA049103.1 JP 2018019694-A/1538: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACTTC
>MA049102.1 JP 2018019694-A/1537: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCAGC
>MA049101.1 JP 2018019694-A/1536: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTCC
>MA049100.1 JP 2018019694-A/1535: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCCTG
>MA049099.1 JP 2018019694-A/1534: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATTGTC
>MA049098.1 JP 2018019694-A/1533: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATG
>MA049097.1 JP 2018019694-A/1532: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCCAC
>MA049096.1 JP 2018019694-A/1531: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGGAGCGTA
>MA049095.1 JP 2018019694-A/1530: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGTGTC
>MA049094.1 JP 2018019694-A/1529: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGTGTC
>MA049093.1 JP 2018019694-A/1528: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGGGTC
>MA049092.1 JP 2018019694-A/1527: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGGAGCATC
>MA049091.1 JP 2018019694-A/1526: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTG
>MA049090.1 JP 2018019694-A/1525: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCAGC
>MA049089.1 JP 2018019694-A/1524: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCACAGTC
>MA049088.1 JP 2018019694-A/1523: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAAAGTC
>MA049087.1 JP 2018019694-A/1522: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATTGTC
>MA049086.1 JP 2018019694-A/1521: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAAAGTC
>MA049085.1 JP 2018019694-A/1520: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGAC
>MA049084.1 JP 2018019694-A/1519: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GACAGCGTC
>MA049083.1 JP 2018019694-A/1518: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGAAGCGTG
>MA049082.1 JP 2018019694-A/1517: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATCGTT
>MA049081.1 JP 2018019694-A/1516: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGGC
>MA049080.1 JP 2018019694-A/1515: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGAAGCTTC
>MA049079.1 JP 2018019694-A/1514: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
ACCACCGTC
>MA049078.1 JP 2018019694-A/1513: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGGGTC
>MA049077.1 JP 2018019694-A/1512: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTG
>MA049076.1 JP 2018019694-A/1511: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCACCGTT
>MA049075.1 JP 2018019694-A/1510: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTGC
>MA049074.1 JP 2018019694-A/1509: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCCCC
>MA049073.1 JP 2018019694-A/1508: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGTAGCGGC
>MA049072.1 JP 2018019694-A/1507: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCAAC
>MA049071.1 JP 2018019694-A/1506: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGATC
>MA049070.1 JP 2018019694-A/1505: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACGTA
>MA049069.1 JP 2018019694-A/1504: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACATC
>MA049068.1 JP 2018019694-A/1503: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGCGGC
>MA049067.1 JP 2018019694-A/1502: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTT
>MA049066.1 JP 2018019694-A/1501: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGAC
>MA049065.1 JP 2018019694-A/1500: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCAGC
>MA049064.1 JP 2018019694-A/1499: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
ATCAGTGTC
>MA049063.1 JP 2018019694-A/1498: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCACCTTC
>MA049062.1 JP 2018019694-A/1497: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGAC
>MA049061.1 JP 2018019694-A/1496: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGAGGCGTC
>MA049060.1 JP 2018019694-A/1495: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTT
>MA049059.1 JP 2018019694-A/1494: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTG
>MA049058.1 JP 2018019694-A/1493: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGTTC
>MA049057.1 JP 2018019694-A/1492: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTG
>MA049056.1 JP 2018019694-A/1491: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACGTG
>MA049055.1 JP 2018019694-A/1490: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAAAGTC
>MA049054.1 JP 2018019694-A/1489: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTCC
>MA049053.1 JP 2018019694-A/1488: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACTTC
>MA049052.1 JP 2018019694-A/1487: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGGAGGGTC
>MA049051.1 JP 2018019694-A/1486: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTT
>MA049050.1 JP 2018019694-A/1485: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTT
>MA049049.1 JP 2018019694-A/1484: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGAAGCTTC
>MA049048.1 JP 2018019694-A/1483: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACAGCATC
>MA049047.1 JP 2018019694-A/1482: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGTGTC
>MA049046.1 JP 2018019694-A/1481: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAAGGTC
>MA049045.1 JP 2018019694-A/1480: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTT
>MA049044.1 JP 2018019694-A/1479: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTGC
>MA049043.1 JP 2018019694-A/1478: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACTTC
>MA049042.1 JP 2018019694-A/1477: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TGCAGGGTC
>MA049041.1 JP 2018019694-A/1476: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATTGTC
>MA049040.1 JP 2018019694-A/1475: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGAGTC
>MA049039.1 JP 2018019694-A/1474: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAATC
>MA049038.1 JP 2018019694-A/1473: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TGCAGGGTC
>MA049037.1 JP 2018019694-A/1472: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAAAGTC
>MA049036.1 JP 2018019694-A/1471: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGATTC
>MA049035.1 JP 2018019694-A/1470: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAAGGTC
>MA049034.1 JP 2018019694-A/1469: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGCGTG
>MA049033.1 JP 2018019694-A/1468: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAAGGTC
>MA049032.1 JP 2018019694-A/1467: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCACCTTC
>MA049031.1 JP 2018019694-A/1466: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTGC
>MA049030.1 JP 2018019694-A/1465: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTG
>MA049029.1 JP 2018019694-A/1464: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TGCACCGTC
>MA049028.1 JP 2018019694-A/1463: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACAGCGTA
>MA049027.1 JP 2018019694-A/1462: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACGTG
>MA049026.1 JP 2018019694-A/1461: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGGC
>MA049025.1 JP 2018019694-A/1460: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTGC
>MA049024.1 JP 2018019694-A/1459: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTAC
>MA049023.1 JP 2018019694-A/1458: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAATGTC
>MA049022.1 JP 2018019694-A/1457: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCCAC
>MA049021.1 JP 2018019694-A/1456: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAAGGTC
>MA049020.1 JP 2018019694-A/1455: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACGTG
>MA049019.1 JP 2018019694-A/1454: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGTAGAGTC
>MA049018.1 JP 2018019694-A/1453: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTT
>MA049017.1 JP 2018019694-A/1452: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCACC
>MA049016.1 JP 2018019694-A/1451: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATTGTC
>MA049015.1 JP 2018019694-A/1450: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATT
>MA049014.1 JP 2018019694-A/1449: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTACGTC
>MA049013.1 JP 2018019694-A/1448: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCAAC
>MA049012.1 JP 2018019694-A/1447: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATAGTC
>MA049011.1 JP 2018019694-A/1446: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTT
>MA049010.1 JP 2018019694-A/1445: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTGC
>MA049009.1 JP 2018019694-A/1444: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
ATCAGTGTC
>MA049008.1 JP 2018019694-A/1443: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACAGCATC
>MA049007.1 JP 2018019694-A/1442: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACAGAGTC
>MA049006.1 JP 2018019694-A/1441: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACAGCGTG
>MA049005.1 JP 2018019694-A/1440: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGGC
>MA049004.1 JP 2018019694-A/1439: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATGGTC
>MA049003.1 JP 2018019694-A/1438: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
ATCAGCCTC
>MA049002.1 JP 2018019694-A/1437: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATGGTC
>MA049001.1 JP 2018019694-A/1436: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAGCGGC
>MA049000.1 JP 2018019694-A/1435: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGGGTC
>MA048999.1 JP 2018019694-A/1434: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGGGTC
>MA048998.1 JP 2018019694-A/1433: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGTGTC
>MA048997.1 JP 2018019694-A/1432: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048996.1 JP 2018019694-A/1431: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGAC
>MA048995.1 JP 2018019694-A/1430: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048994.1 JP 2018019694-A/1429: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATC
>MA048993.1 JP 2018019694-A/1428: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048992.1 JP 2018019694-A/1427: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGCGTC
>MA048991.1 JP 2018019694-A/1426: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA048990.1 JP 2018019694-A/1425: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048989.1 JP 2018019694-A/1424: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA048988.1 JP 2018019694-A/1423: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTG
>MA048987.1 JP 2018019694-A/1422: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATC
>MA048986.1 JP 2018019694-A/1421: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048985.1 JP 2018019694-A/1420: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCACCGTC
>MA048984.1 JP 2018019694-A/1419: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTG
>MA048983.1 JP 2018019694-A/1418: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAGCGTC
>MA048982.1 JP 2018019694-A/1417: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048981.1 JP 2018019694-A/1416: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048980.1 JP 2018019694-A/1415: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA048979.1 JP 2018019694-A/1414: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048978.1 JP 2018019694-A/1413: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048977.1 JP 2018019694-A/1412: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048976.1 JP 2018019694-A/1411: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048975.1 JP 2018019694-A/1410: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048974.1 JP 2018019694-A/1409: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048973.1 JP 2018019694-A/1408: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048972.1 JP 2018019694-A/1407: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048971.1 JP 2018019694-A/1406: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048970.1 JP 2018019694-A/1405: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048969.1 JP 2018019694-A/1404: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048968.1 JP 2018019694-A/1403: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048967.1 JP 2018019694-A/1402: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048966.1 JP 2018019694-A/1401: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048965.1 JP 2018019694-A/1400: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA048964.1 JP 2018019694-A/1399: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGCC
>MA048963.1 JP 2018019694-A/1398: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048962.1 JP 2018019694-A/1397: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCACCGTC
>MA048961.1 JP 2018019694-A/1396: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA048960.1 JP 2018019694-A/1395: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTT
>MA048959.1 JP 2018019694-A/1394: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048958.1 JP 2018019694-A/1393: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048957.1 JP 2018019694-A/1392: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATCGTC
>MA048956.1 JP 2018019694-A/1391: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAGCGTC
>MA048955.1 JP 2018019694-A/1390: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048954.1 JP 2018019694-A/1389: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCACCGTC
>MA048953.1 JP 2018019694-A/1388: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACGTC
>MA048952.1 JP 2018019694-A/1387: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATC
>MA048951.1 JP 2018019694-A/1386: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048950.1 JP 2018019694-A/1385: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA048949.1 JP 2018019694-A/1384: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTT
>MA048948.1 JP 2018019694-A/1383: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA048947.1 JP 2018019694-A/1382: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATCGTC
>MA048946.1 JP 2018019694-A/1381: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTA
>MA048945.1 JP 2018019694-A/1380: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048944.1 JP 2018019694-A/1379: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TGCAGCGTC
>MA048943.1 JP 2018019694-A/1378: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA048942.1 JP 2018019694-A/1377: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA048941.1 JP 2018019694-A/1376: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA048940.1 JP 2018019694-A/1375: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA048939.1 JP 2018019694-A/1374: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA048938.1 JP 2018019694-A/1373: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA048937.1 JP 2018019694-A/1372: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA048936.1 JP 2018019694-A/1371: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA048935.1 JP 2018019694-A/1370: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA048934.1 JP 2018019694-A/1369: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA048933.1 JP 2018019694-A/1368: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA048932.1 JP 2018019694-A/1367: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA048931.1 JP 2018019694-A/1366: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048930.1 JP 2018019694-A/1365: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATCGTC
>MA048929.1 JP 2018019694-A/1364: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048928.1 JP 2018019694-A/1363: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA048927.1 JP 2018019694-A/1362: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048926.1 JP 2018019694-A/1361: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048925.1 JP 2018019694-A/1360: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATC
>MA048924.1 JP 2018019694-A/1359: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048923.1 JP 2018019694-A/1358: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048922.1 JP 2018019694-A/1357: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048921.1 JP 2018019694-A/1356: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048920.1 JP 2018019694-A/1355: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048919.1 JP 2018019694-A/1354: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATCGTC
>MA048918.1 JP 2018019694-A/1353: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TGCAGCGTC
>MA048917.1 JP 2018019694-A/1352: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA048916.1 JP 2018019694-A/1351: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA048915.1 JP 2018019694-A/1350: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048914.1 JP 2018019694-A/1349: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA048913.1 JP 2018019694-A/1348: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATC
>MA048912.1 JP 2018019694-A/1347: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048911.1 JP 2018019694-A/1346: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048910.1 JP 2018019694-A/1345: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA048909.1 JP 2018019694-A/1344: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
ATCAGCGTC
>MA048908.1 JP 2018019694-A/1343: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048907.1 JP 2018019694-A/1342: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAGCGTC
>MA048906.1 JP 2018019694-A/1341: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTG
>MA048905.1 JP 2018019694-A/1340: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA048904.1 JP 2018019694-A/1339: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048903.1 JP 2018019694-A/1338: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTA
>MA048902.1 JP 2018019694-A/1337: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048901.1 JP 2018019694-A/1336: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA048900.1 JP 2018019694-A/1335: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048899.1 JP 2018019694-A/1334: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048898.1 JP 2018019694-A/1333: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048897.1 JP 2018019694-A/1332: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048896.1 JP 2018019694-A/1331: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048895.1 JP 2018019694-A/1330: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048894.1 JP 2018019694-A/1329: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA048893.1 JP 2018019694-A/1328: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048892.1 JP 2018019694-A/1327: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCACCGTC
>MA048891.1 JP 2018019694-A/1326: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTG
>MA048890.1 JP 2018019694-A/1325: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA048889.1 JP 2018019694-A/1324: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048888.1 JP 2018019694-A/1323: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATCGTC
>MA048887.1 JP 2018019694-A/1322: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCACCGTC
>MA048886.1 JP 2018019694-A/1321: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048885.1 JP 2018019694-A/1320: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048884.1 JP 2018019694-A/1319: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048883.1 JP 2018019694-A/1318: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA048882.1 JP 2018019694-A/1317: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048881.1 JP 2018019694-A/1316: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTA
>MA048880.1 JP 2018019694-A/1315: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048879.1 JP 2018019694-A/1314: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048878.1 JP 2018019694-A/1313: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048877.1 JP 2018019694-A/1312: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048876.1 JP 2018019694-A/1311: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACGTC
>MA048875.1 JP 2018019694-A/1310: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACGTC
>MA048874.1 JP 2018019694-A/1309: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAGCGTC
>MA048873.1 JP 2018019694-A/1308: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCCTC
>MA048872.1 JP 2018019694-A/1307: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATC
>MA048871.1 JP 2018019694-A/1306: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCACCGTC
>MA048870.1 JP 2018019694-A/1305: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048869.1 JP 2018019694-A/1304: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048868.1 JP 2018019694-A/1303: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048867.1 JP 2018019694-A/1302: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAGCGTC
>MA048866.1 JP 2018019694-A/1301: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA048865.1 JP 2018019694-A/1300: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048864.1 JP 2018019694-A/1299: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATC
>MA048863.1 JP 2018019694-A/1298: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048862.1 JP 2018019694-A/1297: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048861.1 JP 2018019694-A/1296: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGTAGCGTC
>MA048860.1 JP 2018019694-A/1295: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048859.1 JP 2018019694-A/1294: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048858.1 JP 2018019694-A/1293: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048857.1 JP 2018019694-A/1292: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048856.1 JP 2018019694-A/1291: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048855.1 JP 2018019694-A/1290: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048854.1 JP 2018019694-A/1289: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048853.1 JP 2018019694-A/1288: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048852.1 JP 2018019694-A/1287: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048851.1 JP 2018019694-A/1286: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048850.1 JP 2018019694-A/1285: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048849.1 JP 2018019694-A/1284: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048848.1 JP 2018019694-A/1283: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048847.1 JP 2018019694-A/1282: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048846.1 JP 2018019694-A/1281: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048845.1 JP 2018019694-A/1280: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048844.1 JP 2018019694-A/1279: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048843.1 JP 2018019694-A/1278: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048842.1 JP 2018019694-A/1277: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048841.1 JP 2018019694-A/1276: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048840.1 JP 2018019694-A/1275: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048839.1 JP 2018019694-A/1274: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048838.1 JP 2018019694-A/1273: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048837.1 JP 2018019694-A/1272: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048836.1 JP 2018019694-A/1271: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048835.1 JP 2018019694-A/1270: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048834.1 JP 2018019694-A/1269: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048833.1 JP 2018019694-A/1268: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048832.1 JP 2018019694-A/1267: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048831.1 JP 2018019694-A/1266: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048830.1 JP 2018019694-A/1265: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048829.1 JP 2018019694-A/1264: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048828.1 JP 2018019694-A/1263: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048827.1 JP 2018019694-A/1262: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048826.1 JP 2018019694-A/1261: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048825.1 JP 2018019694-A/1260: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048824.1 JP 2018019694-A/1259: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048823.1 JP 2018019694-A/1258: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048822.1 JP 2018019694-A/1257: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048821.1 JP 2018019694-A/1256: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048820.1 JP 2018019694-A/1255: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048819.1 JP 2018019694-A/1254: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048818.1 JP 2018019694-A/1253: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048817.1 JP 2018019694-A/1252: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048816.1 JP 2018019694-A/1251: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048815.1 JP 2018019694-A/1250: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048814.1 JP 2018019694-A/1249: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048813.1 JP 2018019694-A/1248: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048812.1 JP 2018019694-A/1247: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048811.1 JP 2018019694-A/1246: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048810.1 JP 2018019694-A/1245: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048809.1 JP 2018019694-A/1244: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048808.1 JP 2018019694-A/1243: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048807.1 JP 2018019694-A/1242: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048806.1 JP 2018019694-A/1241: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048805.1 JP 2018019694-A/1240: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048804.1 JP 2018019694-A/1239: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTA
>MA048803.1 JP 2018019694-A/1238: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTG
>MA048802.1 JP 2018019694-A/1237: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGATC
>MA048801.1 JP 2018019694-A/1236: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTG
>MA048800.1 JP 2018019694-A/1235: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTA
>MA048799.1 JP 2018019694-A/1234: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGCC
>MA048798.1 JP 2018019694-A/1233: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTG
>MA048797.1 JP 2018019694-A/1232: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TGCAGCATC
>MA048796.1 JP 2018019694-A/1231: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGATC
>MA048795.1 JP 2018019694-A/1230: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCACC
>MA048794.1 JP 2018019694-A/1229: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTT
>MA048793.1 JP 2018019694-A/1228: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTA
>MA048792.1 JP 2018019694-A/1227: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGACTC
>MA048791.1 JP 2018019694-A/1226: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGGAGGGTC
>MA048790.1 JP 2018019694-A/1225: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGCCTC
>MA048789.1 JP 2018019694-A/1224: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTG
>MA048788.1 JP 2018019694-A/1223: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGAC
>MA048787.1 JP 2018019694-A/1222: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTA
>MA048786.1 JP 2018019694-A/1221: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTA
>MA048785.1 JP 2018019694-A/1220: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATCCTC
>MA048784.1 JP 2018019694-A/1219: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCCTA
>MA048783.1 JP 2018019694-A/1218: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGCTC
>MA048782.1 JP 2018019694-A/1217: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGAC
>MA048781.1 JP 2018019694-A/1216: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TGCAGCGTC
>MA048780.1 JP 2018019694-A/1215: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA048779.1 JP 2018019694-A/1214: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCCTC
>MA048778.1 JP 2018019694-A/1213: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTA
>MA048777.1 JP 2018019694-A/1212: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048776.1 JP 2018019694-A/1211: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGAC
>MA048775.1 JP 2018019694-A/1210: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048774.1 JP 2018019694-A/1209: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
ACCAGCGTC
>MA048773.1 JP 2018019694-A/1208: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTG
>MA048772.1 JP 2018019694-A/1207: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA048771.1 JP 2018019694-A/1206: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048770.1 JP 2018019694-A/1205: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATC
>MA048769.1 JP 2018019694-A/1204: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCCTC
>MA048768.1 JP 2018019694-A/1203: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA048767.1 JP 2018019694-A/1202: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATC
>MA048766.1 JP 2018019694-A/1201: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGCC
>MA048765.1 JP 2018019694-A/1200: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGCC
>MA048764.1 JP 2018019694-A/1199: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGCC
>MA048763.1 JP 2018019694-A/1198: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGCC
>MA048762.1 JP 2018019694-A/1197: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGCC
>MA048761.1 JP 2018019694-A/1196: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGCC
>MA048760.1 JP 2018019694-A/1195: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGCC
>MA048759.1 JP 2018019694-A/1194: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGCC
>MA048758.1 JP 2018019694-A/1193: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACAGCGTC
>MA048757.1 JP 2018019694-A/1192: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATC
>MA048756.1 JP 2018019694-A/1191: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048755.1 JP 2018019694-A/1190: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048754.1 JP 2018019694-A/1189: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA048753.1 JP 2018019694-A/1188: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA048752.1 JP 2018019694-A/1187: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048751.1 JP 2018019694-A/1186: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGCGTC
>MA048750.1 JP 2018019694-A/1185: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGCC
>MA048749.1 JP 2018019694-A/1184: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAGCGTC
>MA048748.1 JP 2018019694-A/1183: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA048747.1 JP 2018019694-A/1182: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATC
>MA048746.1 JP 2018019694-A/1181: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATC
>MA048745.1 JP 2018019694-A/1180: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTG
>MA048744.1 JP 2018019694-A/1179: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATC
>MA048743.1 JP 2018019694-A/1178: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCCTC
>MA048742.1 JP 2018019694-A/1177: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048741.1 JP 2018019694-A/1176: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCCTC
>MA048740.1 JP 2018019694-A/1175: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCCTC
>MA048739.1 JP 2018019694-A/1174: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA048738.1 JP 2018019694-A/1173: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATC
>MA048737.1 JP 2018019694-A/1172: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048736.1 JP 2018019694-A/1171: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048735.1 JP 2018019694-A/1170: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048734.1 JP 2018019694-A/1169: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGCGTC
>MA048733.1 JP 2018019694-A/1168: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATC
>MA048732.1 JP 2018019694-A/1167: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048731.1 JP 2018019694-A/1166: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA048730.1 JP 2018019694-A/1165: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATC
>MA048729.1 JP 2018019694-A/1164: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA048728.1 JP 2018019694-A/1163: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAGCGTC
>MA048727.1 JP 2018019694-A/1162: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048726.1 JP 2018019694-A/1161: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048725.1 JP 2018019694-A/1160: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATTGTT
>MA048724.1 JP 2018019694-A/1159: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTCTT
>MA048723.1 JP 2018019694-A/1158: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAAGGTT
>MA048722.1 JP 2018019694-A/1157: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATTGTT
>MA048721.1 JP 2018019694-A/1156: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGTAGTCTC
>MA048720.1 JP 2018019694-A/1155: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATGGTG
>MA048719.1 JP 2018019694-A/1154: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
ATCAACTTC
>MA048718.1 JP 2018019694-A/1153: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACATTGTC
>MA048717.1 JP 2018019694-A/1152: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACATTGTC
>MA048716.1 JP 2018019694-A/1151: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACATTGTC
>MA048715.1 JP 2018019694-A/1150: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACATTGTC
>MA048714.1 JP 2018019694-A/1149: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACATTGTC
>MA048713.1 JP 2018019694-A/1148: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACATTGTC
>MA048712.1 JP 2018019694-A/1147: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACATTGTC
>MA048711.1 JP 2018019694-A/1146: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACATTGTC
>MA048710.1 JP 2018019694-A/1145: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACATTGTC
>MA048709.1 JP 2018019694-A/1144: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACATTGTC
>MA048708.1 JP 2018019694-A/1143: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACATTGTC
>MA048707.1 JP 2018019694-A/1142: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACATTGTC
>MA049301.1 JP 2018019694-A/1736: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACGTC
>MA049105.1 JP 2018019694-A/1540: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCCTT
>MA048706.1 JP 2018019694-A/1141: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACATTGTC
>MA048705.1 JP 2018019694-A/1140: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACATTGTC
>MA048704.1 JP 2018019694-A/1139: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AAAAGTGTC
>MA048703.1 JP 2018019694-A/1138: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GCCACCGTC
>MA048702.1 JP 2018019694-A/1137: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAATGGC
>MA048701.1 JP 2018019694-A/1136: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AAAAGTGTC
>MA048700.1 JP 2018019694-A/1135: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGGC
>MA048699.1 JP 2018019694-A/1134: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACAGCGGC
>MA048698.1 JP 2018019694-A/1133: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGAAGTGTC
>MA048697.1 JP 2018019694-A/1132: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATGGTC
>MA048696.1 JP 2018019694-A/1131: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACTTC
>MA048695.1 JP 2018019694-A/1130: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGTAGCTTC
>MA048694.1 JP 2018019694-A/1129: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACAGCGTG
>MA048693.1 JP 2018019694-A/1128: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
ATCAGGGTC
>MA048692.1 JP 2018019694-A/1127: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATGGTC
>MA048691.1 JP 2018019694-A/1126: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGGAGAGTC
>MA048690.1 JP 2018019694-A/1125: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTA
>MA048689.1 JP 2018019694-A/1124: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAGCATC
>MA048688.1 JP 2018019694-A/1123: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAGCATC
>MA048687.1 JP 2018019694-A/1122: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGGC
>MA048686.1 JP 2018019694-A/1121: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTT
>MA048685.1 JP 2018019694-A/1120: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GCCAGCGTC
>MA048684.1 JP 2018019694-A/1119: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAACGTC
>MA048683.1 JP 2018019694-A/1118: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTA
>MA048682.1 JP 2018019694-A/1117: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATGGTC
>MA048681.1 JP 2018019694-A/1116: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
ATCAGGGTC
>MA048680.1 JP 2018019694-A/1115: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGTAGGGTC
>MA048679.1 JP 2018019694-A/1114: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATGGTC
>MA048678.1 JP 2018019694-A/1113: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAAGGTC
>MA048677.1 JP 2018019694-A/1112: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA048676.1 JP 2018019694-A/1111: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTT
>MA048675.1 JP 2018019694-A/1110: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGTAGCGTC
>MA048674.1 JP 2018019694-A/1109: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACGTC
>MA048673.1 JP 2018019694-A/1108: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA048672.1 JP 2018019694-A/1107: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACGTC
>MA048671.1 JP 2018019694-A/1106: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATC
>MA048670.1 JP 2018019694-A/1105: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048669.1 JP 2018019694-A/1104: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTG
>MA048668.1 JP 2018019694-A/1103: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TGCAGCGTC
>MA048667.1 JP 2018019694-A/1102: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA048666.1 JP 2018019694-A/1101: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA048665.1 JP 2018019694-A/1100: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048664.1 JP 2018019694-A/1099: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048663.1 JP 2018019694-A/1098: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048662.1 JP 2018019694-A/1097: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCGCCGTC
>MA048661.1 JP 2018019694-A/1096: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGGC
>MA048660.1 JP 2018019694-A/1095: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
ATCAGCGTG
>MA048659.1 JP 2018019694-A/1094: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGATTC
>MA048658.1 JP 2018019694-A/1093: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGAC
>MA048657.1 JP 2018019694-A/1092: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTG
>MA048656.1 JP 2018019694-A/1091: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATG
>MA048655.1 JP 2018019694-A/1090: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
ACCAGGGTC
>MA048654.1 JP 2018019694-A/1089: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATG
>MA048653.1 JP 2018019694-A/1088: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATG
>MA048652.1 JP 2018019694-A/1087: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGGC
>MA048651.1 JP 2018019694-A/1086: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTGC
>MA048650.1 JP 2018019694-A/1085: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048649.1 JP 2018019694-A/1084: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048648.1 JP 2018019694-A/1083: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAGCGTC
>MA048647.1 JP 2018019694-A/1082: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048646.1 JP 2018019694-A/1081: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA048645.1 JP 2018019694-A/1080: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048644.1 JP 2018019694-A/1079: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048643.1 JP 2018019694-A/1078: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
ATCAACGTG
>MA048642.1 JP 2018019694-A/1077: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAAGGTC
>MA048641.1 JP 2018019694-A/1076: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TGCTGTGTC
>MA048640.1 JP 2018019694-A/1075: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAAAGTC
>MA048639.1 JP 2018019694-A/1074: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAGTGTC
>MA048638.1 JP 2018019694-A/1073: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACGTC
>MA048637.1 JP 2018019694-A/1072: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACGTC
>MA048636.1 JP 2018019694-A/1071: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TGCAAAGTC
>MA048635.1 JP 2018019694-A/1070: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GCCAGTGTC
>MA048634.1 JP 2018019694-A/1069: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
ATCAAGGTC
>MA048633.1 JP 2018019694-A/1068: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAAAGGC
>MA048632.1 JP 2018019694-A/1067: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTTTGTC
>MA048631.1 JP 2018019694-A/1066: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACATGGTC
>MA048630.1 JP 2018019694-A/1065: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAAAGGC
>MA048629.1 JP 2018019694-A/1064: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATAGTG
>MA048628.1 JP 2018019694-A/1063: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCCTGGTC
>MA048627.1 JP 2018019694-A/1062: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATTGTA
>MA048626.1 JP 2018019694-A/1061: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TGCAGTCTC
>MA048625.1 JP 2018019694-A/1060: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCCTGGTC
>MA048624.1 JP 2018019694-A/1059: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
CCCAGCGGC
>MA048623.1 JP 2018019694-A/1058: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAACATC
>MA048622.1 JP 2018019694-A/1057: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTG
>MA048621.1 JP 2018019694-A/1056: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAGAGTC
>MA048620.1 JP 2018019694-A/1055: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCTGCGTC
>MA048619.1 JP 2018019694-A/1054: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAATGTC
>MA048618.1 JP 2018019694-A/1053: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAATGTC
>MA048617.1 JP 2018019694-A/1052: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCCACGTC
>MA048616.1 JP 2018019694-A/1051: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGATC
>MA048615.1 JP 2018019694-A/1050: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
ATCAGAGTC
>MA048614.1 JP 2018019694-A/1049: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGCATC
>MA048613.1 JP 2018019694-A/1048: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGTAGCGTG
>MA048612.1 JP 2018019694-A/1047: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGG
>MA048611.1 JP 2018019694-A/1046: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACTTC
>MA048610.1 JP 2018019694-A/1045: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TTCAGCGTC
>MA048609.1 JP 2018019694-A/1044: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
ATCAGTGTC
>MA048608.1 JP 2018019694-A/1043: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTG
>MA048607.1 JP 2018019694-A/1042: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATCTTC
>MA048606.1 JP 2018019694-A/1041: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTG
>MA048605.1 JP 2018019694-A/1040: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAGAGTC
>MA048604.1 JP 2018019694-A/1039: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCCGC
>MA048603.1 JP 2018019694-A/1038: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGGAGAGTC
>MA048602.1 JP 2018019694-A/1037: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACAGGGTC
>MA048601.1 JP 2018019694-A/1036: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAGGGTC
>MA048600.1 JP 2018019694-A/1035: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACAGGGTC
>MA048599.1 JP 2018019694-A/1034: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGTAGCGCC
>MA048598.1 JP 2018019694-A/1033: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCCACGTC
>MA048597.1 JP 2018019694-A/1032: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCACCGTC
>MA048596.1 JP 2018019694-A/1031: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048595.1 JP 2018019694-A/1030: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048594.1 JP 2018019694-A/1029: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048593.1 JP 2018019694-A/1028: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048592.1 JP 2018019694-A/1027: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA048591.1 JP 2018019694-A/1026: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA048590.1 JP 2018019694-A/1025: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAGCGTC
>MA048589.1 JP 2018019694-A/1024: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048588.1 JP 2018019694-A/1023: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATCGTC
>MA048587.1 JP 2018019694-A/1022: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATC
>MA048586.1 JP 2018019694-A/1021: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA048585.1 JP 2018019694-A/1020: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048584.1 JP 2018019694-A/1019: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAGCGTC
>MA048583.1 JP 2018019694-A/1018: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAGCGTC
>MA048582.1 JP 2018019694-A/1017: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048581.1 JP 2018019694-A/1016: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048580.1 JP 2018019694-A/1015: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048579.1 JP 2018019694-A/1014: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048578.1 JP 2018019694-A/1013: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048577.1 JP 2018019694-A/1012: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048576.1 JP 2018019694-A/1011: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048575.1 JP 2018019694-A/1010: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048574.1 JP 2018019694-A/1009: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048573.1 JP 2018019694-A/1008: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048572.1 JP 2018019694-A/1007: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048571.1 JP 2018019694-A/1006: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGA
>MA048570.1 JP 2018019694-A/1005: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCGGGGTC
>MA048569.1 JP 2018019694-A/1004: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
ATCAGAGTC
>MA048568.1 JP 2018019694-A/1003: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCAGC
>MA048567.1 JP 2018019694-A/1002: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCCTG
>MA048566.1 JP 2018019694-A/1001: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACAGAGTC
>MA048565.1 JP 2018019694-A/1000: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
ACCAGTGTC
>MA048564.1 JP 2018019694-A/999: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCCTG
>MA048563.1 JP 2018019694-A/998: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGGAGCTTC
>MA048562.1 JP 2018019694-A/997: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCAGC
>MA048561.1 JP 2018019694-A/996: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTG
>MA048560.1 JP 2018019694-A/995: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048559.1 JP 2018019694-A/994: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA048558.1 JP 2018019694-A/993: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA048557.1 JP 2018019694-A/992: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA048556.1 JP 2018019694-A/991: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTT
>MA048555.1 JP 2018019694-A/990: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA048554.1 JP 2018019694-A/989: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTG
>MA048553.1 JP 2018019694-A/988: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
ATCAGCGTC
>MA048552.1 JP 2018019694-A/987: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048551.1 JP 2018019694-A/986: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048550.1 JP 2018019694-A/985: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA048549.1 JP 2018019694-A/984: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGCC
>MA048548.1 JP 2018019694-A/983: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTG
>MA048547.1 JP 2018019694-A/982: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048546.1 JP 2018019694-A/981: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TGCAGTCTC
>MA048545.1 JP 2018019694-A/980: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATTGTT
>MA048544.1 JP 2018019694-A/979: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGTAAAGTC
>MA048543.1 JP 2018019694-A/978: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATAGTT
>MA048542.1 JP 2018019694-A/977: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TGCAGCTTC
>MA048541.1 JP 2018019694-A/976: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAGAGTC
>MA048540.1 JP 2018019694-A/975: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGTAGCGTT
>MA048539.1 JP 2018019694-A/974: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAATGTC
>MA048538.1 JP 2018019694-A/973: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTCC
>MA048537.1 JP 2018019694-A/972: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAAAGTC
>MA048536.1 JP 2018019694-A/971: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATGGTC
>MA048535.1 JP 2018019694-A/970: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACATC
>MA048534.1 JP 2018019694-A/969: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
ATCAGTGTC
>MA048533.1 JP 2018019694-A/968: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
ATCAGAGTC
>MA048532.1 JP 2018019694-A/967: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCAGC
>MA048531.1 JP 2018019694-A/966: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCAGC
>MA048530.1 JP 2018019694-A/965: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATTGTC
>MA048529.1 JP 2018019694-A/964: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAGCGGC
>MA048528.1 JP 2018019694-A/963: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACATC
>MA048527.1 JP 2018019694-A/962: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACTTC
>MA048526.1 JP 2018019694-A/961: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCACCGTG
>MA048525.1 JP 2018019694-A/960: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATTGTC
>MA048524.1 JP 2018019694-A/959: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCACGGTC
>MA048523.1 JP 2018019694-A/958: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTG
>MA048522.1 JP 2018019694-A/957: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACTTC
>MA048521.1 JP 2018019694-A/956: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATAGTC
>MA048520.1 JP 2018019694-A/955: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGAAACGTC
>MA048519.1 JP 2018019694-A/954: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACGTC
>MA048518.1 JP 2018019694-A/953: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA048517.1 JP 2018019694-A/952: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA048516.1 JP 2018019694-A/951: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCACCGTC
>MA048515.1 JP 2018019694-A/950: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACGTC
>MA048514.1 JP 2018019694-A/949: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA048513.1 JP 2018019694-A/948: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGTGTC
>MA048512.1 JP 2018019694-A/947: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGTGGCGTC
>MA048511.1 JP 2018019694-A/946: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGTGTC
>MA048510.1 JP 2018019694-A/945: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAGAGTC
>MA048509.1 JP 2018019694-A/944: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACAGCTTC
>MA048508.1 JP 2018019694-A/943: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGT
>MA048507.1 JP 2018019694-A/942: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATA
>MA048506.1 JP 2018019694-A/941: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATA
>MA048505.1 JP 2018019694-A/940: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TGCAGTGTC
>MA048504.1 JP 2018019694-A/939: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGAG
>MA048503.1 JP 2018019694-A/938: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGAGTC
>MA048502.1 JP 2018019694-A/937: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGTAGCGGC
>MA048501.1 JP 2018019694-A/936: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACAGCTTC
>MA048500.1 JP 2018019694-A/935: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAAAGTC
>MA048499.1 JP 2018019694-A/934: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TGCAGGGTC
>MA048498.1 JP 2018019694-A/933: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACAGCTTC
>MA048497.1 JP 2018019694-A/932: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATA
>MA048496.1 JP 2018019694-A/931: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTT
>MA048495.1 JP 2018019694-A/930: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TGCAGCGGC
>MA048494.1 JP 2018019694-A/929: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCACCTTC
>MA048493.1 JP 2018019694-A/928: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TGCAGCGTT
>MA048492.1 JP 2018019694-A/927: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TCCAGCGTC
>MA048491.1 JP 2018019694-A/926: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGAGTC
>MA048490.1 JP 2018019694-A/925: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACTTC
>MA048489.1 JP 2018019694-A/924: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGGGTC
>MA048488.1 JP 2018019694-A/923: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGGGTC
>MA048487.1 JP 2018019694-A/922: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACGTC
>MA048486.1 JP 2018019694-A/921: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATCGTC
>MA048485.1 JP 2018019694-A/920: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA048117.1 JP 2018019694-A/552: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGT
>MA048116.1 JP 2018019694-A/551: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048115.1 JP 2018019694-A/550: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048114.1 JP 2018019694-A/549: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGC
>MA048113.1 JP 2018019694-A/548: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGT
>MA048112.1 JP 2018019694-A/547: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGC
>MA048111.1 JP 2018019694-A/546: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGC
>MA048110.1 JP 2018019694-A/545: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGC
>MA048108.1 JP 2018019694-A/543: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGG
>MA048107.1 JP 2018019694-A/542: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGT
>MA048106.1 JP 2018019694-A/541: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGG
>MA048105.1 JP 2018019694-A/540: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGC
>MA048104.1 JP 2018019694-A/539: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGC
>MA048103.1 JP 2018019694-A/538: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGT
>MA048102.1 JP 2018019694-A/537: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGG
>MA048101.1 JP 2018019694-A/536: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGG
>MA048100.1 JP 2018019694-A/535: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGC
>MA048099.1 JP 2018019694-A/534: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGC
>MA048098.1 JP 2018019694-A/533: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGC
>MA048097.1 JP 2018019694-A/532: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGG
>MA048096.1 JP 2018019694-A/531: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGG
>MA048095.1 JP 2018019694-A/530: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGG
>MA048094.1 JP 2018019694-A/529: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGG
>MA048093.1 JP 2018019694-A/528: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGG
>MA048092.1 JP 2018019694-A/527: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGG
>MA048091.1 JP 2018019694-A/526: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGAT
>MA048090.1 JP 2018019694-A/525: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGGTGAGGT
>MA048089.1 JP 2018019694-A/524: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
CAGTGAGGC
>MA048088.1 JP 2018019694-A/523: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
CAGTGAGGC
>MA048087.1 JP 2018019694-A/522: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGTTGA
>MA048086.1 JP 2018019694-A/521: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GTGTGAGAA
>MA048085.1 JP 2018019694-A/520: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048084.1 JP 2018019694-A/519: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048083.1 JP 2018019694-A/518: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048082.1 JP 2018019694-A/517: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048081.1 JP 2018019694-A/516: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048080.1 JP 2018019694-A/515: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048079.1 JP 2018019694-A/514: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048078.1 JP 2018019694-A/513: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048077.1 JP 2018019694-A/512: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048076.1 JP 2018019694-A/511: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048075.1 JP 2018019694-A/510: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048074.1 JP 2018019694-A/509: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048073.1 JP 2018019694-A/508: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048072.1 JP 2018019694-A/507: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048071.1 JP 2018019694-A/506: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048070.1 JP 2018019694-A/505: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048069.1 JP 2018019694-A/504: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048068.1 JP 2018019694-A/503: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048067.1 JP 2018019694-A/502: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048066.1 JP 2018019694-A/501: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048065.1 JP 2018019694-A/500: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048064.1 JP 2018019694-A/499: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048063.1 JP 2018019694-A/498: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048062.1 JP 2018019694-A/497: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048061.1 JP 2018019694-A/496: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048060.1 JP 2018019694-A/495: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048059.1 JP 2018019694-A/494: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGC
>MA048058.1 JP 2018019694-A/493: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGTA
>MA048057.1 JP 2018019694-A/492: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGC
>MA048056.1 JP 2018019694-A/491: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
CAGTGAGGA
>MA048055.1 JP 2018019694-A/490: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGGTGAGGA
>MA048054.1 JP 2018019694-A/489: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GTGTGAGGA
>MA048053.1 JP 2018019694-A/488: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GTGTGAGGA
>MA048052.1 JP 2018019694-A/487: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GTGTGAGGA
>MA048051.1 JP 2018019694-A/486: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GTGTGAGGA
>MA048050.1 JP 2018019694-A/485: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GTGTGAGGA
>MA048049.1 JP 2018019694-A/484: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGC
>MA048048.1 JP 2018019694-A/483: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGG
>MA048047.1 JP 2018019694-A/482: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGAA
>MA048046.1 JP 2018019694-A/481: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GTGTGAGGA
>MA048045.1 JP 2018019694-A/480: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGC
>MA048044.1 JP 2018019694-A/479: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGT
>MA048043.1 JP 2018019694-A/478: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGT
>MA048042.1 JP 2018019694-A/477: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGC
>MA048041.1 JP 2018019694-A/476: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGC
>MA048040.1 JP 2018019694-A/475: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGC
>MA048039.1 JP 2018019694-A/474: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGT
>MA048038.1 JP 2018019694-A/473: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TAGTGAGGA
>MA048037.1 JP 2018019694-A/472: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GATTGAGGA
>MA048036.1 JP 2018019694-A/471: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
CAGTGAGGA
>MA048035.1 JP 2018019694-A/470: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGGTGAGGA
>MA048034.1 JP 2018019694-A/469: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGT
>MA048033.1 JP 2018019694-A/468: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAAAA
>MA048032.1 JP 2018019694-A/467: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGATGG
>MA048031.1 JP 2018019694-A/466: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGTGCA
>MA048030.1 JP 2018019694-A/465: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGGGAGGG
>MA048029.1 JP 2018019694-A/464: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGGGAAGA
>MA048028.1 JP 2018019694-A/463: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AAGTGGGGA
>MA048027.1 JP 2018019694-A/462: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GTGTGAGGT
>MA048026.1 JP 2018019694-A/461: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
CAGTGAGCA
>MA048025.1 JP 2018019694-A/460: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048024.1 JP 2018019694-A/459: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048023.1 JP 2018019694-A/458: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAAGA
>MA048022.1 JP 2018019694-A/457: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA048021.1 JP 2018019694-A/456: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TGCAGTCTC
>MA048020.1 JP 2018019694-A/455: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGTAAAGTC
>MA048019.1 JP 2018019694-A/454: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATAGTT
>MA048018.1 JP 2018019694-A/453: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TGCAGCTTC
>MA048017.1 JP 2018019694-A/452: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAGCGGC
>MA048016.1 JP 2018019694-A/451: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAGAGTC
>MA048015.1 JP 2018019694-A/450: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
ATCAGTGTC
>MA048014.1 JP 2018019694-A/449: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
ATCAGAGTC
>MA048013.1 JP 2018019694-A/448: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGTAGCGTT
>MA048012.1 JP 2018019694-A/447: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATTGTC
>MA048011.1 JP 2018019694-A/446: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATTGTC
>MA048010.1 JP 2018019694-A/445: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATGGTC
>MA048009.1 JP 2018019694-A/444: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATAGTC
>MA048008.1 JP 2018019694-A/443: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTG
>MA048007.1 JP 2018019694-A/442: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTCC
>MA048006.1 JP 2018019694-A/441: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCAGC
>MA048005.1 JP 2018019694-A/440: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCAGC
>MA048004.1 JP 2018019694-A/439: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCACGGTC
>MA048003.1 JP 2018019694-A/438: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCACCGTG
>MA048002.1 JP 2018019694-A/437: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAATGTC
>MA048001.1 JP 2018019694-A/436: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACTTC
>MA048000.1 JP 2018019694-A/435: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACTTC
>MA047999.1 JP 2018019694-A/434: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACATC
>MA047998.1 JP 2018019694-A/433: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACATC
>MA047997.1 JP 2018019694-A/432: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAAAGTC
>MA047996.1 JP 2018019694-A/431: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGAAACGTC
>MA047995.1 JP 2018019694-A/430: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA047994.1 JP 2018019694-A/429: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA047993.1 JP 2018019694-A/428: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGC
>MA047992.1 JP 2018019694-A/427: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCACCGTC
>MA047991.1 JP 2018019694-A/426: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACGTC
>MA047990.1 JP 2018019694-A/425: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACGTC
>MA047989.1 JP 2018019694-A/424: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TGCAGTGTC
>MA047988.1 JP 2018019694-A/423: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TGCAGGGTC
>MA047987.1 JP 2018019694-A/422: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TGCAGCGTT
>MA047986.1 JP 2018019694-A/421: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TGCAGCGGC
>MA047985.1 JP 2018019694-A/420: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
TCCAGCGTC
>MA047984.1 JP 2018019694-A/419: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GGCAGAGTC
>MA047983.1 JP 2018019694-A/418: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGTGGCGTC
>MA047982.1 JP 2018019694-A/417: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGTAGCGGC
>MA047981.1 JP 2018019694-A/416: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGTGTC
>MA047980.1 JP 2018019694-A/415: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGTGTC
>MA047979.1 JP 2018019694-A/414: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGGGTC
>MA047978.1 JP 2018019694-A/413: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGGGTC
>MA047977.1 JP 2018019694-A/412: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGAGTC
>MA047976.1 JP 2018019694-A/411: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCTGAGTC
>MA047975.1 JP 2018019694-A/410: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTT
>MA047974.1 JP 2018019694-A/409: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGGT
>MA047973.1 JP 2018019694-A/408: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGAG
>MA047972.1 JP 2018019694-A/407: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATA
>MA047971.1 JP 2018019694-A/406: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATA
>MA047970.1 JP 2018019694-A/405: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATA
>MA047969.1 JP 2018019694-A/404: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCACCTTC
>MA047968.1 JP 2018019694-A/403: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACTTC
>MA047967.1 JP 2018019694-A/402: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAAAGTC
>MA047966.1 JP 2018019694-A/401: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACAGCTTC
>MA047965.1 JP 2018019694-A/400: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACAGCTTC
>MA047964.1 JP 2018019694-A/399: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AACAGCTTC
>MA047963.1 JP 2018019694-A/398: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGGAGCGTC
>MA047962.1 JP 2018019694-A/397: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATCGTC
>MA047961.1 JP 2018019694-A/396: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATCGTC
>MA047960.1 JP 2018019694-A/395: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCATCGTC
>MA047959.1 JP 2018019694-A/394: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA047958.1 JP 2018019694-A/393: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA047957.1 JP 2018019694-A/392: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA047956.1 JP 2018019694-A/391: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA047955.1 JP 2018019694-A/390: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA047954.1 JP 2018019694-A/389: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGTGTC
>MA047953.1 JP 2018019694-A/388: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGGGTC
>MA047952.1 JP 2018019694-A/387: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA047951.1 JP 2018019694-A/386: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA047950.1 JP 2018019694-A/385: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCTTC
>MA047949.1 JP 2018019694-A/384: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTG
>MA047948.1 JP 2018019694-A/383: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGAC
>MA047947.1 JP 2018019694-A/382: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCCTC
>MA047946.1 JP 2018019694-A/381: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCCTC
>MA047945.1 JP 2018019694-A/380: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCATC
>MA047944.1 JP 2018019694-A/379: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA047943.1 JP 2018019694-A/378: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGAGTC
>MA047942.1 JP 2018019694-A/377: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCACCGTC
>MA047941.1 JP 2018019694-A/376: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACGTC
>MA047940.1 JP 2018019694-A/375: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACGTC
>MA047939.1 JP 2018019694-A/374: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAACGTC
>MA047938.1 JP 2018019694-A/373: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGAAGCGTC
>MA047937.1 JP 2018019694-A/372: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA047936.1 JP 2018019694-A/371: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA047935.1 JP 2018019694-A/370: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA047934.1 JP 2018019694-A/369: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA047933.1 JP 2018019694-A/368: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA047932.1 JP 2018019694-A/367: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA047931.1 JP 2018019694-A/366: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA047930.1 JP 2018019694-A/365: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA047929.1 JP 2018019694-A/364: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTT
>MA047928.1 JP 2018019694-A/363: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCCTC
>MA047927.1 JP 2018019694-A/362: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA047926.1 JP 2018019694-A/361: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA048109.1 JP 2018019694-A/544: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGT
>MA047697.1 JP 2018019694-A/132: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA047696.1 JP 2018019694-A/131: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
AGCAGCGTC
>MA047692.1 JP 2018019694-A/127: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA047690.1 JP 2018019694-A/125: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GACGCTGCT
>MA047589.1 JP 2018019694-A/24: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GACGAAACC
>MA047588.1 JP 2018019694-A/23: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GACGTTGCT
>MA047587.1 JP 2018019694-A/22: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GACGTTACT
>MA047586.1 JP 2018019694-A/21: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GACGTTGCT
>MA047585.1 JP 2018019694-A/20: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GACGCTGCT
>MA047584.1 JP 2018019694-A/19: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA047583.1 JP 2018019694-A/18: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GTGTGAAAA
>MA047582.1 JP 2018019694-A/17: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGTC
>MA047581.1 JP 2018019694-A/16: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAAAC
>MA047580.1 JP 2018019694-A/15: EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY
GAGTGAGGA
>MA046167.1 JP 2018023373-A/26368: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS
ATGGCCTAG
>MA041651.1 JP 2018023373-A/21852: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS
ATGGCCTAG
>MA037135.1 JP 2018023373-A/17336: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS
ATGGCCTAG
>LQ714547.1 Sequence 12 from Patent EP3212666
GGTGGATCC
>LP787994.1 Sequence 1893 from Patent WO2018058001
ACTGCATCC
>LP958214.1 Sequence 349 from Patent WO2017218515
GATGCATCC
>LP958198.1 Sequence 333 from Patent WO2017218515
GGTGCATCC
>LP958182.1 Sequence 317 from Patent WO2017218515
GATGCATCC
>LP958166.1 Sequence 301 from Patent WO2017218515
GCTGCATCC
>LP958126.1 Sequence 261 from Patent WO2017218515
GCTGCATCC
>LP958110.1 Sequence 245 from Patent WO2017218515
GATGCATCC
>LP958094.1 Sequence 229 from Patent WO2017218515
GCTGCATCC
>LP958078.1 Sequence 213 from Patent WO2017218515
AAGGCGTCT
>LP958062.1 Sequence 197 from Patent WO2017218515
GATGCATCC
>LP958046.1 Sequence 181 from Patent WO2017218515
ACTGCATCC
>LP958030.1 Sequence 165 from Patent WO2017218515
ACTGCATCC
>LP957998.1 Sequence 133 from Patent WO2017218515
GCTGCATCC
>LP957982.1 Sequence 117 from Patent WO2017218515
GCTGCATCC
>LP957974.1 Sequence 109 from Patent WO2017218515
GCTGCATCC
>LP957958.1 Sequence 93 from Patent WO2017218515
GATGCATCG
>LP957942.1 Sequence 77 from Patent WO2017218515
GCTGCATCC
>LP957926.1 Sequence 61 from Patent WO2017218515
GCTGCATCC
>LP957910.1 Sequence 45 from Patent WO2017218515
AAGGCGTCT
>LP957894.1 Sequence 29 from Patent WO2017218515
GATGCATCC
>LP957878.1 Sequence 13 from Patent WO2017218515
AAGGCGTCT
>LP841025.1 Sequence 8 from Patent EP3198010
GATCCCAAA
>LP955424.1 Sequence 405 from Patent WO2017214548
GCTGCATCC
>LP955336.1 Sequence 317 from Patent WO2017214548
GGTGCATCC
>LP955320.1 Sequence 301 from Patent WO2017214548
GCTGCATCC
>LP955304.1 Sequence 285 from Patent WO2017214548
GATGTATCC
>LP955288.1 Sequence 269 from Patent WO2017214548
GATGCATCC
>LP955272.1 Sequence 253 from Patent WO2017214548
GCTGCATCC
>LP955256.1 Sequence 237 from Patent WO2017214548
GCTGCATCC
>LP955240.1 Sequence 221 from Patent WO2017214548
GATGCATCC
>LP955224.1 Sequence 205 from Patent WO2017214548
GCTGCATCC
>LP955208.1 Sequence 189 from Patent WO2017214548
GGTGCATCC
>LP955192.1 Sequence 173 from Patent WO2017214548
ACTGCATCC
>LP955176.1 Sequence 157 from Patent WO2017214548
GCTGCATCC
>LP955160.1 Sequence 141 from Patent WO2017214548
GCTGCATCC
>LP955144.1 Sequence 125 from Patent WO2017214548
AAGGTTTCT
>LP955128.1 Sequence 109 from Patent WO2017214548
GGTGCATCC
>LP955112.1 Sequence 93 from Patent WO2017214548
TCTACATCC
>LP955096.1 Sequence 77 from Patent WO2017214548
GCTACATCC
>LP955080.1 Sequence 61 from Patent WO2017214548
GCTGCATCC
>LP955064.1 Sequence 45 from Patent WO2017214548
GCTGCTTCC
>LP955048.1 Sequence 29 from Patent WO2017214548
TCTGCATCC
>LP955032.1 Sequence 13 from Patent WO2017214548
GGTGCATCC
>LP777220.1 Sequence 276 from Patent WO2018023025
TGGGCCTCT
>LP777209.1 Sequence 265 from Patent WO2018023025
TGGGCCTCC
>LP777195.1 Sequence 251 from Patent WO2018023025
TGGGCATCC
>LP839332.1 Sequence 15 from Patent EP3199548
GGGGCATCC
>LP837079.1 Sequence 27 from Patent WO2017108741
AATTCCGCT
>LP837078.1 Sequence 26 from Patent WO2017108741
GTCTTGCCG
>LP832936.1 Sequence 202 from Patent EP3190187
GAAGATGAG
>LP889381.1 Sequence 68 from Patent WO2017201204
ACCACATCC
>LP889352.1 Sequence 39 from Patent WO2017201204
GCTGCAACA
>LP889347.1 Sequence 34 from Patent WO2017201204
CGTGCATCC
>LP888253.1 Sequence 22 from Patent WO2017199041
AACTGAGGC
>LP888221.1 Sequence 232 from Patent WO2017201350
CCRCCATGG
>LP824226.1 Sequence 1955 from Patent WO2018067331
GGTGCATCC
>LP824210.1 Sequence 1939 from Patent WO2018067331
GGTGCATCC
>LP824164.1 Sequence 1893 from Patent WO2018067331
ACTGCATCC
>LP823988.1 Sequence 1717 from Patent WO2018067331
GGTGCATCC
>LP823972.1 Sequence 1701 from Patent WO2018067331
GGTGCATCC
>LP823956.1 Sequence 1685 from Patent WO2018067331
GGTGCATCC
>LP823940.1 Sequence 1669 from Patent WO2018067331
GGTGCATCC
>LP823924.1 Sequence 1653 from Patent WO2018067331
GGTGCATCC
>LP823908.1 Sequence 1637 from Patent WO2018067331
GCTGCATCC
>LP823708.1 Sequence 1437 from Patent WO2018067331
GTTGCATCC
>LP823692.1 Sequence 1421 from Patent WO2018067331
ACTGCATCC
>LP823676.1 Sequence 1405 from Patent WO2018067331
ACTGCATCC
>LP823660.1 Sequence 1389 from Patent WO2018067331
GTTGCATCC
>LP823644.1 Sequence 1373 from Patent WO2018067331
GCTGCATCC
>LP823628.1 Sequence 1357 from Patent WO2018067331
ACTGCATCC
>LP823612.1 Sequence 1341 from Patent WO2018067331
GTTGCATCC
>LP823596.1 Sequence 1325 from Patent WO2018067331
ACTGCATCC
>LP823580.1 Sequence 1309 from Patent WO2018067331
ACTGCATCC
>LP823564.1 Sequence 1293 from Patent WO2018067331
ACTGCATCC
>LP823548.1 Sequence 1277 from Patent WO2018067331
GGTGCATCC
>LP823532.1 Sequence 1261 from Patent WO2018067331
ACTGCATCC
>LP823516.1 Sequence 1245 from Patent WO2018067331
TGGGCATCT
>LP823500.1 Sequence 1229 from Patent WO2018067331
AAGGCGTCT
>LP823484.1 Sequence 1213 from Patent WO2018067331
GGTGCGTCC
>LP823468.1 Sequence 1197 from Patent WO2018067331
GGTGCGTCC
>LP823452.1 Sequence 1181 from Patent WO2018067331
GGTGCATCC
>LP823436.1 Sequence 1165 from Patent WO2018067331
GGTGCGTCC
>LP823420.1 Sequence 1149 from Patent WO2018067331
GGTGCGTCC
>LP823404.1 Sequence 1133 from Patent WO2018067331
GGTGCGTCC
>LP823388.1 Sequence 1117 from Patent WO2018067331
GGTGCGTCC
>LP823372.1 Sequence 1101 from Patent WO2018067331
GCTGCATCC
>LP823356.1 Sequence 1085 from Patent WO2018067331
GCTGCGTCC
>LP823340.1 Sequence 1069 from Patent WO2018067331
GCTGCATCC
>LP823324.1 Sequence 1053 from Patent WO2018067331
GCTGCATCC
>LP823308.1 Sequence 1037 from Patent WO2018067331
GCTGCATCC
>LP823292.1 Sequence 1021 from Patent WO2018067331
GCTGCATCC
>LP823276.1 Sequence 1005 from Patent WO2018067331
GCTGCATCC
>LP823260.1 Sequence 989 from Patent WO2018067331
GATGCATCC
>LP823244.1 Sequence 973 from Patent WO2018067331
GCTGTATCC
>LP823228.1 Sequence 957 from Patent WO2018067331
GAAGCTTCT
>LP823212.1 Sequence 941 from Patent WO2018067331
GCTGCTTCC
>LP823196.1 Sequence 925 from Patent WO2018067331
GCTGCATCC
>LP823180.1 Sequence 909 from Patent WO2018067331
GCTGCATCC
>LP823164.1 Sequence 893 from Patent WO2018067331
GCTGCATCC
>LP823148.1 Sequence 877 from Patent WO2018067331
GCTGCATCC
>LP823132.1 Sequence 861 from Patent WO2018067331
GCTGCATCC
>LP823116.1 Sequence 845 from Patent WO2018067331
GCTGCATCC
>LP823100.1 Sequence 829 from Patent WO2018067331
GGTGCAACC
>LP823084.1 Sequence 813 from Patent WO2018067331
GGTGCAACC
>LP823068.1 Sequence 797 from Patent WO2018067331
GGTGCATCC
>LP823052.1 Sequence 781 from Patent WO2018067331
GCTGCATCC
>LP823036.1 Sequence 765 from Patent WO2018067331
TGGGCATCT
>LP823020.1 Sequence 749 from Patent WO2018067331
GGTGCATCC
>LP823004.1 Sequence 733 from Patent WO2018067331
GGTGCATCC
>LP822988.1 Sequence 717 from Patent WO2018067331
GGTGCAACC
>LP822972.1 Sequence 701 from Patent WO2018067331
GGTGCAACC
>LP822956.1 Sequence 685 from Patent WO2018067331
GGTGCATCC
>LP822940.1 Sequence 669 from Patent WO2018067331
GGTGCATCC
>LP822924.1 Sequence 653 from Patent WO2018067331
GGTGCATCC
>LP822908.1 Sequence 637 from Patent WO2018067331
GGTGCATCC
>LP822892.1 Sequence 621 from Patent WO2018067331
GGTGCATCC
>LP822876.1 Sequence 605 from Patent WO2018067331
GGTGCATCC
>LP822860.1 Sequence 589 from Patent WO2018067331
GGTGCATCC
>LP822844.1 Sequence 573 from Patent WO2018067331
GGTGCATCC
>LP822828.1 Sequence 557 from Patent WO2018067331
GGTGCATCC
>LP822812.1 Sequence 541 from Patent WO2018067331
GGTGCATCC
>LP822796.1 Sequence 525 from Patent WO2018067331
GGTGCATCC
>LP822780.1 Sequence 509 from Patent WO2018067331
GATGCATCC
>LP822764.1 Sequence 493 from Patent WO2018067331
GCTGCATCC
>LP822748.1 Sequence 477 from Patent WO2018067331
GCTGCATCC
>LP822732.1 Sequence 461 from Patent WO2018067331
GGTGCATCC
>LP822716.1 Sequence 445 from Patent WO2018067331
GCTGCATCC
>LP822700.1 Sequence 429 from Patent WO2018067331
GGTGCATCC
>LP822684.1 Sequence 413 from Patent WO2018067331
GGTGCATCC
>LP822668.1 Sequence 397 from Patent WO2018067331
GCTGCATCC
>LP822660.1 Sequence 389 from Patent WO2018067331
TGGGCATCT
>LP822644.1 Sequence 373 from Patent WO2018067331
TGGGCATCT
>LP822628.1 Sequence 357 from Patent WO2018067331
TGGGCATCT
>LP822612.1 Sequence 341 from Patent WO2018067331
GGTGCATCC
>LP822596.1 Sequence 325 from Patent WO2018067331
GCTGCATCC
>LP822580.1 Sequence 309 from Patent WO2018067331
GCTGCATCC
>LP822564.1 Sequence 293 from Patent WO2018067331
GGTGCATCC
>LP822540.1 Sequence 269 from Patent WO2018067331
GGTGCATCC
>LP822516.1 Sequence 245 from Patent WO2018067331
GGTGCATCC
>LP822500.1 Sequence 229 from Patent WO2018067331
GGTGCATCC
>LP822484.1 Sequence 213 from Patent WO2018067331
GATGCATCC
>LP822460.1 Sequence 189 from Patent WO2018067331
GGTGCATCC
>LP822444.1 Sequence 173 from Patent WO2018067331
GGTGCATCC
>LP822428.1 Sequence 157 from Patent WO2018067331
GGTGCATCC
>LP822412.1 Sequence 141 from Patent WO2018067331
GGTATATCC
>LP822396.1 Sequence 125 from Patent WO2018067331
GGTGCATCC
>LP822380.1 Sequence 109 from Patent WO2018067331
GGTGCATCC
>LP822364.1 Sequence 93 from Patent WO2018067331
GCTGCATCC
>LP822348.1 Sequence 77 from Patent WO2018067331
GCTGCATCC
>LP822332.1 Sequence 61 from Patent WO2018067331
ACTGCATCC
>LP822316.1 Sequence 45 from Patent WO2018067331
ACTGCATCC
>LP822300.1 Sequence 29 from Patent WO2018067331
ACTGCATCC
>LP822284.1 Sequence 13 from Patent WO2018067331
GCTGCATCC
>LP938318.1 Sequence 27 from Patent EP3184674
AATTCCGCT
>LP938317.1 Sequence 26 from Patent EP3184674
GTCTTGCCG
>LP989402.1 Sequence 41 from Patent WO2017123804
AGCTTCTTG
>LP754760.1 Sequence 36 from Patent WO2018026976
CCCTCAAAG
>LP818412.1 Sequence 589 from Patent WO2018044640
GATGCATCC
>LP818396.1 Sequence 573 from Patent WO2018044640
GCTGCATCC
>LP818380.1 Sequence 557 from Patent WO2018044640
GATTCATCC
>LP818364.1 Sequence 541 from Patent WO2018044640
GGTGCATCC
>LP818348.1 Sequence 525 from Patent WO2018044640
GCTGCATCC
>LP818332.1 Sequence 509 from Patent WO2018044640
GATGCATCC
>LP818316.1 Sequence 493 from Patent WO2018044640
GCTGCATCC
>LP818300.1 Sequence 477 from Patent WO2018044640
GATGCATCC
>LP818284.1 Sequence 461 from Patent WO2018044640
GCTGCATCC
>LP818268.1 Sequence 445 from Patent WO2018044640
GATGCATCC
>LP818252.1 Sequence 429 from Patent WO2018044640
GCTGCATCC
>LP818236.1 Sequence 413 from Patent WO2018044640
GATTCATCC
>LP818220.1 Sequence 397 from Patent WO2018044640
GGTGCATCC
>LP818204.1 Sequence 381 from Patent WO2018044640
GCTGCATCC
>LP818188.1 Sequence 365 from Patent WO2018044640
GATGCATCC
>LP818172.1 Sequence 349 from Patent WO2018044640
GCTGCATCC
>LP818156.1 Sequence 333 from Patent WO2018044640
GGTGCATCC
>LP818140.1 Sequence 317 from Patent WO2018044640
GTTGCATCC
>LP818124.1 Sequence 301 from Patent WO2018044640
GATGCATTC
>LP818108.1 Sequence 285 from Patent WO2018044640
GTTGTATCC
>LP818092.1 Sequence 269 from Patent WO2018044640
GCTGCATCC
>LP818076.1 Sequence 253 from Patent WO2018044640
GATGCATCC
>LP818060.1 Sequence 237 from Patent WO2018044640
GCTGCATCC
>LP818044.1 Sequence 221 from Patent WO2018044640
TTGGGTTCT
>LP818028.1 Sequence 205 from Patent WO2018044640
TATGTTTCC
>LP818012.1 Sequence 189 from Patent WO2018044640
GCTGCATCC
>LP817996.1 Sequence 173 from Patent WO2018044640
GTTGTATCA
>LP817980.1 Sequence 157 from Patent WO2018044640
GATGCATCC
>LP817964.1 Sequence 141 from Patent WO2018044640
GCTGCATCC
>LP817948.1 Sequence 125 from Patent WO2018044640
GATGCATCC
>LP817932.1 Sequence 109 from Patent WO2018044640
GATGCATCC
>LP817916.1 Sequence 93 from Patent WO2018044640
GATGCATCC
>LP817900.1 Sequence 77 from Patent WO2018044640
GATGCATCC
>LP817884.1 Sequence 61 from Patent WO2018044640
GATGCATCC
>LP817868.1 Sequence 45 from Patent WO2018044640
GCTGCATCC
>LP817852.1 Sequence 29 from Patent WO2018044640
TCTGCATCC
>LP817836.1 Sequence 13 from Patent WO2018044640
GATGCATCC
>LP933812.1 Sequence 76 from Patent WO2017122096
AGAACCTGG
>LP933802.1 Sequence 66 from Patent WO2017122096
AGAACCTGG
>LP933790.1 Sequence 54 from Patent WO2017122096
GTTGGAAAG
>LP874866.1 Sequence 42 from Patent WO2017106290
TATCCCAAC
>LP874860.1 Sequence 36 from Patent WO2017106290
TTGTATGCG
>LP814859.1 Sequence 305 from Patent WO2018044903
TGGGCATCT
>LP814843.1 Sequence 289 from Patent WO2018044903
TGGGCATCT
>LP814827.1 Sequence 273 from Patent WO2018044903
TGGGCATCT
>LP814811.1 Sequence 257 from Patent WO2018044903
TGGGCATCT
>LP814795.1 Sequence 241 from Patent WO2018044903
TGGGCATCT
>LP814779.1 Sequence 225 from Patent WO2018044903
TGGGCATCT
>LP814763.1 Sequence 209 from Patent WO2018044903
TGGGCATCT
>LP814747.1 Sequence 193 from Patent WO2018044903
TGGGCATCT
>LP814731.1 Sequence 177 from Patent WO2018044903
TGGGCATCT
>LP814715.1 Sequence 161 from Patent WO2018044903
TGGGCATCT
>LP814695.1 Sequence 141 from Patent WO2018044903
ACTGCATTC
>LP814675.1 Sequence 121 from Patent WO2018044903
GCTGCATCC
>LP814655.1 Sequence 101 from Patent WO2018044903
GCTACATCC
>LP814635.1 Sequence 81 from Patent WO2018044903
GCTGCATCC
>LP814615.1 Sequence 61 from Patent WO2018044903
ACTGCATCC
>LP814599.1 Sequence 45 from Patent WO2018044903
TTGGGTTCT
>LP814583.1 Sequence 29 from Patent WO2018044903
TTGGGTTCT
>LP814567.1 Sequence 13 from Patent WO2018044903
TTGGGTTCT
>LP813638.1 Sequence 110 from Patent EP3307319
GGTAAAAAC
>LP813632.1 Sequence 104 from Patent EP3307319
GATGATGAC
>LP813626.1 Sequence 98 from Patent EP3307319
GGTAAAAAC
>LP813620.1 Sequence 92 from Patent EP3307319
TATAATAAC
>LP813614.1 Sequence 86 from Patent EP3307319
GATGTCAGT
>LP813608.1 Sequence 80 from Patent EP3307319
TATAATACT
>LP813602.1 Sequence 74 from Patent EP3307319
TATGATAGC
>LP748318.1 Sequence 213 from Patent WO2018009732
GGTGCATCC
>LP748254.1 Sequence 149 from Patent WO2018009732
GGGGCAAGT
>LP748198.1 Sequence 93 from Patent WO2018009732
GCTGCATCC
>LP748182.1 Sequence 77 from Patent WO2018009732
GATGCATCC
>LP748166.1 Sequence 61 from Patent WO2018009732
GATGCTTCC
>LP748150.1 Sequence 45 from Patent WO2018009732
GAGACATCC
>LP748134.1 Sequence 29 from Patent WO2018009732
GCTGCATCC
>LP748118.1 Sequence 13 from Patent WO2018009732
TGGGCATCT
>LP986747.1 Sequence 385 from Patent EP3201339
CAGGTAAGT
>LP869841.1 Sequence 16 from Patent EP3192529
TATGCTTCT
>LP927952.1 Sequence 326 from Patent EP3223848
TCTGCATCC
>LP927930.1 Sequence 304 from Patent EP3223848
AGCGCTTCC
>LP927892.1 Sequence 266 from Patent EP3223848
AGCGCCTCC
>LP927826.1 Sequence 200 from Patent EP3223848
AGTGCATCA
>LP927804.1 Sequence 178 from Patent EP3223848
TCTGCATCC
>LP927782.1 Sequence 156 from Patent EP3223848
TCTGCATCC
>LP927748.1 Sequence 122 from Patent EP3223848
AGCGCCTCC
>LP927704.1 Sequence 78 from Patent EP3223848
AGCGCCTCC
>LP927692.1 Sequence 66 from Patent EP3223848
AGTGCATCA
>LP927680.1 Sequence 54 from Patent EP3223848
AGTGCATCA
>LP927668.1 Sequence 42 from Patent EP3223848
AGCGCCTCC
>LP868632.1 Sequence 140 from Patent EP3222715
GAAGCAGCA
>LP868550.1 Sequence 58 from Patent EP3222715
GGAGAAAGG
>LP742691.1 Sequence 111 from Patent EP3298171
CTGAGTCGH
>LP742673.1 Sequence 93 from Patent EP3298171
CTGAGTCGH
>LP742663.1 Sequence 83 from Patent EP3298171
CTGAGTCGG
>LP742653.1 Sequence 73 from Patent EP3298171
CTGAGTCGH
>LP742619.1 Sequence 39 from Patent EP3298171
GATCGGAAH
>LP742609.1 Sequence 29 from Patent EP3298171
GATCGGAAH
>LP742603.1 Sequence 23 from Patent EP3298171
GATCGGAAG
>LP742598.1 Sequence 18 from Patent EP3298171
GATCGGAAH
>LP742412.1 Sequence 9 from Patent EP3274293
ANNNNNNNG
>LP806545.1 Sequence 23 from Patent EP3266871
GCGNNACGC
>LP806524.1 Sequence 2 from Patent EP3266871
GCCGAAGGC
>LP806523.1 Sequence 1 from Patent EP3266871
CGCGAAGCG
>LP920802.1 Sequence 4 from Patent EP3240795
TGGCTGAGG
>LP805439.1 Sequence 9 from Patent EP3265561
AACAATCGT
>LP918281.1 Sequence 9 from Patent EP3241900
GTCCAGAAC
>LP918280.1 Sequence 8 from Patent EP3241900
GACCAGAAC
>LP983218.1 Sequence 31 from Patent WO2017102523
TTTTTTTAT
>LP983217.1 Sequence 30 from Patent WO2017102523
TTTTATTTT
>LP983216.1 Sequence 29 from Patent WO2017102523
ATTTAAAAT
>LP983215.1 Sequence 28 from Patent WO2017102523
ATTTATAAT
>LP983214.1 Sequence 27 from Patent WO2017102523
TATTATGTT
>LP983213.1 Sequence 26 from Patent WO2017102523
TATTAAAAT
>LP983212.1 Sequence 25 from Patent WO2017102523
TAATATAAT
>LP983211.1 Sequence 24 from Patent WO2017102523
TATTATAAT
>LP983210.1 Sequence 23 from Patent WO2017102523
TGTTATTAA
>LP983209.1 Sequence 22 from Patent WO2017102523
TGATATCAT
>LP983208.1 Sequence 21 from Patent WO2017102523
TGTTATGAT
>LP983207.1 Sequence 20 from Patent WO2017102523
TGTTATAAT
>LP983206.1 Sequence 19 from Patent WO2017102523
TGTTATCAT
>LP983136.1 Sequence 167 from Patent WO2017143042
AGAGAAAGA
>LP983134.1 Sequence 165 from Patent WO2017143042
AGAAAAAAG
>LP983101.1 Sequence 132 from Patent WO2017143042
TNTTNTTNT
>LP983088.1 Sequence 119 from Patent WO2017143042
TNTNTTTNT
>LP983083.1 Sequence 114 from Patent WO2017143042
TCTTTCTCT
>LP983082.1 Sequence 113 from Patent WO2017143042
TCTCTTTCT
>LP983075.1 Sequence 106 from Patent WO2017143042
TTNNTNTTT
>LP983058.1 Sequence 89 from Patent WO2017143042
CTTTCCCTT
>LP983057.1 Sequence 88 from Patent WO2017143042
TTCCCTTTC
>LP983049.1 Sequence 80 from Patent WO2017143042
AAGGGAAAG
>LP983047.1 Sequence 78 from Patent WO2017143042
CTTTCCCTT
>LP983007.1 Sequence 38 from Patent WO2017143042
TTNTTNTTT
>LP983005.1 Sequence 36 from Patent WO2017143042
TNTTTTNTT
>LP982962.1 Sequence 167 from Patent WO2017143061
AGAGAAAGA
>LP982927.1 Sequence 132 from Patent WO2017143061
TNTTNTTNT
>LP982914.1 Sequence 119 from Patent WO2017143061
TNTNTTTNT
>LP982909.1 Sequence 114 from Patent WO2017143061
TCTTTCTCT
>LP982908.1 Sequence 113 from Patent WO2017143061
TCTCTTTCT
>LP982901.1 Sequence 106 from Patent WO2017143061
TTNNTNTTT
>LP982884.1 Sequence 89 from Patent WO2017143061
CTTTCCCTT
>LP982883.1 Sequence 88 from Patent WO2017143061
TTCCCTTTC
>LP917679.1 Sequence 50 from Patent WO2017153982
TTTGTGTAG
>LP917678.1 Sequence 49 from Patent WO2017153982
TTCAAGAGA
>LP982875.1 Sequence 80 from Patent WO2017143061
AAGGGAAAG
>LP982873.1 Sequence 78 from Patent WO2017143061
CTTTCCCTT
>LP982834.1 Sequence 38 from Patent WO2017143061
TTNTTNTTT
>LP982832.1 Sequence 36 from Patent WO2017143061
TNTTTTNTT
>LP859119.1 Sequence 195 from Patent WO2017141208
TGGGCCTCT
>LP859107.1 Sequence 183 from Patent WO2017141208
TGGGCCTCT
>LP797227.1 Sequence 18 from Patent WO2018071493
GCCGCCACC
>LP910598.1 Sequence 3 from Patent EP3218519
CAGCAGCAG
>LP732348.1 Sequence 768 from Patent WO2018003727
GTCACGTAA
>LP732347.1 Sequence 767 from Patent WO2018003727
ATTGTCGCA
>LP732346.1 Sequence 766 from Patent WO2018003727
TGTACCGTT
>LP732345.1 Sequence 765 from Patent WO2018003727
ATAGACGCA
>LP732344.1 Sequence 764 from Patent WO2018003727
GATAGTGTG
>LP732343.1 Sequence 763 from Patent WO2018003727
TAATTGCGC
>LP732342.1 Sequence 762 from Patent WO2018003727
TGTCCTGTT
>LP732341.1 Sequence 761 from Patent WO2018003727
CCATGTACT
>LP732340.1 Sequence 760 from Patent WO2018003727
ATTCGCACA
>LP732339.1 Sequence 759 from Patent WO2018003727
AATCAGGAC
>LP732338.1 Sequence 758 from Patent WO2018003727
TTGAACGCT
>LP732337.1 Sequence 757 from Patent WO2018003727
AACATTGCG
>LP732336.1 Sequence 756 from Patent WO2018003727
TGTACGTCT
>LP732335.1 Sequence 755 from Patent WO2018003727
GAATGTCAC
>LP732334.1 Sequence 754 from Patent WO2018003727
TAGAACGGT
>LP732333.1 Sequence 753 from Patent WO2018003727
AACTACGGT
>LP732332.1 Sequence 752 from Patent WO2018003727
TACTTACGC
>LP732331.1 Sequence 751 from Patent WO2018003727
ATACAGCAC
>LP732330.1 Sequence 750 from Patent WO2018003727
ATGTCGACA
>LP732329.1 Sequence 749 from Patent WO2018003727
GTCGTATAC
>LP732328.1 Sequence 748 from Patent WO2018003727
GAACGTTAC
>LP732327.1 Sequence 747 from Patent WO2018003727
TATCACGTG
>LP732326.1 Sequence 746 from Patent WO2018003727
CGTATACCT
>LP732325.1 Sequence 745 from Patent WO2018003727
CATAACGAG
>LP732324.1 Sequence 744 from Patent WO2018003727
TACTAACCG
>LP732323.1 Sequence 743 from Patent WO2018003727
TGTCACAGA
>LP732322.1 Sequence 742 from Patent WO2018003727
GAGCGATTA
>LP732321.1 Sequence 741 from Patent WO2018003727
GATGCGATA
>LP732320.1 Sequence 740 from Patent WO2018003727
GATGACGTA
>LP732319.1 Sequence 739 from Patent WO2018003727
TATGTGCAC
>LP732318.1 Sequence 738 from Patent WO2018003727
AATTCACGC
>LP732317.1 Sequence 737 from Patent WO2018003727
ATACAGTCC
>LP732316.1 Sequence 736 from Patent WO2018003727
CGAGAGTAT
>LP732315.1 Sequence 735 from Patent WO2018003727
GGTCGTTAT
>LP732314.1 Sequence 734 from Patent WO2018003727
CTGTTATCG
>LP732313.1 Sequence 733 from Patent WO2018003727
GACACTGAA
>LP732312.1 Sequence 732 from Patent WO2018003727
GTGTTAACG
>LP732311.1 Sequence 731 from Patent WO2018003727
TTCGCGTTA
>LP732310.1 Sequence 730 from Patent WO2018003727
TGCCTTACA
>LP732309.1 Sequence 729 from Patent WO2018003727
GAGCGTTAT
>LP732308.1 Sequence 728 from Patent WO2018003727
TGCATAGTG
>LP732307.1 Sequence 727 from Patent WO2018003727
TAAGACGGT
>LP732306.1 Sequence 726 from Patent WO2018003727
CATCATGTC
>LP732305.1 Sequence 725 from Patent WO2018003727
TCGTTAGTC
>LP732304.1 Sequence 724 from Patent WO2018003727
AATCACGTG
>LP732303.1 Sequence 723 from Patent WO2018003727
AATGCCGTA
>LP732302.1 Sequence 722 from Patent WO2018003727
TAAGACACG
>LP732301.1 Sequence 721 from Patent WO2018003727
ATCACCGTA
>LP732300.1 Sequence 720 from Patent WO2018003727
ACTTAGACG
>LP732299.1 Sequence 719 from Patent WO2018003727
ATATCTGCG
>LP732298.1 Sequence 718 from Patent WO2018003727
GATAAGCGT
>LP732297.1 Sequence 717 from Patent WO2018003727
ATGCGCATA
>LP732296.1 Sequence 716 from Patent WO2018003727
CCGATAACA
>LP732295.1 Sequence 715 from Patent WO2018003727
TATGACGCA
>LP732294.1 Sequence 714 from Patent WO2018003727
CTACGTTGT
>LP732293.1 Sequence 713 from Patent WO2018003727
ATAACGTGC
>LP732292.1 Sequence 712 from Patent WO2018003727
ATGCCGTTA
>LP732291.1 Sequence 711 from Patent WO2018003727
GTAATCGTG
>LP732290.1 Sequence 710 from Patent WO2018003727
ACTTAGCGT
>LP732289.1 Sequence 709 from Patent WO2018003727
ATCACGTGT
>LP732288.1 Sequence 708 from Patent WO2018003727
GTACCTTAG
>LP732287.1 Sequence 707 from Patent WO2018003727
GTAATCGAG
>LP732286.1 Sequence 706 from Patent WO2018003727
TGTCCGTAA
>LP732285.1 Sequence 705 from Patent WO2018003727
TGCGACTTA
>LP732284.1 Sequence 704 from Patent WO2018003727
AGACTGTAC
>LP732283.1 Sequence 703 from Patent WO2018003727
GAGTGTTAC
>LP732282.1 Sequence 702 from Patent WO2018003727
GTCGTGCAT
>LP732281.1 Sequence 701 from Patent WO2018003727
TGCACGTAC
>LP732280.1 Sequence 700 from Patent WO2018003727
ATCGTCAGG
>LP732279.1 Sequence 699 from Patent WO2018003727
TACACTGCG
>LP732278.1 Sequence 698 from Patent WO2018003727
GACGTCTGA
>LP732277.1 Sequence 697 from Patent WO2018003727
ATGTCGACG
>LP732276.1 Sequence 696 from Patent WO2018003727
ATGGTGAGG
>LP732275.1 Sequence 695 from Patent WO2018003727
CTCGAGATC
>LP732274.1 Sequence 694 from Patent WO2018003727
ATACCTGGC
>LP732273.1 Sequence 693 from Patent WO2018003727
TATAAGCGT
>LP732272.1 Sequence 692 from Patent WO2018003727
AAGACGTTA
>LP732271.1 Sequence 691 from Patent WO2018003727
TAGGACAAT
>LP732270.1 Sequence 690 from Patent WO2018003727
ATTAACGCT
>LP732269.1 Sequence 689 from Patent WO2018003727
TATGACACT
>LP732268.1 Sequence 688 from Patent WO2018003727
TTAGCGTTA
>LP732267.1 Sequence 687 from Patent WO2018003727
AGTATACAC
>LP732266.1 Sequence 686 from Patent WO2018003727
ATTATGCGA
>LP732265.1 Sequence 685 from Patent WO2018003727
ATGACGTTA
>LP732264.1 Sequence 684 from Patent WO2018003727
AGTAACTGT
>LP732263.1 Sequence 683 from Patent WO2018003727
ATATCTACG
>LP732262.1 Sequence 682 from Patent WO2018003727
CATATTACG
>LP732261.1 Sequence 681 from Patent WO2018003727
ACATTAAGC
>LP732260.1 Sequence 680 from Patent WO2018003727
ACTGCATTA
>LP732259.1 Sequence 679 from Patent WO2018003727
TATACACTG
>LP732258.1 Sequence 678 from Patent WO2018003727
GACTGTAAT
>LP732257.1 Sequence 677 from Patent WO2018003727
CACACTTAT
>LP732256.1 Sequence 676 from Patent WO2018003727
TCAATAACG
>LP732255.1 Sequence 675 from Patent WO2018003727
CAGTATGTA
>LP732254.1 Sequence 674 from Patent WO2018003727
TAACGTATG
>LP732253.1 Sequence 673 from Patent WO2018003727
TTGCTACAT
>LP793096.1 Sequence 3 from Patent EP3289064
AGCGTGTAA
>LP968449.1 Sequence 11 from Patent EP3250677
GTGGGCTTC
>LP968448.1 Sequence 10 from Patent EP3250677
GAGTGCAAC
>LP792802.1 Sequence 58 from Patent EP3288568
AGGAAAAAC
>LP967346.1 Sequence 43 from Patent EP3194595
CTTTACAAA
>LP967342.1 Sequence 39 from Patent EP3194595
GCATTATCC
>LP967341.1 Sequence 38 from Patent EP3194595
GCATTATCC
>LP967325.1 Sequence 22 from Patent EP3194595
TTTACAAAA
>LP967324.1 Sequence 21 from Patent EP3194595
CTTTACAAA
>LP967323.1 Sequence 20 from Patent EP3194595
CTTGTAAAA
>LP904590.1 Sequence 54 from Patent EP3231866
AGCNGCAGC
>LP790489.1 Sequence 7 from Patent EP3272872
CCTGTTAAG
>LP964333.1 Sequence 40 from Patent WO2017177131
CTTCCCTTC
>LP964317.1 Sequence 24 from Patent WO2017177131
GTCGTCGTC
>LP787818.1 Sequence 1717 from Patent WO2018058001
GGTGCATCC
>LP787802.1 Sequence 1701 from Patent WO2018058001
GGTGCATCC
>LP787786.1 Sequence 1685 from Patent WO2018058001
GGTGCATCC
>LP787770.1 Sequence 1669 from Patent WO2018058001
GGTGCATCC
>LP787754.1 Sequence 1653 from Patent WO2018058001
GGTGCATCC
>LP787738.1 Sequence 1637 from Patent WO2018058001
GCTGCATCC
>LP787538.1 Sequence 1437 from Patent WO2018058001
GTTGCATCC
>LP901956.1 Sequence 13 from Patent EP3180464
ACCCGGTGA
>LP901950.1 Sequence 7 from Patent EP3180464
GCCAATATT
>LP787522.1 Sequence 1421 from Patent WO2018058001
ACTGCATCC
>LP787506.1 Sequence 1405 from Patent WO2018058001
ACTGCATCC
>LP787490.1 Sequence 1389 from Patent WO2018058001
GTTGCATCC
>LP787474.1 Sequence 1373 from Patent WO2018058001
GCTGCATCC
>LP787458.1 Sequence 1357 from Patent WO2018058001
ACTGCATCC
>LP787442.1 Sequence 1341 from Patent WO2018058001
GTTGCATCC
>LP787426.1 Sequence 1325 from Patent WO2018058001
ACTGCATCC
>LP787410.1 Sequence 1309 from Patent WO2018058001
ACTGCATCC
>LP787394.1 Sequence 1293 from Patent WO2018058001
ACTGCATCC
>LP787378.1 Sequence 1277 from Patent WO2018058001
GGTGCATCC
>LP787362.1 Sequence 1261 from Patent WO2018058001
ACTGCATCC
>LP787346.1 Sequence 1245 from Patent WO2018058001
TGGGCATCT
>LP787330.1 Sequence 1229 from Patent WO2018058001
AAGGCGTCT
>LP787314.1 Sequence 1213 from Patent WO2018058001
GGTGCGTCC
>LP787298.1 Sequence 1197 from Patent WO2018058001
GGTGCGTCC
>LP787282.1 Sequence 1181 from Patent WO2018058001
GGTGCATCC
>LP787266.1 Sequence 1165 from Patent WO2018058001
GGTGCGTCC
>LP787250.1 Sequence 1149 from Patent WO2018058001
GGTGCGTCC
>LP787234.1 Sequence 1133 from Patent WO2018058001
GGTGCGTCC
>LP787218.1 Sequence 1117 from Patent WO2018058001
GGTGCGTCC
>LP787202.1 Sequence 1101 from Patent WO2018058001
GCTGCATCC
>LP787186.1 Sequence 1085 from Patent WO2018058001
GCTGCGTCC
>LP787170.1 Sequence 1069 from Patent WO2018058001
GCTGCATCC
>LP787154.1 Sequence 1053 from Patent WO2018058001
GCTGCATCC
>LP787138.1 Sequence 1037 from Patent WO2018058001
GCTGCATCC
>LP787122.1 Sequence 1021 from Patent WO2018058001
GCTGCATCC
>LP787106.1 Sequence 1005 from Patent WO2018058001
GCTGCATCC
>LP787090.1 Sequence 989 from Patent WO2018058001
GATGCATCC
>LP787074.1 Sequence 973 from Patent WO2018058001
GCTGTATCC
>LP787058.1 Sequence 957 from Patent WO2018058001
GAAGCTTCT
>LP787042.1 Sequence 941 from Patent WO2018058001
GCTGCTTCC
>LP787026.1 Sequence 925 from Patent WO2018058001
GCTGCATCC
>LP787010.1 Sequence 909 from Patent WO2018058001
GCTGCATCC
>LP786994.1 Sequence 893 from Patent WO2018058001
GCTGCATCC
>LP786978.1 Sequence 877 from Patent WO2018058001
GCTGCATCC
>LP786962.1 Sequence 861 from Patent WO2018058001
GCTGCATCC
>LP786946.1 Sequence 845 from Patent WO2018058001
GCTGCATCC
>LP786930.1 Sequence 829 from Patent WO2018058001
GGTGCAACC
>LP786914.1 Sequence 813 from Patent WO2018058001
GGTGCAACC
>LP786898.1 Sequence 797 from Patent WO2018058001
GGTGCATCC
>LP786882.1 Sequence 781 from Patent WO2018058001
GCTGCATCC
>LP786866.1 Sequence 765 from Patent WO2018058001
TGGGCATCT
>LP786850.1 Sequence 749 from Patent WO2018058001
GGTGCATCC
>LP786834.1 Sequence 733 from Patent WO2018058001
GGTGCATCC
>LP786818.1 Sequence 717 from Patent WO2018058001
GGTGCAACC
>LP786802.1 Sequence 701 from Patent WO2018058001
GGTGCAACC
>LP786786.1 Sequence 685 from Patent WO2018058001
GGTGCATCC
>LP786770.1 Sequence 669 from Patent WO2018058001
GGTGCATCC
>LP786754.1 Sequence 653 from Patent WO2018058001
GGTGCATCC
>LP786738.1 Sequence 637 from Patent WO2018058001
GGTGCATCC
>LP786722.1 Sequence 621 from Patent WO2018058001
GGTGCATCC
>LP786706.1 Sequence 605 from Patent WO2018058001
GGTGCATCC
>LP786690.1 Sequence 589 from Patent WO2018058001
GGTGCATCC
>LP786674.1 Sequence 573 from Patent WO2018058001
GGTGCATCC
>LP786658.1 Sequence 557 from Patent WO2018058001
GGTGCATCC
>LP786642.1 Sequence 541 from Patent WO2018058001
GGTGCATCC
>LP786626.1 Sequence 525 from Patent WO2018058001
GGTGCATCC
>LP786610.1 Sequence 509 from Patent WO2018058001
GATGCATCC
>LP786594.1 Sequence 493 from Patent WO2018058001
GCTGCATCC
>LP786578.1 Sequence 477 from Patent WO2018058001
GCTGCATCC
>LP786562.1 Sequence 461 from Patent WO2018058001
GGTGCATCC
>LP786546.1 Sequence 445 from Patent WO2018058001
GCTGCATCC
>LP786530.1 Sequence 429 from Patent WO2018058001
GGTGCATCC
>LP786514.1 Sequence 413 from Patent WO2018058001
GGTGCATCC
>LP786498.1 Sequence 389 from Patent WO2018058001
AAGGCGTCT
>LP786482.1 Sequence 373 from Patent WO2018058001
AAGGCGTCT
>LP786466.1 Sequence 357 from Patent WO2018058001
AAGGCGTCT
>LP786450.1 Sequence 341 from Patent WO2018058001
GGTGCATCC
>LP786434.1 Sequence 325 from Patent WO2018058001
AAGGCGTCT
>LP786418.1 Sequence 309 from Patent WO2018058001
GCTGCATCC
>LP786402.1 Sequence 293 from Patent WO2018058001
GTTGCATCC
>LP786386.1 Sequence 277 from Patent WO2018058001
GCTGCATCC
>LP786370.1 Sequence 261 from Patent WO2018058001
GCTGCATCC
>LP786354.1 Sequence 245 from Patent WO2018058001
GATGCATCC
>LP786338.1 Sequence 229 from Patent WO2018058001
AAGGCGTCT
>LP786322.1 Sequence 213 from Patent WO2018058001
AAGGCGTCT
>LP786306.1 Sequence 197 from Patent WO2018058001
GGTGCATCC
>LP786290.1 Sequence 181 from Patent WO2018058001
GCTGCATCC
>LP786274.1 Sequence 165 from Patent WO2018058001
GCTGCATCC
>LP786258.1 Sequence 149 from Patent WO2018058001
GCTGCATCC
>LP786242.1 Sequence 133 from Patent WO2018058001
GCTGCATCC
>LP786170.1 Sequence 61 from Patent WO2018058001
GCTGCATCC
>LP786154.1 Sequence 45 from Patent WO2018058001
GGTGCATCC
>LP786138.1 Sequence 29 from Patent WO2018058001
GCTGCATCC
>LP786122.1 Sequence 13 from Patent WO2018058001
GCTGCATCC
>LP786057.1 Sequence 1955 from Patent WO2018058003
GGTGCATCC
>LP786041.1 Sequence 1939 from Patent WO2018058003
GGTGCATCC
>LP785995.1 Sequence 1893 from Patent WO2018058003
ACTGCATCC
>LP785819.1 Sequence 1717 from Patent WO2018058003
GGTGCATCC
>LP785803.1 Sequence 1701 from Patent WO2018058003
GGTGCATCC
>LP785787.1 Sequence 1685 from Patent WO2018058003
GGTGCATCC
>LP785771.1 Sequence 1669 from Patent WO2018058003
GGTGCATCC
>LP785755.1 Sequence 1653 from Patent WO2018058003
GGTGCATCC
>LP785739.1 Sequence 1637 from Patent WO2018058003
GCTGCATCC
>LP785539.1 Sequence 1437 from Patent WO2018058003
GTTGCATCC
>LP785523.1 Sequence 1421 from Patent WO2018058003
ACTGCATCC
>LP785507.1 Sequence 1405 from Patent WO2018058003
ACTGCATCC
>LP785491.1 Sequence 1389 from Patent WO2018058003
GTTGCATCC
>LP785475.1 Sequence 1373 from Patent WO2018058003
GCTGCATCC
>LP785459.1 Sequence 1357 from Patent WO2018058003
ACTGCATCC
>LP785443.1 Sequence 1341 from Patent WO2018058003
GTTGCATCC
>LP785427.1 Sequence 1325 from Patent WO2018058003
ACTGCATCC
>LP785411.1 Sequence 1309 from Patent WO2018058003
ACTGCATCC
>LP785395.1 Sequence 1293 from Patent WO2018058003
ACTGCATCC
>LP785379.1 Sequence 1277 from Patent WO2018058003
GGTGCATCC
>LP785363.1 Sequence 1261 from Patent WO2018058003
ACTGCATCC
>LP784643.1 Sequence 541 from Patent WO2018058003
GGTGCATCC
>LP784627.1 Sequence 525 from Patent WO2018058003
GGTGCATCC
>LP784611.1 Sequence 509 from Patent WO2018058003
GATGCATCC
>LP784595.1 Sequence 493 from Patent WO2018058003
GCTGCATCC
>LP784579.1 Sequence 477 from Patent WO2018058003
GCTGCATCC
>LP784563.1 Sequence 461 from Patent WO2018058003
GGTGCATCC
>LP784547.1 Sequence 445 from Patent WO2018058003
GCTGCATCC
>LP784531.1 Sequence 429 from Patent WO2018058003
GGTGCATCC
>LP784515.1 Sequence 413 from Patent WO2018058003
GGTGCATCC
>LP784499.1 Sequence 397 from Patent WO2018058003
GCTGCATCC
>LP784491.1 Sequence 389 from Patent WO2018058003
TGGGCATCT
>LP784475.1 Sequence 373 from Patent WO2018058003
TGGGCATCT
>LP784459.1 Sequence 357 from Patent WO2018058003
TGGGCATCT
>LP784443.1 Sequence 341 from Patent WO2018058003
GGTGCATCC
>LP784427.1 Sequence 325 from Patent WO2018058003
GCTGCATCC
>LP784411.1 Sequence 309 from Patent WO2018058003
GCTGCATCC
>LP784395.1 Sequence 293 from Patent WO2018058003
GGTGCATCC
>LP784371.1 Sequence 269 from Patent WO2018058003
GGTGCATCC
>LP785347.1 Sequence 1245 from Patent WO2018058003
TGGGCATCT
>LP785331.1 Sequence 1229 from Patent WO2018058003
AAGGCGTCT
>LP785315.1 Sequence 1213 from Patent WO2018058003
GGTGCGTCC
>LP785299.1 Sequence 1197 from Patent WO2018058003
GGTGCGTCC
>LP785283.1 Sequence 1181 from Patent WO2018058003
GGTGCATCC
>LP785267.1 Sequence 1165 from Patent WO2018058003
GGTGCGTCC
>LP785251.1 Sequence 1149 from Patent WO2018058003
GGTGCGTCC
>LP785235.1 Sequence 1133 from Patent WO2018058003
GGTGCGTCC
>LP785219.1 Sequence 1117 from Patent WO2018058003
GGTGCGTCC
>LP785203.1 Sequence 1101 from Patent WO2018058003
GCTGCATCC
>LP785187.1 Sequence 1085 from Patent WO2018058003
GCTGCGTCC
>LP785171.1 Sequence 1069 from Patent WO2018058003
GCTGCATCC
>LP785155.1 Sequence 1053 from Patent WO2018058003
GCTGCATCC
>LP785139.1 Sequence 1037 from Patent WO2018058003
GCTGCATCC
>LP785123.1 Sequence 1021 from Patent WO2018058003
GCTGCATCC
>LP785107.1 Sequence 1005 from Patent WO2018058003
GCTGCATCC
>LP785091.1 Sequence 989 from Patent WO2018058003
GATGCATCC
>LP785075.1 Sequence 973 from Patent WO2018058003
GCTGTATCC
>LP785059.1 Sequence 957 from Patent WO2018058003
GAAGCTTCT
>LP785043.1 Sequence 941 from Patent WO2018058003
GCTGCTTCC
>LP785027.1 Sequence 925 from Patent WO2018058003
GCTGCATCC
>LP785011.1 Sequence 909 from Patent WO2018058003
GCTGCATCC
>LP784995.1 Sequence 893 from Patent WO2018058003
GCTGCATCC
>LP784979.1 Sequence 877 from Patent WO2018058003
GCTGCATCC
>LP784963.1 Sequence 861 from Patent WO2018058003
GCTGCATCC
>LP784947.1 Sequence 845 from Patent WO2018058003
GCTGCATCC
>LP784931.1 Sequence 829 from Patent WO2018058003
GGTGCAACC
>LP784915.1 Sequence 813 from Patent WO2018058003
GGTGCAACC
>LP784899.1 Sequence 797 from Patent WO2018058003
GGTGCATCC
>LP784883.1 Sequence 781 from Patent WO2018058003
GCTGCATCC
>LP784867.1 Sequence 765 from Patent WO2018058003
TGGGCATCT
>LP784851.1 Sequence 749 from Patent WO2018058003
GGTGCATCC
>LP784835.1 Sequence 733 from Patent WO2018058003
GGTGCATCC
>LP784819.1 Sequence 717 from Patent WO2018058003
GGTGCAACC
>LP784803.1 Sequence 701 from Patent WO2018058003
GGTGCAACC
>LP784787.1 Sequence 685 from Patent WO2018058003
GGTGCATCC
>LP784771.1 Sequence 669 from Patent WO2018058003
GGTGCATCC
>LP784755.1 Sequence 653 from Patent WO2018058003
GGTGCATCC
>LP784739.1 Sequence 637 from Patent WO2018058003
GGTGCATCC
>LP784723.1 Sequence 621 from Patent WO2018058003
GGTGCATCC
>LP784707.1 Sequence 605 from Patent WO2018058003
GGTGCATCC
>LP784691.1 Sequence 589 from Patent WO2018058003
GGTGCATCC
>LP784675.1 Sequence 573 from Patent WO2018058003
GGTGCATCC
>LP784659.1 Sequence 557 from Patent WO2018058003
GGTGCATCC
>LP784347.1 Sequence 245 from Patent WO2018058003
GGTGCATCC
>LP784331.1 Sequence 229 from Patent WO2018058003
GGTGCATCC
>LP784315.1 Sequence 213 from Patent WO2018058003
GATGCATCC
>LP784291.1 Sequence 189 from Patent WO2018058003
GGTGCATCC
>LP784275.1 Sequence 173 from Patent WO2018058003
GGTGCATCC
>LP961124.1 Sequence 2 from Patent WO2017214127
CTACTACCT
>LP784259.1 Sequence 157 from Patent WO2018058003
GGTGCATCC
>LP784243.1 Sequence 141 from Patent WO2018058003
GGTATATCC
>LP784227.1 Sequence 125 from Patent WO2018058003
GGTGCATCC
>LP784211.1 Sequence 109 from Patent WO2018058003
GGTGCATCC
>LP784195.1 Sequence 93 from Patent WO2018058003
GCTGCATCC
>LP784179.1 Sequence 77 from Patent WO2018058003
GCTGCATCC
>LP784163.1 Sequence 61 from Patent WO2018058003
ACTGCATCC
>LP784147.1 Sequence 45 from Patent WO2018058003
ACTGCATCC
>LP784131.1 Sequence 29 from Patent WO2018058003
ACTGCATCC
>LP784115.1 Sequence 13 from Patent WO2018058003
GCTGCATCC
>LP782870.1 Sequence 2 from Patent WO2018054571
ACGTTGAAG
>LP782061.1 Sequence 142 from Patent WO2018055503
TGGGCCTCT
>LP781805.1 Sequence 2 from Patent WO2018054964
ATATGGCAA
>LP780088.1 Sequence 349 from Patent WO2018017497
GGTGCATCC
>LP780072.1 Sequence 333 from Patent WO2018017497
GGTGCATCC
>LP780056.1 Sequence 317 from Patent WO2018017497
GGTGCATCC
>LP780040.1 Sequence 301 from Patent WO2018017497
AAGATTTCT
>LP780024.1 Sequence 285 from Patent WO2018017497
GGTGCATCC
>LP780008.1 Sequence 269 from Patent WO2018017497
GGTGCATCC
>LP779992.1 Sequence 253 from Patent WO2018017497
GGTGCATCC
>LP779976.1 Sequence 237 from Patent WO2018017497
GGTGCATCC
>LP779960.1 Sequence 221 from Patent WO2018017497
GGTGCATCT
>LP779944.1 Sequence 205 from Patent WO2018017497
GGTGCGTCC
>LP779928.1 Sequence 189 from Patent WO2018017497
TTTACATCC
>LP779912.1 Sequence 173 from Patent WO2018017497
GGTGCATCC
>LP779896.1 Sequence 157 from Patent WO2018017497
GCTGCATCC
>LP779880.1 Sequence 141 from Patent WO2018017497
GCTGCATCC
>LP779864.1 Sequence 125 from Patent WO2018017497
GCTGCGTCC
>LP779848.1 Sequence 109 from Patent WO2018017497
GATGCATCC
>LP779832.1 Sequence 93 from Patent WO2018017497
GCTGCATCC
>LP779816.1 Sequence 77 from Patent WO2018017497
TCTGCATCC
>LP779800.1 Sequence 61 from Patent WO2018017497
GCTGCATCC
>LP779784.1 Sequence 45 from Patent WO2018017497
GGTGCATCC
>LP779768.1 Sequence 29 from Patent WO2018017497
GCTGCATCC
>LP779752.1 Sequence 13 from Patent WO2018017497
GCTGCATCC
>MA010861.1 WO 2018003220-A/768: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
GTCACGTAA
>MA010860.1 WO 2018003220-A/767: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
ATTGTCGCA
>MA010859.1 WO 2018003220-A/766: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TGTACCGTT
>MA010858.1 WO 2018003220-A/765: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
ATAGACGCA
>MA010857.1 WO 2018003220-A/764: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
GATAGTGTG
>MA010856.1 WO 2018003220-A/763: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TAATTGCGC
>MA010855.1 WO 2018003220-A/762: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TGTCCTGTT
>MA010854.1 WO 2018003220-A/761: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
CCATGTACT
>MA010853.1 WO 2018003220-A/760: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
ATTCGCACA
>MA010852.1 WO 2018003220-A/759: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
AATCAGGAC
>MA010851.1 WO 2018003220-A/758: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TTGAACGCT
>MA010850.1 WO 2018003220-A/757: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
AACATTGCG
>MA010849.1 WO 2018003220-A/756: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TGTACGTCT
>MA010848.1 WO 2018003220-A/755: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
GAATGTCAC
>MA010847.1 WO 2018003220-A/754: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TAGAACGGT
>MA010846.1 WO 2018003220-A/753: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
AACTACGGT
>MA010845.1 WO 2018003220-A/752: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TACTTACGC
>MA010844.1 WO 2018003220-A/751: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
ATACAGCAC
>MA010843.1 WO 2018003220-A/750: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
ATGTCGACA
>MA010842.1 WO 2018003220-A/749: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
GTCGTATAC
>MA010841.1 WO 2018003220-A/748: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
GAACGTTAC
>MA010840.1 WO 2018003220-A/747: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TATCACGTG
>MA010839.1 WO 2018003220-A/746: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
CGTATACCT
>MA010838.1 WO 2018003220-A/745: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
CATAACGAG
>MA010837.1 WO 2018003220-A/744: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TACTAACCG
>MA010836.1 WO 2018003220-A/743: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TGTCACAGA
>MA010835.1 WO 2018003220-A/742: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
GAGCGATTA
>MA010834.1 WO 2018003220-A/741: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
GATGCGATA
>MA010833.1 WO 2018003220-A/740: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
GATGACGTA
>MA010832.1 WO 2018003220-A/739: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TATGTGCAC
>MA010831.1 WO 2018003220-A/738: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
AATTCACGC
>MA010830.1 WO 2018003220-A/737: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
ATACAGTCC
>MA010829.1 WO 2018003220-A/736: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
CGAGAGTAT
>MA010828.1 WO 2018003220-A/735: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
GGTCGTTAT
>MA010827.1 WO 2018003220-A/734: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
CTGTTATCG
>MA010826.1 WO 2018003220-A/733: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
GACACTGAA
>MA010825.1 WO 2018003220-A/732: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
GTGTTAACG
>MA010824.1 WO 2018003220-A/731: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TTCGCGTTA
>MA010823.1 WO 2018003220-A/730: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TGCCTTACA
>MA010822.1 WO 2018003220-A/729: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
GAGCGTTAT
>MA010821.1 WO 2018003220-A/728: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TGCATAGTG
>MA010820.1 WO 2018003220-A/727: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TAAGACGGT
>MA010819.1 WO 2018003220-A/726: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
CATCATGTC
>MA010818.1 WO 2018003220-A/725: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TCGTTAGTC
>MA010817.1 WO 2018003220-A/724: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
AATCACGTG
>MA010816.1 WO 2018003220-A/723: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
AATGCCGTA
>MA010815.1 WO 2018003220-A/722: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TAAGACACG
>MA010814.1 WO 2018003220-A/721: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
ATCACCGTA
>MA010813.1 WO 2018003220-A/720: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
ACTTAGACG
>MA010812.1 WO 2018003220-A/719: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
ATATCTGCG
>MA010811.1 WO 2018003220-A/718: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
GATAAGCGT
>MA010810.1 WO 2018003220-A/717: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
ATGCGCATA
>MA010809.1 WO 2018003220-A/716: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
CCGATAACA
>MA010808.1 WO 2018003220-A/715: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TATGACGCA
>MA010807.1 WO 2018003220-A/714: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
CTACGTTGT
>MA010806.1 WO 2018003220-A/713: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
ATAACGTGC
>MA010805.1 WO 2018003220-A/712: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
ATGCCGTTA
>MA010804.1 WO 2018003220-A/711: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
GTAATCGTG
>MA010803.1 WO 2018003220-A/710: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
ACTTAGCGT
>MA010802.1 WO 2018003220-A/709: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
ATCACGTGT
>MA010801.1 WO 2018003220-A/708: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
GTACCTTAG
>MA010800.1 WO 2018003220-A/707: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
GTAATCGAG
>MA010799.1 WO 2018003220-A/706: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TGTCCGTAA
>MA010798.1 WO 2018003220-A/705: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TGCGACTTA
>MA010797.1 WO 2018003220-A/704: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
AGACTGTAC
>MA010796.1 WO 2018003220-A/703: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
GAGTGTTAC
>MA010795.1 WO 2018003220-A/702: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
GTCGTGCAT
>MA010794.1 WO 2018003220-A/701: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TGCACGTAC
>MA010793.1 WO 2018003220-A/700: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
ATCGTCAGG
>MA010792.1 WO 2018003220-A/699: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TACACTGCG
>MA010791.1 WO 2018003220-A/698: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
GACGTCTGA
>MA010790.1 WO 2018003220-A/697: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
ATGTCGACG
>MA010789.1 WO 2018003220-A/696: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
ATGGTGAGG
>MA010788.1 WO 2018003220-A/695: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
CTCGAGATC
>MA010787.1 WO 2018003220-A/694: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
ATACCTGGC
>MA010786.1 WO 2018003220-A/693: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TATAAGCGT
>MA010785.1 WO 2018003220-A/692: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
AAGACGTTA
>MA010784.1 WO 2018003220-A/691: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TAGGACAAT
>MA010783.1 WO 2018003220-A/690: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
ATTAACGCT
>MA010782.1 WO 2018003220-A/689: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TATGACACT
>MA010781.1 WO 2018003220-A/688: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TTAGCGTTA
>MA010780.1 WO 2018003220-A/687: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
AGTATACAC
>MA010779.1 WO 2018003220-A/686: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
ATTATGCGA
>MA010778.1 WO 2018003220-A/685: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
ATGACGTTA
>MA010777.1 WO 2018003220-A/684: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
AGTAACTGT
>MA010776.1 WO 2018003220-A/683: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
ATATCTACG
>MA010775.1 WO 2018003220-A/682: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
CATATTACG
>MA010774.1 WO 2018003220-A/681: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
ACATTAAGC
>MA010773.1 WO 2018003220-A/680: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
ACTGCATTA
>MA010772.1 WO 2018003220-A/679: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TATACACTG
>MA010771.1 WO 2018003220-A/678: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
GACTGTAAT
>MA010770.1 WO 2018003220-A/677: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
CACACTTAT
>MA010769.1 WO 2018003220-A/676: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TCAATAACG
>MA010768.1 WO 2018003220-A/675: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
CAGTATGTA
>MA010767.1 WO 2018003220-A/674: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TAACGTATG
>MA010766.1 WO 2018003220-A/673: A method for producing a DNA library and a method for analyzing genomic DNA using the DNA library
TTGCTACAT
>MA004775.1 JP 2018008987-A/10: USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS TO TREAT OR PREVENT CHRONIC AND ACUTE FORMS OF DIARRHEA
GGGGACATC
>MA004905.1 JP 2018008987-A/140: USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS TO TREAT OR PREVENT CHRONIC AND ACUTE FORMS OF DIARRHEA
GGGGACATC
>MA004885.1 JP 2018008987-A/120: USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS TO TREAT OR PREVENT CHRONIC AND ACUTE FORMS OF DIARRHEA
GGGGACATC
>MA004875.1 JP 2018008987-A/110: USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS TO TREAT OR PREVENT CHRONIC AND ACUTE FORMS OF DIARRHEA
GGCGACATC
>MA004865.1 JP 2018008987-A/100: USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS TO TREAT OR PREVENT CHRONIC AND ACUTE FORMS OF DIARRHEA
GGGGACATC
>MA004855.1 JP 2018008987-A/90: USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS TO TREAT OR PREVENT CHRONIC AND ACUTE FORMS OF DIARRHEA
GGGGACATC
>MA004845.1 JP 2018008987-A/80: USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS TO TREAT OR PREVENT CHRONIC AND ACUTE FORMS OF DIARRHEA
GGGGACATC
>MA004835.1 JP 2018008987-A/70: USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS TO TREAT OR PREVENT CHRONIC AND ACUTE FORMS OF DIARRHEA
GGGGACATC
>MA004825.1 JP 2018008987-A/60: USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS TO TREAT OR PREVENT CHRONIC AND ACUTE FORMS OF DIARRHEA
GGGGACATC
>MA004815.1 JP 2018008987-A/50: USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS TO TREAT OR PREVENT CHRONIC AND ACUTE FORMS OF DIARRHEA
GGGGACATC
>MA004805.1 JP 2018008987-A/40: USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS TO TREAT OR PREVENT CHRONIC AND ACUTE FORMS OF DIARRHEA
GGGGACATC
>MA004795.1 JP 2018008987-A/30: USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS TO TREAT OR PREVENT CHRONIC AND ACUTE FORMS OF DIARRHEA
GGGGACATC
>MA004785.1 JP 2018008987-A/20: USE OF ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES OR ANTIBODY FRAGMENTS TO TREAT OR PREVENT CHRONIC AND ACUTE FORMS OF DIARRHEA
GGGGACATC
>LZ998870.1 JP 2018000057-A/768: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
GTCACGTAA
>LZ998869.1 JP 2018000057-A/767: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
ATTGTCGCA
>LZ998868.1 JP 2018000057-A/766: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TGTACCGTT
>LZ998867.1 JP 2018000057-A/765: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
ATAGACGCA
>LZ998866.1 JP 2018000057-A/764: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
GATAGTGTG
>LZ998865.1 JP 2018000057-A/763: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TAATTGCGC
>LZ998864.1 JP 2018000057-A/762: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TGTCCTGTT
>LZ998863.1 JP 2018000057-A/761: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
CCATGTACT
>LZ998862.1 JP 2018000057-A/760: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
ATTCGCACA
>LZ998861.1 JP 2018000057-A/759: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
AATCAGGAC
>LZ998860.1 JP 2018000057-A/758: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TTGAACGCT
>LZ998859.1 JP 2018000057-A/757: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
AACATTGCG
>LZ998858.1 JP 2018000057-A/756: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TGTACGTCT
>LZ998857.1 JP 2018000057-A/755: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
GAATGTCAC
>LZ998856.1 JP 2018000057-A/754: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TAGAACGGT
>LZ998855.1 JP 2018000057-A/753: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
AACTACGGT
>LZ998854.1 JP 2018000057-A/752: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TACTTACGC
>LZ998853.1 JP 2018000057-A/751: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
ATACAGCAC
>LZ998852.1 JP 2018000057-A/750: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
ATGTCGACA
>LZ998851.1 JP 2018000057-A/749: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
GTCGTATAC
>LZ998850.1 JP 2018000057-A/748: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
GAACGTTAC
>LZ998849.1 JP 2018000057-A/747: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TATCACGTG
>LZ998848.1 JP 2018000057-A/746: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
CGTATACCT
>LZ998847.1 JP 2018000057-A/745: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
CATAACGAG
>LZ998846.1 JP 2018000057-A/744: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TACTAACCG
>LZ998845.1 JP 2018000057-A/743: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TGTCACAGA
>LZ998844.1 JP 2018000057-A/742: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
GAGCGATTA
>LZ998843.1 JP 2018000057-A/741: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
GATGCGATA
>LZ998842.1 JP 2018000057-A/740: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
GATGACGTA
>LZ998841.1 JP 2018000057-A/739: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TATGTGCAC
>LZ998840.1 JP 2018000057-A/738: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
AATTCACGC
>LZ998839.1 JP 2018000057-A/737: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
ATACAGTCC
>LZ998838.1 JP 2018000057-A/736: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
CGAGAGTAT
>LZ998837.1 JP 2018000057-A/735: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
GGTCGTTAT
>LZ998836.1 JP 2018000057-A/734: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
CTGTTATCG
>LZ998835.1 JP 2018000057-A/733: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
GACACTGAA
>LZ998834.1 JP 2018000057-A/732: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
GTGTTAACG
>LZ998833.1 JP 2018000057-A/731: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TTCGCGTTA
>LZ998832.1 JP 2018000057-A/730: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TGCCTTACA
>LZ998831.1 JP 2018000057-A/729: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
GAGCGTTAT
>LZ998830.1 JP 2018000057-A/728: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TGCATAGTG
>LZ998829.1 JP 2018000057-A/727: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TAAGACGGT
>LZ998828.1 JP 2018000057-A/726: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
CATCATGTC
>LZ998827.1 JP 2018000057-A/725: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TCGTTAGTC
>LZ998826.1 JP 2018000057-A/724: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
AATCACGTG
>LZ998825.1 JP 2018000057-A/723: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
AATGCCGTA
>LZ998824.1 JP 2018000057-A/722: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TAAGACACG
>LZ998823.1 JP 2018000057-A/721: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
ATCACCGTA
>LZ998822.1 JP 2018000057-A/720: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
ACTTAGACG
>LZ998821.1 JP 2018000057-A/719: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
ATATCTGCG
>LZ998820.1 JP 2018000057-A/718: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
GATAAGCGT
>LZ998819.1 JP 2018000057-A/717: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
ATGCGCATA
>LZ998818.1 JP 2018000057-A/716: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
CCGATAACA
>LZ998817.1 JP 2018000057-A/715: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TATGACGCA
>LZ998816.1 JP 2018000057-A/714: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
CTACGTTGT
>LZ998815.1 JP 2018000057-A/713: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
ATAACGTGC
>LZ998814.1 JP 2018000057-A/712: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
ATGCCGTTA
>LZ998813.1 JP 2018000057-A/711: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
GTAATCGTG
>LZ998812.1 JP 2018000057-A/710: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
ACTTAGCGT
>LZ998811.1 JP 2018000057-A/709: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
ATCACGTGT
>LZ998810.1 JP 2018000057-A/708: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
GTACCTTAG
>LZ998809.1 JP 2018000057-A/707: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
GTAATCGAG
>LZ998808.1 JP 2018000057-A/706: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TGTCCGTAA
>LZ998807.1 JP 2018000057-A/705: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TGCGACTTA
>LZ998806.1 JP 2018000057-A/704: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
AGACTGTAC
>LZ998805.1 JP 2018000057-A/703: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
GAGTGTTAC
>LZ998804.1 JP 2018000057-A/702: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
GTCGTGCAT
>LZ998803.1 JP 2018000057-A/701: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TGCACGTAC
>LZ998802.1 JP 2018000057-A/700: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
ATCGTCAGG
>LZ998801.1 JP 2018000057-A/699: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TACACTGCG
>LZ998800.1 JP 2018000057-A/698: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
GACGTCTGA
>LZ998799.1 JP 2018000057-A/697: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
ATGTCGACG
>LZ998798.1 JP 2018000057-A/696: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
ATGGTGAGG
>LZ998797.1 JP 2018000057-A/695: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
CTCGAGATC
>LZ998796.1 JP 2018000057-A/694: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
ATACCTGGC
>LZ998795.1 JP 2018000057-A/693: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TATAAGCGT
>LZ998794.1 JP 2018000057-A/692: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
AAGACGTTA
>LZ998793.1 JP 2018000057-A/691: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TAGGACAAT
>LZ998792.1 JP 2018000057-A/690: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
ATTAACGCT
>LZ998791.1 JP 2018000057-A/689: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TATGACACT
>LZ998790.1 JP 2018000057-A/688: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TTAGCGTTA
>LZ998789.1 JP 2018000057-A/687: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
AGTATACAC
>LZ998788.1 JP 2018000057-A/686: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
ATTATGCGA
>LZ998787.1 JP 2018000057-A/685: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
ATGACGTTA
>LZ998786.1 JP 2018000057-A/684: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
AGTAACTGT
>LZ998785.1 JP 2018000057-A/683: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
ATATCTACG
>LZ998784.1 JP 2018000057-A/682: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
CATATTACG
>LZ998783.1 JP 2018000057-A/681: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
ACATTAAGC
>LZ998782.1 JP 2018000057-A/680: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
ACTGCATTA
>LZ998781.1 JP 2018000057-A/679: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TATACACTG
>LZ998780.1 JP 2018000057-A/678: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
GACTGTAAT
>LZ998779.1 JP 2018000057-A/677: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
CACACTTAT
>LZ998778.1 JP 2018000057-A/676: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TCAATAACG
>LZ998777.1 JP 2018000057-A/675: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
CAGTATGTA
>LZ998776.1 JP 2018000057-A/674: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TAACGTATG
>LZ998775.1 JP 2018000057-A/673: A method for producing a DNA probe and a method for analyzing genomic DNA using the DNA probe
TTGCTACAT
>MA015265.1 JP 2017538401-A/37: T CELL RECEPTORS DIRECTED AGAINST BOB1 AND USES THEREOF
GCTAGCAGA
>MA014907.1 JP 2017536099-A/119: ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF
TGGGCCTCT
>MA014857.1 JP 2017536099-A/69: ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF
TGGGCCTCT
>MA014846.1 JP 2017536099-A/58: ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF
TGGGCATCC
>LZ995362.1 JP 2017533888-A/135: Anti-IL-25 Antibodies and Uses Thereof
GCTGCGTCC
>LZ995354.1 JP 2017533888-A/127: Anti-IL-25 Antibodies and Uses Thereof
TGGGCATCT
>LZ995346.1 JP 2017533888-A/119: Anti-IL-25 Antibodies and Uses Thereof
GATGCATCC
>LZ995338.1 JP 2017533888-A/111: Anti-IL-25 Antibodies and Uses Thereof
TGGGCTTCC
>LZ995330.1 JP 2017533888-A/103: Anti-IL-25 Antibodies and Uses Thereof
TGGGCATCT
>LZ995322.1 JP 2017533888-A/95: Anti-IL-25 Antibodies and Uses Thereof
TGGGCATCT
>LZ995314.1 JP 2017533888-A/87: Anti-IL-25 Antibodies and Uses Thereof
GCTGCATCC
>LZ995306.1 JP 2017533888-A/79: Anti-IL-25 Antibodies and Uses Thereof
TGGGCATCT
>LZ995298.1 JP 2017533888-A/71: Anti-IL-25 Antibodies and Uses Thereof
ACTGCATCC
>LZ995290.1 JP 2017533888-A/63: Anti-IL-25 Antibodies and Uses Thereof
GCTGCATCC
>LZ995282.1 JP 2017533888-A/55: Anti-IL-25 Antibodies and Uses Thereof
GCTGCATCC
>LZ995274.1 JP 2017533888-A/47: Anti-IL-25 Antibodies and Uses Thereof
TCTACATCC
>LZ995266.1 JP 2017533888-A/39: Anti-IL-25 Antibodies and Uses Thereof
TGGTCATCT
>LZ995258.1 JP 2017533888-A/31: Anti-IL-25 Antibodies and Uses Thereof
TGGGCGTCT
>LZ995250.1 JP 2017533888-A/23: Anti-IL-25 Antibodies and Uses Thereof
GCTGCATCC
>LZ995242.1 JP 2017533888-A/15: Anti-IL-25 Antibodies and Uses Thereof
GCTGCATCC
>LZ995234.1 JP 2017533888-A/7: Anti-IL-25 Antibodies and Uses Thereof
GCTGCATCC
>LZ995011.1 JP 2017533695-A/63: Anti-Glucagon Antibodies and Uses Thereof
TGGGCATCT
>LZ995003.1 JP 2017533695-A/55: Anti-Glucagon Antibodies and Uses Thereof
TGGGCATCT
>LZ994995.1 JP 2017533695-A/47: Anti-Glucagon Antibodies and Uses Thereof
TGGGCATCT
>LZ994987.1 JP 2017533695-A/39: Anti-Glucagon Antibodies and Uses Thereof
TGGGCATCT
>LZ994979.1 JP 2017533695-A/31: Anti-Glucagon Antibodies and Uses Thereof
TGGGCATCT
>LZ994971.1 JP 2017533695-A/23: Anti-Glucagon Antibodies and Uses Thereof
TGGGCATCT
>LZ994963.1 JP 2017533695-A/15: Anti-Glucagon Antibodies and Uses Thereof
TGGGCATCT
>LZ994955.1 JP 2017533695-A/7: Anti-Glucagon Antibodies and Uses Thereof
TGGGCATCT
>LZ995027.1 JP 2017533695-A/79: Anti-Glucagon Antibodies and Uses Thereof
TGGGCATCT
>LZ995019.1 JP 2017533695-A/71: Anti-Glucagon Antibodies and Uses Thereof
TGGGCATCT
>LZ992294.1 JP 2017532001-A/381: SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH OPTIMIZED FUNCTIONAL CRISPR-CAS SYSTEMS
GGCTAGTCC
>LZ991075.1 JP 2017213003-A/130: Sequences and their use for detection of Salmonella
GGGCACCTT
>LZ991073.1 JP 2017213003-A/128: Sequences and their use for detection of Salmonella
GCGGTCCGT
>LZ991064.1 JP 2017213003-A/119: Sequences and their use for detection of Salmonella
AAGGTGCCC
>LZ991062.1 JP 2017213003-A/117: Sequences and their use for detection of Salmonella
ACGGACCGC
>LZ989568.1 JP 2017212998-A/37: METHODS OF TRANSCRIPTION ACTIVATOR LIKE EFFECTOR ASSEMBLY
TCTAATGGG
>LZ989567.1 JP 2017212998-A/36: METHODS OF TRANSCRIPTION ACTIVATOR LIKE EFFECTOR ASSEMBLY
TCCAATAAA
>LZ989566.1 JP 2017212998-A/35: METHODS OF TRANSCRIPTION ACTIVATOR LIKE EFFECTOR ASSEMBLY
AATAATAAC
>LZ989565.1 JP 2017212998-A/34: METHODS OF TRANSCRIPTION ACTIVATOR LIKE EFFECTOR ASSEMBLY
TCCCACGAC
>LZ989564.1 JP 2017212998-A/33: METHODS OF TRANSCRIPTION ACTIVATOR LIKE EFFECTOR ASSEMBLY
TCTAACATC
>LY502384.1 KR 1020170020470-A/700: GENOMEWIDE UNBIASED IDENTIFICATION OF DSBS EVALUATED BY SEQUENCING (GUIDE-SEQ)
GGGGAAATA
>LY493338.1 KR 1020170047192-A/37: EBOLA MONOCLONAL ANTIBODIES
GGCACATCC
>LY493322.1 KR 1020170047192-A/13: EBOLA MONOCLONAL ANTIBODIES
GCCACTTCC
>LY493265.1 KR 1020170020703-A/3: ENGINEERED ESCHERICHIA COLI FOR PRODUCING 1,5-PENTANEDIAMINE BY WHOLE-CELL CATALYSIS AND APPLICATION THEREOF
CTAGGAAGT
>LY511471.1 KR 1020170052647-A/121: PRODUCTION OF STEVIOL GLYCOSIDES IN RECOMBINANT HOSTS
CCATCAAGA
>LY510235.1 KR 1020170038121-A/109: FC-FREE ANTIBODIES COMPRISING TWO FAB FRAGMENTS AND METHODS OF USE
TTTGACTAC
>LY508013.1 KR 1020170033439-A/24: TARGETING MICRORNAS FOR METABOLIC DISORDERS
CAATGCTGC
>LY509298.1 KR 1020170042725-A/24: METHODS FOR RAPID AND SENSITIVE DETECTION OF HOTSPOT MUTATIONS
ATGACTTAC
>LY509296.1 KR 1020170042725-A/22: METHODS FOR RAPID AND SENSITIVE DETECTION OF HOTSPOT MUTATIONS
CGGGTCCCC
>LY506519.1 KR 1020170055474-A/5: AN ANTAGONISTIC PD-1 APTAMER AND ITS APPLICATIONS IN CANCER THERAPY RELATED APPLICATIONS
GTACATCAN
>LY506517.1 KR 1020170055474-A/3: AN ANTAGONISTIC PD-1 APTAMER AND ITS APPLICATIONS IN CANCER THERAPY RELATED APPLICATIONS
GTACAGTTN
>LY506515.1 KR 1020170055474-A/1: AN ANTAGONISTIC PD-1 APTAMER AND ITS APPLICATIONS IN CANCER THERAPY RELATED APPLICATIONS
CCATCTCCC
>LZ958327.1 JP 2017197545-A/5722: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES
ATGGCCTAG
>LZ976279.1 JP 2017197545-A/23674: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES
ATGGCCTAG
>LZ941375.1 JP 2016522211-A/367: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
TTGGGTTTT
>LZ941363.1 JP 2016522211-A/355: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
GGTGCATCC
>LZ941351.1 JP 2016522211-A/343: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
AAGGTTTCT
>LZ941339.1 JP 2016522211-A/331: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
AAGGTTTCT
>LZ941327.1 JP 2016522211-A/319: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
AAGGTTTCT
>LZ941315.1 JP 2016522211-A/307: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
GGTGCATCC
>LZ941303.1 JP 2016522211-A/295: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
GATGCATCC
>LZ941795.1 JP 2016524906-A/115: MOLECULAR IDENTIFICATION OF ALLERGY CAUSING MITES BY PCR
CGACCTCAG
>LZ941291.1 JP 2016522211-A/283: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
GGTGCATCC
>LZ941279.1 JP 2016522211-A/271: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
GGTGCATCC
>LZ941267.1 JP 2016522211-A/259: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
TTGGGTTTT
>LZ941255.1 JP 2016522211-A/247: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
GGTGCATCC
>LZ941243.1 JP 2016522211-A/235: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
AAGGCGTCT
>LZ941231.1 JP 2016522211-A/223: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
AAGGCGTCT
>LZ941219.1 JP 2016522211-A/211: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
AAGGCGTCT
>LZ941207.1 JP 2016522211-A/199: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
AAGGCGTCT
>LZ941195.1 JP 2016522211-A/187: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
GGTGCATCC
>LZ941183.1 JP 2016522211-A/175: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
AAGGCGTCT
>LZ941171.1 JP 2016522211-A/163: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
AAGGTTTCT
>LZ941159.1 JP 2016522211-A/151: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
TTGGGTTCT
>LZ941147.1 JP 2016522211-A/139: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
TTGGGTTTT
>LZ941135.1 JP 2016522211-A/127: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
TTGGGTTTT
>LZ941123.1 JP 2016522211-A/115: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
TTGGGTTCT
>LZ941111.1 JP 2016522211-A/103: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
TTGGGTTCT
>LZ941099.1 JP 2016522211-A/91: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
TTGGGTTCT
>LZ941087.1 JP 2016522211-A/79: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
AAGGTTTCT
>LZ941075.1 JP 2016522211-A/67: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
GCTGCATCC
>LZ941063.1 JP 2016522211-A/55: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
GCTGCATCC
>LZ941051.1 JP 2016522211-A/43: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
TGGGCATCT
>LZ941039.1 JP 2016522211-A/31: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
TGGGCCTCT
>LZ941027.1 JP 2016522211-A/19: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
AAGGCGTCT
>LZ941015.1 JP 2016522211-A/7: Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-of-Function Mutations
GGTGCATCC
>LZ985821.1 JP 2017531664-A/11: TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORS
TCGTCGTTT
>LZ985397.1 JP 2017529851-A/3: GLYPICAN-3 SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY
GATCCCAAA
>LZ982524.1 JP 2017206520-A/367: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TTGGGTTTT
>LZ982512.1 JP 2017206520-A/355: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GGTGCATCC
>LZ982500.1 JP 2017206520-A/343: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGTTTCT
>LZ982488.1 JP 2017206520-A/331: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGTTTCT
>LZ982476.1 JP 2017206520-A/319: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGTTTCT
>LZ982428.1 JP 2017206520-A/271: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GGTGCATCC
>LZ982416.1 JP 2017206520-A/259: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TTGGGTTTT
>LZ982404.1 JP 2017206520-A/247: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GGTGCATCC
>LZ982392.1 JP 2017206520-A/235: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGCGTCT
>LZ982380.1 JP 2017206520-A/223: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGCGTCT
>LZ982368.1 JP 2017206520-A/211: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGCGTCT
>LZ982356.1 JP 2017206520-A/199: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGCGTCT
>LZ982344.1 JP 2017206520-A/187: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GGTGCATCC
>LZ982332.1 JP 2017206520-A/175: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGCGTCT
>LZ982320.1 JP 2017206520-A/163: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGTTTCT
>LZ982308.1 JP 2017206520-A/151: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TTGGGTTCT
>LZ982296.1 JP 2017206520-A/139: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TTGGGTTTT
>LZ982284.1 JP 2017206520-A/127: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TTGGGTTTT
>LZ982272.1 JP 2017206520-A/115: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TTGGGTTCT
>LZ982260.1 JP 2017206520-A/103: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TTGGGTTCT
>LZ982248.1 JP 2017206520-A/91: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TTGGGTTCT
>LZ971791.1 JP 2017197545-A/19186: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES
ATGGCCTAG
>LZ255085.1 JP 2016185991-A/53: PEPTIDE OLIGONUCLEOTIDE CONJUGATES
CAGGCAGGC
>LZ255079.1 JP 2016185991-A/47: PEPTIDE OLIGONUCLEOTIDE CONJUGATES
GCAGCAGCA
>LZ255075.1 JP 2016185991-A/43: PEPTIDE OLIGONUCLEOTIDE CONJUGATES
AGCAGCAGC
>LZ255071.1 JP 2016185991-A/39: PEPTIDE OLIGONUCLEOTIDE CONJUGATES
CAGCAGCAG
>LZ967303.1 JP 2017197545-A/14698: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES
ATGGCCTAG
>LZ253829.1 JP 2016180011-A/202: REAGENTS AND METHODS FOR TREATING CANCER
GAAGATGAG
>LZ252574.1 JP 2016179998-A/2: HUMANIZED ANTIBODY AGAINST AMYLOID BETA
GGTGACTAC
>LZ962815.1 JP 2017197545-A/10210: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES
ATGGCTTAG
>LZ247044.1 JP 2016152818-A/180: COMPOSITIONS AND METHOD FOR DETECTING HUMAN PARVOVIRUS NUCLEIC ACID AND FOR DETECTING HEPATITIS A VIRUS NUCLEIC ACIDS IN SINGLE-PLEX OR MULTIPLEX ASSAYS
CATGGACAG
>LZ246848.1 JP 2016146850-A/30: COMPOSITIONS AND METHODS OF USE FOR MGD-CSF IN DISEASE TREATMENT
GCCGCCACC
>LZ246563.1 JP 2016144474-A/333: PRODUCTS AND PROCESSES FOR MULTIPLEX NUCLEIC ACID IDENTIFICATION
TTTCTCCCC
>LZ982236.1 JP 2017206520-A/79: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGTTTCT
>LZ982224.1 JP 2017206520-A/67: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GCTGCATCC
>LZ982464.1 JP 2017206520-A/307: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GGTGCATCC
>LZ982452.1 JP 2017206520-A/295: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GATGCATCC
>LZ982440.1 JP 2017206520-A/283: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GGTGCATCC
>LZ982212.1 JP 2017206520-A/55: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GCTGCATCC
>LZ982200.1 JP 2017206520-A/43: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TGGGCATCT
>LZ982188.1 JP 2017206520-A/31: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
TGGGCCTCT
>LZ982176.1 JP 2017206520-A/19: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
AAGGCGTCT
>LZ982164.1 JP 2017206520-A/7: Methods for Reducing Lipoprotein(a) Levels by Administering an Inhibitor of Proprotein Convertase Subtilisin Kexin-9 (PCSK9)
GGTGCATCC
>LZ952588.1 JP 2017200477-A/2: Polycistronic expression system for bacteria
TAATCCATG
>LZ244204.1 JP 2016121175-A/35: NANOPARTICLE COMPOSITIONS
GGGTTAGGG
>LZ244203.1 JP 2016121175-A/34: NANOPARTICLE COMPOSITIONS
GAGTATGAG
>LZ244196.1 JP 2016121175-A/27: NANOPARTICLE COMPOSITIONS
TTAGGGTTA
>LZ244195.1 JP 2016121175-A/26: NANOPARTICLE COMPOSITIONS
GTTAGGGTT
>LZ233251.1 JP 2017186341-A/643: METHODS FOR USE OF A SPECIFIC ANTI-ANGIOGENIC ADENOVIRAL AGENT
GCTTCTGGA
>LZ233248.1 JP 2017186341-A/640: METHODS FOR USE OF A SPECIFIC ANTI-ANGIOGENIC ADENOVIRAL AGENT
GCTTCTGGA
>LZ230377.1 JP 2017184651-A/60: Method of Discriminating a Cultivar of Hevea brasiliensis and Kit for Discriminating a Cultivar of Hevea brasiliensis
GCCTCCATC
>LZ230376.1 JP 2017184651-A/59: Method of Discriminating a Cultivar of Hevea brasiliensis and Kit for Discriminating a Cultivar of Hevea brasiliensis
CCTCCGTCA
>LZ230372.1 JP 2017184651-A/55: Method of Discriminating a Cultivar of Hevea brasiliensis and Kit for Discriminating a Cultivar of Hevea brasiliensis
CCGCCAATT
>LZ230353.1 JP 2017184651-A/36: Method of Discriminating a Cultivar of Hevea brasiliensis and Kit for Discriminating a Cultivar of Hevea brasiliensis
GCCTGTAGG
>LZ230352.1 JP 2017184651-A/35: Method of Discriminating a Cultivar of Hevea brasiliensis and Kit for Discriminating a Cultivar of Hevea brasiliensis
CCTGTCGGA
>LZ231136.1 JP 2017176165-A/3: METHOD FOR DETERMINING WHETHER OR NOT AQUEOUS SOLUTION CONTAINS TWO OR MORE CANCER CELLS
CCCTAACCC
>LZ227918.1 JP 2017524339-A/139: Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
GCTGCATCC
>LZ227910.1 JP 2017524339-A/131: Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
GGTGCATCC
>LZ227902.1 JP 2017524339-A/123: Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
GCTGCATCC
>LZ227894.1 JP 2017524339-A/115: Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
GATGCATCC
>LZ227886.1 JP 2017524339-A/107: Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
GGTGCATCC
>LZ227878.1 JP 2017524339-A/99: Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
GGTGCATCC
>LZ227834.1 JP 2017524339-A/55: Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
GCTGCATCC
>LZ227826.1 JP 2017524339-A/47: Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
AAGGCGTCT
>LZ227818.1 JP 2017524339-A/39: Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
AAGGCGTCT
>LZ227810.1 JP 2017524339-A/31: Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
GCTGCATCC
>LZ227802.1 JP 2017524339-A/23: Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
AAGGCGTCT
>LZ227794.1 JP 2017524339-A/15: Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
TTGGTTTCT
>LZ227786.1 JP 2017524339-A/7: Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
AAGGCGTCT
>LZ228096.1 JP 2017522005-A/15: HUNTINGTON'S DISEASE THERAPEUTIC COMPOUNDS
TAAACTCGA
>LZ228006.1 JP 2017524339-A/227: Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
GCTGCATCC
>LZ227998.1 JP 2017524339-A/219: Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
GCTGCATCC
>LZ227990.1 JP 2017524339-A/211: Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
GAGGCGTCT
>LZ227982.1 JP 2017524339-A/203: Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
GCTGCATCC
>LZ227974.1 JP 2017524339-A/195: Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
GGTGCATCC
>LZ227966.1 JP 2017524339-A/187: Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
GGTGCATCC
>LZ227958.1 JP 2017524339-A/179: Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
GCTGCATCC
>LZ227950.1 JP 2017524339-A/171: Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
GGTACATCC
>LZ227942.1 JP 2017524339-A/163: Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
AGTGCATCC
>LZ227934.1 JP 2017524339-A/155: Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
GATGCATCC
>LZ227926.1 JP 2017524339-A/147: Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
GCTGCATCC
>LZ227627.1 JP 2017524335-A/3: E. coli engineering bacteria producing 1,5-pentanediamine through whole cell catalysis and application thereof
CTAGGAAGT
>LZ220438.1 JP 2017158565-A/16: Bispecific T cell activating antigen binding molecules
TTCGACTAC
>LZ217064.1 JP 2017519508-A/699: GENOMEWIDE UNBIASED IDENTIFICATION OF DSBS EVALUATED BY SEQUENCING (GUIDE-SEQ)
GGGGAAATA
>LZ186214.1 JP 2017137334-A/140: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>LZ186114.1 JP 2017137334-A/40: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>LZ186194.1 JP 2017137334-A/120: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>LZ186184.1 JP 2017137334-A/110: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGCGACATC
>LZ186174.1 JP 2017137334-A/100: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>LZ186164.1 JP 2017137334-A/90: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>LZ186154.1 JP 2017137334-A/80: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>LZ186144.1 JP 2017137334-A/70: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>LZ186134.1 JP 2017137334-A/60: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>LZ186124.1 JP 2017137334-A/50: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>LZ186104.1 JP 2017137334-A/30: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>LZ186094.1 JP 2017137334-A/20: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>LZ186084.1 JP 2017137334-A/10: USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS
GGGGACATC
>LZ185530.1 JP 2017137329-A/29: BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USE
TTTGACTAC
>LZ178470.1 JP 2017140031-A/30: CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
TGGTGCGTA
>LZ178451.1 JP 2017140031-A/11: CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
TGGTGCGAA
>LX337357.1 JP 2017121240-A/39507: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGATCTAG
>LZ074538.1 JP 2017123847-A/12598: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS
ATGCAGTAG
>LX264238.1 JP 2016034977-A/63: IMMUNOGLOBULIN CHIMERIC MONOMER-DIMER HYBRIDS
GCCGCCACC
>LX485861.1 JP 2017121241-A/139902: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGGGCTAG
>LX336237.1 JP 2017121240-A/38387: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGGCTAG
>LX313393.1 JP 2017121240-A/15543: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGATCTAG
>LX336135.1 JP 2017121240-A/38285: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGCCTAG
>LX335483.1 JP 2017121240-A/37633: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGAAGTAG
>LX312273.1 JP 2017121240-A/14423: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGGCTAG
>LX312171.1 JP 2017121240-A/14321: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGCCTAG
>LX462726.1 JP 2017121241-A/116767: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGAGGTAG
>LX334660.1 JP 2017121240-A/36810: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGTGTAG
>LX334659.1 JP 2017121240-A/36809: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGTGTAG
>LX311519.1 JP 2017121240-A/13669: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGAAGTAG
>LZ070836.1 JP 2017123847-A/8896: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS
ATGCAATAG
>LX310696.1 JP 2017121240-A/12846: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGTGTAG
>LX310695.1 JP 2017121240-A/12845: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGTGTAG
>LZ067134.1 JP 2017123847-A/5194: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS
ATGCAGTAG
>LZ000924.1 JP 2017121241-A/154964: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGCAGTAG
>LX394729.1 JP 2017121241-A/48770: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGCAGTAG
>LZ021260.1 JP 2017121241-A/175300: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGGGCTAG
>LX415065.1 JP 2017121241-A/69106: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGGGCTAG
>LX329369.1 JP 2017121240-A/31519: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGATCTAG
>LX282388.1 JP 2016503069-A/15: New antibody fragments, compositions and uses thereof
GCTGCATCC
>LX282238.1 JP 2016512554-A/175: Human Antibodies to Respiratory Syncytial Virus F Protein and Methods of Use Thereof
TCTACATCC
>LX282230.1 JP 2016512554-A/167: Human Antibodies to Respiratory Syncytial Virus F Protein and Methods of Use Thereof
GGTGCATCC
>LX282222.1 JP 2016512554-A/159: Human Antibodies to Respiratory Syncytial Virus F Protein and Methods of Use Thereof
AAGATTTCT
>LX282214.1 JP 2016512554-A/151: Human Antibodies to Respiratory Syncytial Virus F Protein and Methods of Use Thereof
GGTGCATCC
>LX282206.1 JP 2016512554-A/143: Human Antibodies to Respiratory Syncytial Virus F Protein and Methods of Use Thereof
GGTGCATCC
>LX282198.1 JP 2016512554-A/135: Human Antibodies to Respiratory Syncytial Virus F Protein and Methods of Use Thereof
GGTGCATCC
>LX282190.1 JP 2016512554-A/127: Human Antibodies to Respiratory Syncytial Virus F Protein and Methods of Use Thereof
TTGGGTTCT
>LX282182.1 JP 2016512554-A/119: Human Antibodies to Respiratory Syncytial Virus F Protein and Methods of Use Thereof
GCTGCGTCC
>LX282174.1 JP 2016512554-A/111: Human Antibodies to Respiratory Syncytial Virus F Protein and Methods of Use Thereof
TGGGCATCT
>LX282166.1 JP 2016512554-A/103: Human Antibodies to Respiratory Syncytial Virus F Protein and Methods of Use Thereof
GATGCATCC
>LX282158.1 JP 2016512554-A/95: Human Antibodies to Respiratory Syncytial Virus F Protein and Methods of Use Thereof
GCTGCATCC
>LX282150.1 JP 2016512554-A/87: Human Antibodies to Respiratory Syncytial Virus F Protein and Methods of Use Thereof
TTGGGTTCT
>LX282134.1 JP 2016512554-A/71: Human Antibodies to Respiratory Syncytial Virus F Protein and Methods of Use Thereof
GGTGCATCC
>LX282126.1 JP 2016512554-A/63: Human Antibodies to Respiratory Syncytial Virus F Protein and Methods of Use Thereof
GGTGCATCC
>LX282118.1 JP 2016512554-A/55: Human Antibodies to Respiratory Syncytial Virus F Protein and Methods of Use Thereof
GCTGCATCC
>LX282110.1 JP 2016512554-A/47: Human Antibodies to Respiratory Syncytial Virus F Protein and Methods of Use Thereof
GATGTATCC
>LX282102.1 JP 2016512554-A/39: Human Antibodies to Respiratory Syncytial Virus F Protein and Methods of Use Thereof
GCTGCATCC
>LX282094.1 JP 2016512554-A/31: Human Antibodies to Respiratory Syncytial Virus F Protein and Methods of Use Thereof
GCTTCATCC
>LX282086.1 JP 2016512554-A/23: Human Antibodies to Respiratory Syncytial Virus F Protein and Methods of Use Thereof
GGTGCATCC
>LX282078.1 JP 2016512554-A/15: Human Antibodies to Respiratory Syncytial Virus F Protein and Methods of Use Thereof
GGTGCATCC
>LX282070.1 JP 2016512554-A/7: Human Antibodies to Respiratory Syncytial Virus F Protein and Methods of Use Thereof
GCTGCATCC
>LX282004.1 JP 2016512430-A/408: Human Antibodies to Nav1.7
TTGGGTTCT
>LX281996.1 JP 2016512430-A/400: Human Antibodies to Nav1.7
AAGATTTCT
>LX281988.1 JP 2016512430-A/392: Human Antibodies to Nav1.7
GATGCATCC
>LX281980.1 JP 2016512430-A/384: Human Antibodies to Nav1.7
GATATATCC
>LX281972.1 JP 2016512430-A/376: Human Antibodies to Nav1.7
AAGATTTCT
>LX281964.1 JP 2016512430-A/368: Human Antibodies to Nav1.7
AAGATTTCT
>LX281956.1 JP 2016512430-A/360: Human Antibodies to Nav1.7
AAGATTTCT
>LX328249.1 JP 2017121240-A/30399: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGGCTAG
>LX328147.1 JP 2017121240-A/30297: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGCCTAG
>LX282142.1 JP 2016512554-A/79: Human Antibodies to Respiratory Syncytial Virus F Protein and Methods of Use Thereof
TTGGGTTCT
>LX281411.1 JP 2016510601-A/256: RNASE H-BASED ASSAYS UTILIZING MODIFIED RNA MONOMERS
TAGCTGAAG
>LX281410.1 JP 2016510601-A/255: RNASE H-BASED ASSAYS UTILIZING MODIFIED RNA MONOMERS
AAGCTGAAG
>LX281409.1 JP 2016510601-A/254: RNASE H-BASED ASSAYS UTILIZING MODIFIED RNA MONOMERS
GAGCTGAAG
>LX281408.1 JP 2016510601-A/253: RNASE H-BASED ASSAYS UTILIZING MODIFIED RNA MONOMERS
CAGCTGAAG
>LX391930.1 JP 2017121241-A/45971: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGAGATAG
>LX498124.1 JP 2017121241-A/152165: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGCGGTAG
>LX327495.1 JP 2017121240-A/29645: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGAAGTAG
>LX281008.1 JP 2016508367-A/46: LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES
CAATGTAGC
>LX281003.1 JP 2016508367-A/41: LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES
TGATAAGCT
>LX280998.1 JP 2016508367-A/36: LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES
ACAATGCAC
>LX280997.1 JP 2016508367-A/35: LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES
TACAATGCA
>LX280995.1 JP 2016508367-A/33: LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES
TCACACTCC
>LX280540.1 JP 2016117765-A/34: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
GAGTATGAG
>LX280532.1 JP 2016117765-A/26: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
GTTAGGGTT
>LX280541.1 JP 2016117765-A/35: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
GGGTTAGGG
>LX280533.1 JP 2016117765-A/27: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
TTAGGGTTA
>LX326671.1 JP 2017121240-A/28821: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGTGTAG
>LX326672.1 JP 2017121240-A/28822: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGTGTAG
>LX279306.1 JP 2016105724-A/67: Complexation of nucleic acids with disulfide-linked cationic polymers for transfection and immunostimulation
GGGTTTGGG
>LX279295.1 JP 2016105724-A/56: Complexation of nucleic acids with disulfide-linked cationic polymers for transfection and immunostimulation
GGTTTTTGG
>LZ105731.1 JP 2017516489-A/116: ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF
TACACTAGC
>LZ105720.1 JP 2017516489-A/105: ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF
TACACCTCC
>LZ105709.1 JP 2017516489-A/94: ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF
TATACATCC
>LZ105698.1 JP 2017516489-A/83: ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF
TACACATCA
>LX430127.1 JP 2017121241-A/84168: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGCAGTAG
>LZ103523.1 JP 2017513904-A/2: ANTIBODY-DRUG CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER
TCTGGATCC
>LZ081942.1 JP 2017123847-A/20002: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS
ATGCAGTAG
>LX345345.1 JP 2017121240-A/47495: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGATATAG
>LX450463.1 JP 2017121241-A/104504: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGGGTTAG
>LZ036322.1 JP 2017121241-A/190362: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGCAGTAG
>LX321381.1 JP 2017121240-A/23531: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGATCTAG
>LX344225.1 JP 2017121240-A/46375: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGGATAG
>LX344123.1 JP 2017121240-A/46273: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGCGTAG
>LZ174201.1 JP 2017516494-A/25: MODIFIED THYMINE POLYNUCLEOTIDE OLIGOMERS AND METHODS
CGATACTGC
>LZ174200.1 JP 2017516494-A/24: MODIFIED THYMINE POLYNUCLEOTIDE OLIGOMERS AND METHODS
CGATACTGC
>LZ174199.1 JP 2017516494-A/23: MODIFIED THYMINE POLYNUCLEOTIDE OLIGOMERS AND METHODS
CGATACTGC
>LZ174198.1 JP 2017516494-A/22: MODIFIED THYMINE POLYNUCLEOTIDE OLIGOMERS AND METHODS
CGATACTGC
>LZ173994.1 JP 2017516487-A/138: METHOD FOR IDENTIFICATION AND ENUMERATION OF NUCLEIC ACID SEQUENCE, EXPRESSION, COPY, OR DNA METHYLATION CHANGES, USING COMBINED NUCLEASE, LIGASE, POLYMERASE, AND SEQUENCING REACTIONS
CTCCGACCG
>LX320261.1 JP 2017121240-A/22411: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGGGTAG
>LX320159.1 JP 2017121240-A/22309: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGCGTAG
>LX343471.1 JP 2017121240-A/45621: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGAAGTAG
>LX427328.1 JP 2017121241-A/81369: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGCGTTAG
>LZ056658.1 JP 2017121241-A/210698: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGGGGTAG
>LZ100587.1 JP 2017513813-A/56: ANTIBODIES, USES & METHODS
GCTGCATCC
>LZ100573.1 JP 2017513813-A/42: ANTIBODIES, USES & METHODS
GATGCCTCC
>LZ100557.1 JP 2017513813-A/26: ANTIBODIES, USES & METHODS
GCTGCATCC
>LZ100541.1 JP 2017513813-A/10: ANTIBODIES, USES & METHODS
GCTGCATCC
>LX342648.1 JP 2017121240-A/44798: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGTGTAG
>LX342647.1 JP 2017121240-A/44797: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGTCTAG
>LX319507.1 JP 2017121240-A/21657: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGAAATAG
>LZ078240.1 JP 2017123847-A/16300: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS
ATGCAGTAG
>LZ033523.1 JP 2017121241-A/187563: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGCGGTAG
>LX295713.1 JP 2016519111-A/4: IL4 conjugated to antibodies against extracellular matrix components
ATGCCGTTT
>LX295710.1 JP 2016519111-A/1: IL4 conjugated to antibodies against extracellular matrix components
CTGTTTACG
>LX318684.1 JP 2017121240-A/20834: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGTTTAG
>LX318683.1 JP 2017121240-A/20833: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
ATGGTGTAG
>LX295428.1 JP 2015529449-A/2: DNA-ENCODED LIBRARIES HAVING ENCODING OLIGONUCLEOTIDE LINKAGES NOT READABLE BY POLYMERASES
GCAGCACCC
>LZ098899.1 JP 2017127305-A/8: Prostate-Specific Membrane Antigen Binding Proteins and Related Compositions and Methods
TCTGGATCC
>LX294088.1 JP 2016512691-A/2772: USING TRUNCATED GUIDE RNAS (TRU-GRNAS) TO INCREASE SPECIFICITY FOR RNA-GUIDED GENOME EDITING
TGGGAGGTC
>LX294049.1 JP 2016512691-A/2733: USING TRUNCATED GUIDE RNAS (TRU-GRNAS) TO INCREASE SPECIFICITY FOR RNA-GUIDED GENOME EDITING
CCAAAGCCC
>LX465525.1 JP 2017121241-A/119566: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
ATGCAGTAG
>LY480708.1 KR 1020170005133-A/453: HUMAN ANTIBODIES TO MIDDLE EAST RESPIRATORY SYNDROME -CORONAVIRUS SPIKE PROTEIN
GCTGCATCC
>LY480700.1 KR 1020170005133-A/437: HUMAN ANTIBODIES TO MIDDLE EAST RESPIRATORY SYNDROME -CORONAVIRUS SPIKE PROTEIN
GCTGCATCC
>LY480692.1 KR 1020170005133-A/421: HUMAN ANTIBODIES TO MIDDLE EAST RESPIRATORY SYNDROME -CORONAVIRUS SPIKE PROTEIN
GAGGCGTCT
>LY480684.1 KR 1020170005133-A/405: HUMAN ANTIBODIES TO MIDDLE EAST RESPIRATORY SYNDROME -CORONAVIRUS SPIKE PROTEIN
GCTGCATCC
>LY480676.1 KR 1020170005133-A/389: HUMAN ANTIBODIES TO MIDDLE EAST RESPIRATORY SYNDROME -CORONAVIRUS SPIKE PROTEIN
GGTGCATCC
>LY480668.1 KR 1020170005133-A/373: HUMAN ANTIBODIES TO MIDDLE EAST RESPIRATORY SYNDROME -CORONAVIRUS SPIKE PROTEIN
GGTGCATCC
>LY480660.1 KR 1020170005133-A/357: HUMAN ANTIBODIES TO MIDDLE EAST RESPIRATORY SYNDROME -CORONAVIRUS SPIKE PROTEIN
GCTGCATCC
>LY480652.1 KR 1020170005133-A/341: HUMAN ANTIBODIES TO MIDDLE EAST RESPIRATORY SYNDROME -CORONAVIRUS SPIKE PROTEIN
GGTACATCC
>LY480644.1 KR 1020170005133-A/325: HUMAN ANTIBODIES TO MIDDLE EAST RESPIRATORY SYNDROME -CORONAVIRUS SPIKE PROTEIN
AGTGCATCC
>LY480636.1 KR 1020170005133-A/309: HUMAN ANTIBODIES TO MIDDLE EAST RESPIRATORY SYNDROME -CORONAVIRUS SPIKE PROTEIN
GATGCATCC
>LY480628.1 KR 1020170005133-A/293: HUMAN ANTIBODIES TO MIDDLE EAST RESPIRATORY SYNDROME -CORONAVIRUS SPIKE PROTEIN
GCTGCATCC
>LY480620.1 KR 1020170005133-A/277: HUMAN ANTIBODIES TO MIDDLE EAST RESPIRATORY SYNDROME -CORONAVIRUS SPIKE PROTEIN
GCTGCATCC
>LY480612.1 KR 1020170005133-A/261: HUMAN ANTIBODIES TO MIDDLE EAST RESPIRATORY SYNDROME -CORONAVIRUS SPIKE PROTEIN
GGTGCATCC
>LY480604.1 KR 1020170005133-A/245: HUMAN ANTIBODIES TO MIDDLE EAST RESPIRATORY SYNDROME -CORONAVIRUS SPIKE PROTEIN
GCTGCATCC
>LY480596.1 KR 1020170005133-A/229: HUMAN ANTIBODIES TO MIDDLE EAST RESPIRATORY SYNDROME -CORONAVIRUS SPIKE PROTEIN
GATGCATCC
>LY480588.1 KR 1020170005133-A/213: HUMAN ANTIBODIES TO MIDDLE EAST RESPIRATORY SYNDROME -CORONAVIRUS SPIKE PROTEIN
GGTGCATCC
>LY480580.1 KR 1020170005133-A/197: HUMAN ANTIBODIES TO MIDDLE EAST RESPIRATORY SYNDROME -CORONAVIRUS SPIKE PROTEIN
GGTGCATCC
>LY480536.1 KR 1020170005133-A/109: HUMAN ANTIBODIES TO MIDDLE EAST RESPIRATORY SYNDROME -CORONAVIRUS SPIKE PROTEIN
GCTGCATCC
>LY480528.1 KR 1020170005133-A/93: HUMAN ANTIBODIES TO MIDDLE EAST RESPIRATORY SYNDROME -CORONAVIRUS SPIKE PROTEIN
AAGGCGTCT
>LY480520.1 KR 1020170005133-A/77: HUMAN ANTIBODIES TO MIDDLE EAST RESPIRATORY SYNDROME -CORONAVIRUS SPIKE PROTEIN
AAGGCGTCT
>LY480512.1 KR 1020170005133-A/61: HUMAN ANTIBODIES TO MIDDLE EAST RESPIRATORY SYNDROME -CORONAVIRUS SPIKE PROTEIN
GCTGCATCC
>LY468919.1 KR 1020160138583-A/109: BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USE
TTTGACTAC
>LY411668.1 KR 1020160142360-A/44: HUMANIZED ANTIBODIES THAT BIND LGR5
CTGACCAGC
>LY411662.1 KR 1020160142360-A/32: HUMANIZED ANTIBODIES THAT BIND LGR5
CTGACCTCC
>LY411358.1 KR 1020160127143-A/21: ANTIBODY COMPOSITIONS FOR TUMOR TREATMENT
GGTGCATCC
>LY269607.1 KR 1020160028986-A/12: Oyster peptide for treating or preventing liver disease
AAGTATTGG
>LY269606.1 KR 1020160028986-A/11: Oyster peptide for treating or preventing liver disease
AAGTACTGG
>LY269605.1 KR 1020160028986-A/10: Oyster peptide for treating or preventing liver disease
AAATATTGG
>LY269604.1 KR 1020160028986-A/9: Oyster peptide for treating or preventing liver disease
AAATACTGG
>LY269603.1 KR 1020160028986-A/8: Oyster peptide for treating or preventing liver disease
GTTAAGTGG
>LY269602.1 KR 1020160028986-A/7: Oyster peptide for treating or preventing liver disease
GTGAAGTGG
>LY269601.1 KR 1020160028986-A/6: Oyster peptide for treating or preventing liver disease
GTCAAGTGG
>LY269600.1 KR 1020160028986-A/5: Oyster peptide for treating or preventing liver disease
GTAAAGTGG
>LY269599.1 KR 1020160028986-A/4: Oyster peptide for treating or preventing liver disease
GTTAAATGG
>LY269598.1 KR 1020160028986-A/3: Oyster peptide for treating or preventing liver disease
GTGAAATGG
>LY269597.1 KR 1020160028986-A/2: Oyster peptide for treating or preventing liver disease
GTCAAATGG
>LY269596.1 KR 1020160028986-A/1: Oyster peptide for treating or preventing liver disease
GTAAAATGG
>LY409553.1 KR 1020160135738-A/345: EXPRESSION CONSTRUCTS AND METHODS FOR SELECTING HOST CELLS EXPRESSING POLYPEPTIDES
MAGGTRAGT
>LY330064.1 KR 1020160085324-A/250: METHODS USING MONOVALENT ANTIGEN BINDING CONSTRUCTS TARGETING HER2
AGTGCATCA
>LY330050.1 KR 1020160085324-A/222: METHODS USING MONOVALENT ANTIGEN BINDING CONSTRUCTS TARGETING HER2
TCTGCATCC
>LY330025.1 KR 1020160085324-A/172: METHODS USING MONOVALENT ANTIGEN BINDING CONSTRUCTS TARGETING HER2
AGCGCCTCC
>LY330019.1 KR 1020160085324-A/160: METHODS USING MONOVALENT ANTIGEN BINDING CONSTRUCTS TARGETING HER2
AGCGCCTCC
>LY329996.1 KR 1020160085324-A/114: METHODS USING MONOVALENT ANTIGEN BINDING CONSTRUCTS TARGETING HER2
GACCACACA
>LY329986.1 KR 1020160085324-A/94: METHODS USING MONOVALENT ANTIGEN BINDING CONSTRUCTS TARGETING HER2
AGCGCCTCC
>LY342076.1 KR 1020160093723-A/17: Novel anti ADAM17 antibody and its use for the treatment of cancer
TACACATCA
>LY408678.1 KR 1020160131032-A/3: FURTHER IMPROVED AAV VECTORS PRODUCED IN INSECT CELLS
CCTGTTAAG
>LY285303.1 KR 1020170008181-A/13: Antibody for sperm sexing and use thereof
CTTGTATCC
>LY285301.1 KR 1020170008181-A/11: Antibody for sperm sexing and use thereof
GCAAGACCA
>LY285170.1 KR 1020170000346-A/19: CD154 binding polypeptide and its use
GCTGCAAGC
>LY408424.1 KR 1020160131026-A/141: ANTI-EGFRVIII ANTIBODIES AND USES THEREOF
GCTACATCC
>LY408416.1 KR 1020160131026-A/125: ANTI-EGFRVIII ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY408408.1 KR 1020160131026-A/109: ANTI-EGFRVIII ANTIBODIES AND USES THEREOF
GCTACATCC
>LY408400.1 KR 1020160131026-A/93: ANTI-EGFRVIII ANTIBODIES AND USES THEREOF
AAGGTTTCT
>LY408392.1 KR 1020160131026-A/77: ANTI-EGFRVIII ANTIBODIES AND USES THEREOF
GGTGCATCC
>LY408384.1 KR 1020160131026-A/61: ANTI-EGFRVIII ANTIBODIES AND USES THEREOF
AAGGCGTCT
>LY408376.1 KR 1020160131026-A/45: ANTI-EGFRVIII ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY408368.1 KR 1020160131026-A/29: ANTI-EGFRVIII ANTIBODIES AND USES THEREOF
GCTGCATCC
>LY408360.1 KR 1020160131026-A/13: ANTI-EGFRVIII ANTIBODIES AND USES THEREOF
TGGGCATCT
>LY340674.1 KR 1020160110368-A/77: IMMUNOGENIC COMPOSITIONS AND VACCINES DERIVED FROM BACTERIAL SURFACE RECEPTOR PROTEINS
ATTGATGGG
>LY407784.1 KR 1020160134668-A/182: ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF
TACACTAGC
>LY407773.1 KR 1020160134668-A/171: ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF
TACACCTCC
>LY407762.1 KR 1020160134668-A/160: ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF
TATACATCC
>LY407751.1 KR 1020160134668-A/149: ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF
TACACATCA
>LY284213.1 KR 1020160146588-A/43: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
GNNGTGGNC
>LY284212.1 KR 1020160146588-A/42: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
CTNNGCACN
>LY284211.1 KR 1020160146588-A/41: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
TGNNCNNTT
>LY284210.1 KR 1020160146588-A/40: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
CNTGNNCGA
>LY284209.1 KR 1020160146588-A/39: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
NTNTATTNT
>LY284208.1 KR 1020160146588-A/38: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
CCGGNNGNG
>LY284207.1 KR 1020160146588-A/37: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
GNNCNGATT
>LY284206.1 KR 1020160146588-A/36: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
CNNACNANC
>LY284205.1 KR 1020160146588-A/35: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
TNGNAANTT
>LY284204.1 KR 1020160146588-A/34: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
NTTNGNNTA
>LY284203.1 KR 1020160146588-A/33: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
GCCNACNNT
>LY284202.1 KR 1020160146588-A/32: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
TTGCANNNC
>LY284201.1 KR 1020160146588-A/31: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
GTNCCGCNC
>LY284200.1 KR 1020160146588-A/30: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
CGANCNACC
>LY284199.1 KR 1020160146588-A/29: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
CANNANGNT
>LY284198.1 KR 1020160146588-A/28: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
TNCGNATTN
>LY284197.1 KR 1020160146588-A/27: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
NACACNNAA
>LY284196.1 KR 1020160146588-A/26: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
GANNCCGGC
>LY284195.1 KR 1020160146588-A/25: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
TNANTNGAC
>LY284194.1 KR 1020160146588-A/24: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
GCGGTTTTN
>LY284193.1 KR 1020160146588-A/23: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
GCAAAAANN
>LY284192.1 KR 1020160146588-A/22: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
AGTNCANNG
>LY284191.1 KR 1020160146588-A/21: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
CACCTNTNC
>LY284190.1 KR 1020160146588-A/20: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
GCCNACNNT
>LY284189.1 KR 1020160146588-A/19: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
ANNAANGCN
>LY284188.1 KR 1020160146588-A/18: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
ANATATNNG
>LY284187.1 KR 1020160146588-A/17: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
NTTNCGTNG
>LY284186.1 KR 1020160146588-A/16: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
ATTNNCNTG
>LY284185.1 KR 1020160146588-A/15: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
NTNNNGAGC
>LY284184.1 KR 1020160146588-A/14: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
NTGCCNGCG
>LY284183.1 KR 1020160146588-A/13: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
GGGNCGNNG
>LY284182.1 KR 1020160146588-A/12: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
TGCNAAGNN
>LY284181.1 KR 1020160146588-A/11: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
ANCAGCATG
>LY284180.1 KR 1020160146588-A/10: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
CANANATNN
>LY284179.1 KR 1020160146588-A/9: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
GGGNANNCA
>LY284178.1 KR 1020160146588-A/8: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
TTGCANATT
>LY284177.1 KR 1020160146588-A/7: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
GTNNANGAT
>LY284176.1 KR 1020160146588-A/6: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
TNGCANANC
>LY284175.1 KR 1020160146588-A/5: Promoter systems induced by 3-hydroxypropionic acid and method for production of 3-hydroxypropionic acid using the same
CANANATNN
>LY264277.1 KR 1020160092331-A/3: A bioprobe for the detection of influenza A virus subtype H1N1
CCCCCAAAA
>LY282455.1 KR 1020160094288-A/1: Method of Solving Nucleic Acid Detection Problem Based on Threshold Cycle(Ct) of Polymerase Chain Reaction Using Peptide Nucleic Acid Probe
CGTCTATCA
>LY338722.1 KR 1020160091961-A/326: BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2
TCTGCATCC
>LY338711.1 KR 1020160091961-A/304: BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2
AGCGCTTCC
>LY338692.1 KR 1020160091961-A/266: BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2
AGCGCCTCC
>LY338659.1 KR 1020160091961-A/200: BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2
AGTGCATCA
>LY338648.1 KR 1020160091961-A/178: BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2
TCTGCATCC
>LY338637.1 KR 1020160091961-A/156: BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2
TCTGCATCC
>LY338620.1 KR 1020160091961-A/122: BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2
AGCGCCTCC
>LY338598.1 KR 1020160091961-A/78: BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2
AGCGCCTCC
>LY338592.1 KR 1020160091961-A/66: BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2
AGTGCATCA
>LY338586.1 KR 1020160091961-A/54: BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2
AGTGCATCA
>LY338580.1 KR 1020160091961-A/42: BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2
AGCGCCTCC
>LG263088.1 KR 1020160067540-A/4: Simultaneous Detection Methods of Multiple Targets in a Sample and Uses Thereof
CTACAACGC
>LG263087.1 KR 1020160067540-A/3: Simultaneous Detection Methods of Multiple Targets in a Sample and Uses Thereof
CCCATAGAG
>LG263086.1 KR 1020160067540-A/2: Simultaneous Detection Methods of Multiple Targets in a Sample and Uses Thereof
AGCGTTGTA
>LG263085.1 KR 1020160067540-A/1: Simultaneous Detection Methods of Multiple Targets in a Sample and Uses Thereof
ACTCTATGG
>LY404412.1 KR 1020160113276-A/4: EXPRESSION AND PURIFICATION OF CRM197 AND RELATED PROTEINS
GATATACCA
>LY335933.1 KR 1020160086942-A/221: APLNR MODULATORS AND USES THEREOF
GCTGCATCC
>LY335925.1 KR 1020160086942-A/205: APLNR MODULATORS AND USES THEREOF
ACTGCATCC
>LY335917.1 KR 1020160086942-A/189: APLNR MODULATORS AND USES THEREOF
GCTGCATCC
>LY335909.1 KR 1020160086942-A/173: APLNR MODULATORS AND USES THEREOF
GCAGCATCC
>LY335901.1 KR 1020160086942-A/157: APLNR MODULATORS AND USES THEREOF
GCTGCATCC
>LY335893.1 KR 1020160086942-A/141: APLNR MODULATORS AND USES THEREOF
TGGGCATCT
>LY335885.1 KR 1020160086942-A/125: APLNR MODULATORS AND USES THEREOF
TGGGCATCT
>LY335877.1 KR 1020160086942-A/109: APLNR MODULATORS AND USES THEREOF
GGTGCATCC
>LY335869.1 KR 1020160086942-A/93: APLNR MODULATORS AND USES THEREOF
GCTGCATCC
>LY335861.1 KR 1020160086942-A/77: APLNR MODULATORS AND USES THEREOF
GCTGCATCC
>LY335853.1 KR 1020160086942-A/61: APLNR MODULATORS AND USES THEREOF
GCTACATCC
>LY335845.1 KR 1020160086942-A/45: APLNR MODULATORS AND USES THEREOF
GCTGCATCC
>LY335837.1 KR 1020160086942-A/29: APLNR MODULATORS AND USES THEREOF
GCTACATCC
>LY335829.1 KR 1020160086942-A/13: APLNR MODULATORS AND USES THEREOF
GCTGCATCC
>LY298318.1 KR 1020160088316-A/85: Nucleic Acid Amplification
GTTTCCCAA
>LY298317.1 KR 1020160088316-A/84: Nucleic Acid Amplification
TTGGGAAAC
>LY402238.1 KR 1020160132010-A/205: HUMAN ANTIBODIES TO PD-1
GCTGCATCC
>LY402230.1 KR 1020160132010-A/189: HUMAN ANTIBODIES TO PD-1
GGGGCAAGT
>LY402222.1 KR 1020160132010-A/173: HUMAN ANTIBODIES TO PD-1
GCTGCGTCC
>LY402214.1 KR 1020160132010-A/157: HUMAN ANTIBODIES TO PD-1
GCTGCATCC
>LY402206.1 KR 1020160132010-A/141: HUMAN ANTIBODIES TO PD-1
TCTGCATCC
>LY402198.1 KR 1020160132010-A/125: HUMAN ANTIBODIES TO PD-1
GGTGCATCC
>LY402190.1 KR 1020160132010-A/109: HUMAN ANTIBODIES TO PD-1
GCTGCATCC
>LY402182.1 KR 1020160132010-A/93: HUMAN ANTIBODIES TO PD-1
GCTGCATCC
>LY402174.1 KR 1020160132010-A/77: HUMAN ANTIBODIES TO PD-1
GCTGCATCC
>LY402166.1 KR 1020160132010-A/61: HUMAN ANTIBODIES TO PD-1
ACTGCATCC
>LY402158.1 KR 1020160132010-A/45: HUMAN ANTIBODIES TO PD-1
GGTGCATCC
>LY402150.1 KR 1020160132010-A/29: HUMAN ANTIBODIES TO PD-1
GGTGCATCC
>LY402142.1 KR 1020160132010-A/13: HUMAN ANTIBODIES TO PD-1
GCTGCATCC
>LY401722.1 KR 1020160128309-A/277: HUMAN ANTIBODIES TO PD-L1
GCTGCATCC
>LY401714.1 KR 1020160128309-A/261: HUMAN ANTIBODIES TO PD-L1
GTTGTGTCC
>LY401706.1 KR 1020160128309-A/245: HUMAN ANTIBODIES TO PD-L1
GCTGCATCC
>LY401698.1 KR 1020160128309-A/229: HUMAN ANTIBODIES TO PD-L1
GCTGCATCC
>LY401690.1 KR 1020160128309-A/213: HUMAN ANTIBODIES TO PD-L1
GCTGCATCC
>LY401682.1 KR 1020160128309-A/197: HUMAN ANTIBODIES TO PD-L1
GCTGCATCC
>LY297419.1 KR 1020160067184-A/45: ONCOLYTIC ADENOVIRUSES ARMED WITH HETEROLOGOUS GENES
GCCACCATG
>LY401670.1 KR 1020160128309-A/173: HUMAN ANTIBODIES TO PD-L1
GCTGCATCC
>LY401662.1 KR 1020160128309-A/157: HUMAN ANTIBODIES TO PD-L1
GGTGCATCC
>LY401654.1 KR 1020160128309-A/141: HUMAN ANTIBODIES TO PD-L1
GCTGCATCC
>LY401646.1 KR 1020160128309-A/125: HUMAN ANTIBODIES TO PD-L1
GCTGCATCC
>LY401638.1 KR 1020160128309-A/109: HUMAN ANTIBODIES TO PD-L1
GTTGCATCC
>LY401630.1 KR 1020160128309-A/93: HUMAN ANTIBODIES TO PD-L1
GTTGCATCC
>LY401622.1 KR 1020160128309-A/77: HUMAN ANTIBODIES TO PD-L1
AAGATTTCT
>LY401614.1 KR 1020160128309-A/61: HUMAN ANTIBODIES TO PD-L1
AAGGTTTCT
>LY401606.1 KR 1020160128309-A/45: HUMAN ANTIBODIES TO PD-L1
GCTGCATCC
>LY401598.1 KR 1020160128309-A/29: HUMAN ANTIBODIES TO PD-L1
ACTGCATCC
>LY401590.1 KR 1020160128309-A/13: HUMAN ANTIBODIES TO PD-L1
AAGGCGTCT
>LY401319.1 KR 1020160110995-A/142: ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
TGGGCCTCT
>LY401308.1 KR 1020160110995-A/131: ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
TGGGCCTCC
>LY401294.1 KR 1020160110995-A/117: ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
TGGGCATCC
>LY478065.1 KR 1020160147066-A/19: HUMANIZED ANTIBODY AGAINST AMYLOID BETA
GGTGACTAC
>LY417276.1 KR 1020160146830-A/65: IGF-1R antibody-drug-conjugate and its use for the treatment of cancer
TCTGGATCC
>LY480504.1 KR 1020170005133-A/45: HUMAN ANTIBODIES TO MIDDLE EAST RESPIRATORY SYNDROME -CORONAVIRUS SPIKE PROTEIN
AAGGCGTCT
>LY480496.1 KR 1020170005133-A/29: HUMAN ANTIBODIES TO MIDDLE EAST RESPIRATORY SYNDROME -CORONAVIRUS SPIKE PROTEIN
TTGGTTTCT
>LY480488.1 KR 1020170005133-A/13: HUMAN ANTIBODIES TO MIDDLE EAST RESPIRATORY SYNDROME -CORONAVIRUS SPIKE PROTEIN
AAGGCGTCT
>LY476392.1 KR 1020170005829-A/429: COMPOSITIONS FOR MOSQUITO CONTROL AND USES OF SAME
TTTGTGTAG
>LY476391.1 KR 1020170005829-A/428: COMPOSITIONS FOR MOSQUITO CONTROL AND USES OF SAME
TTCAAGAGA
>LX156059.1 WO 2017073536-A/26: Aptamers binding to vWF
CGCGTAGCG
>LX156033.1 WO 2017073535-A/83: DNA Aptamers binding to cancer cells
CGCGTAGCG
>LX252279.1 JP 2017512479-A/19: HUMANIZED ANTIBODIES THAT BIND LGR5
CTGACCAGC
>LX252273.1 JP 2017512479-A/13: HUMANIZED ANTIBODIES THAT BIND LGR5
CTGACCTCC
>LX251758.1 JP 2017512774-A/12: SYNTHESIS OF BICYCLIC NUCLEOSIDES
GNGANANGC
>LX251757.1 JP 2017512774-A/11: SYNTHESIS OF BICYCLIC NUCLEOSIDES
GNGANANGC
>LX247861.1 JP 2017101047-A/3: Antibodies directed against ICOS and uses thereof
TTTGATTAC
>LX247684.1 JP 2017099392-A/6: Novel anti-cMet antibody
AGGGCTTCT
>LX246089.1 JP 2017095491-A/367: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
TTGGGTTTT
>LX246077.1 JP 2017095491-A/355: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
GGTGCATCC
>LX246065.1 JP 2017095491-A/343: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
AAGGTTTCT
>LX246053.1 JP 2017095491-A/331: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
AAGGTTTCT
>LX246041.1 JP 2017095491-A/319: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
AAGGTTTCT
>LX246029.1 JP 2017095491-A/307: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
GGTGCATCC
>LX246017.1 JP 2017095491-A/295: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
GATGCATCC
>LX246005.1 JP 2017095491-A/283: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
GGTGCATCC
>LX245993.1 JP 2017095491-A/271: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
GGTGCATCC
>LX245981.1 JP 2017095491-A/259: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
TTGGGTTTT
>LX245969.1 JP 2017095491-A/247: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
GGTGCATCC
>LX245957.1 JP 2017095491-A/235: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
AAGGCGTCT
>LX245945.1 JP 2017095491-A/223: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
AAGGCGTCT
>LX245933.1 JP 2017095491-A/211: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
AAGGCGTCT
>LX245921.1 JP 2017095491-A/199: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
AAGGCGTCT
>LX245909.1 JP 2017095491-A/187: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
GGTGCATCC
>LX245897.1 JP 2017095491-A/175: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
AAGGCGTCT
>LX245885.1 JP 2017095491-A/163: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
AAGGTTTCT
>LX245873.1 JP 2017095491-A/151: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
TTGGGTTCT
>LX245861.1 JP 2017095491-A/139: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
TTGGGTTTT
>LX245849.1 JP 2017095491-A/127: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
TTGGGTTTT
>LX245837.1 JP 2017095491-A/115: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
TTGGGTTCT
>LX245825.1 JP 2017095491-A/103: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
TTGGGTTCT
>LX245813.1 JP 2017095491-A/91: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
TTGGGTTCT
>LX245801.1 JP 2017095491-A/79: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
AAGGTTTCT
>LX245789.1 JP 2017095491-A/67: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
GCTGCATCC
>LX245777.1 JP 2017095491-A/55: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
GCTGCATCC
>LX245765.1 JP 2017095491-A/43: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
TGGGCATCT
>LX245753.1 JP 2017095491-A/31: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
TGGGCCTCT
>LX245741.1 JP 2017095491-A/19: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
AAGGCGTCT
>LX245729.1 JP 2017095491-A/7: PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
GGTGCATCC
>LX245716.1 JP 2017095490-A/367: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTTT
>LX245704.1 JP 2017095490-A/355: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>LX245692.1 JP 2017095490-A/343: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGTTTCT
>LX245680.1 JP 2017095490-A/331: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGTTTCT
>LX245668.1 JP 2017095490-A/319: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGTTTCT
>LX245656.1 JP 2017095490-A/307: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>LX245644.1 JP 2017095490-A/295: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GATGCATCC
>LX245632.1 JP 2017095490-A/283: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>LX245620.1 JP 2017095490-A/271: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>LX245608.1 JP 2017095490-A/259: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTTT
>LX245596.1 JP 2017095490-A/247: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>LX245584.1 JP 2017095490-A/235: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGCGTCT
>LX245572.1 JP 2017095490-A/223: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGCGTCT
>LX245560.1 JP 2017095490-A/211: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGCGTCT
>LX245548.1 JP 2017095490-A/199: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGCGTCT
>LX245536.1 JP 2017095490-A/187: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>LX245524.1 JP 2017095490-A/175: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGCGTCT
>LX245512.1 JP 2017095490-A/163: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGTTTCT
>LX245500.1 JP 2017095490-A/151: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTCT
>LX245488.1 JP 2017095490-A/139: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTTT
>LX245476.1 JP 2017095490-A/127: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTTT
>LX245464.1 JP 2017095490-A/115: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTCT
>LX245452.1 JP 2017095490-A/103: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTCT
>LX245440.1 JP 2017095490-A/91: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTCT
>LX245428.1 JP 2017095490-A/79: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGTTTCT
>LX245416.1 JP 2017095490-A/67: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GCTGCATCC
>LX245404.1 JP 2017095490-A/55: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GCTGCATCC
>LX245392.1 JP 2017095490-A/43: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TGGGCATCT
>LX245380.1 JP 2017095490-A/31: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TGGGCCTCT
>LX245368.1 JP 2017095490-A/19: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGCGTCT
>LX245356.1 JP 2017095490-A/7: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>LX244895.1 JP 2017104109-A/275: RNAse H-Based Assays Utilizing Modified RNA Monomers
TAGCTGAAG
>LX244894.1 JP 2017104109-A/274: RNAse H-Based Assays Utilizing Modified RNA Monomers
AAGCTGAAG
>LX244893.1 JP 2017104109-A/273: RNAse H-Based Assays Utilizing Modified RNA Monomers
GAGCTGAAG
>LX244892.1 JP 2017104109-A/272: RNAse H-Based Assays Utilizing Modified RNA Monomers
CAGCTGAAG
>LX244565.1 JP 2017104108-A/275: RNAse H-Based Assays Utilizing Modified RNA Monomers
TAGCTGAAG
>LX244564.1 JP 2017104108-A/274: RNAse H-Based Assays Utilizing Modified RNA Monomers
AAGCTGAAG
>LX244563.1 JP 2017104108-A/273: RNAse H-Based Assays Utilizing Modified RNA Monomers
GAGCTGAAG
>LX244562.1 JP 2017104108-A/272: RNAse H-Based Assays Utilizing Modified RNA Monomers
CAGCTGAAG
>LX155181.1 JP 2017510277-A/6: Ureohydrolases as dominant selectable markers in yeast
TTGAGGAGG
>LX154286.1 JP 2017510559-A/7: ANTI-EGFRVIII ANTIBODIES AND USES THEREOF
TGGGCATCT
>LX154840.1 JP 2017509643-A/11: ANTIBODY COMPOSITIONS FOR TUMOR TREATMENT
GGTGCATCC
>LX153626.1 JP 2017510264-A/2: Further improved AAV vectors produced in insect cells
CCTGTTAAG
>LX154350.1 JP 2017510559-A/71: ANTI-EGFRVIII ANTIBODIES AND USES THEREOF
GCTACATCC
>LX154342.1 JP 2017510559-A/63: ANTI-EGFRVIII ANTIBODIES AND USES THEREOF
GCTGCATCC
>LX154334.1 JP 2017510559-A/55: ANTI-EGFRVIII ANTIBODIES AND USES THEREOF
GCTACATCC
>LX154326.1 JP 2017510559-A/47: ANTI-EGFRVIII ANTIBODIES AND USES THEREOF
AAGGTTTCT
>LX154318.1 JP 2017510559-A/39: ANTI-EGFRVIII ANTIBODIES AND USES THEREOF
GGTGCATCC
>LX154310.1 JP 2017510559-A/31: ANTI-EGFRVIII ANTIBODIES AND USES THEREOF
AAGGCGTCT
>LX154302.1 JP 2017510559-A/23: ANTI-EGFRVIII ANTIBODIES AND USES THEREOF
GCTGCATCC
>LX154294.1 JP 2017510559-A/15: ANTI-EGFRVIII ANTIBODIES AND USES THEREOF
GCTGCATCC
>LX153762.1 JP 2017510290-A/2: EXPRESSION AND PURIFICATION OF CRM197 AND RELATED PROTEINS
GATATACCA
>LX148229.1 JP 2017086068-A/23: NEUTRALIZING ANTI-INFLUENZA VIRUS ANTIBODIES AND USES THEREOF
TGGGCTTCA
>LX148219.1 JP 2017086068-A/13: NEUTRALIZING ANTI-INFLUENZA VIRUS ANTIBODIES AND USES THEREOF
TGGGCATCT
>LX148211.1 JP 2017086068-A/5: NEUTRALIZING ANTI-INFLUENZA VIRUS ANTIBODIES AND USES THEREOF
TGGGCATCT
>LX097425.1 JP 2017507650-A/139: HUMAN ANTIBODIES TO PD-L1
GCTGCATCC
>LX097417.1 JP 2017507650-A/131: HUMAN ANTIBODIES TO PD-L1
GTTGTGTCC
>LX097409.1 JP 2017507650-A/123: HUMAN ANTIBODIES TO PD-L1
GCTGCATCC
>LX097401.1 JP 2017507650-A/115: HUMAN ANTIBODIES TO PD-L1
GCTGCATCC
>LX097393.1 JP 2017507650-A/107: HUMAN ANTIBODIES TO PD-L1
GCTGCATCC
>LX097385.1 JP 2017507650-A/99: HUMAN ANTIBODIES TO PD-L1
GCTGCATCC
>LX097373.1 JP 2017507650-A/87: HUMAN ANTIBODIES TO PD-L1
GCTGCATCC
>LX097365.1 JP 2017507650-A/79: HUMAN ANTIBODIES TO PD-L1
GGTGCATCC
>LX097357.1 JP 2017507650-A/71: HUMAN ANTIBODIES TO PD-L1
GCTGCATCC
>LX097349.1 JP 2017507650-A/63: HUMAN ANTIBODIES TO PD-L1
GCTGCATCC
>LX097341.1 JP 2017507650-A/55: HUMAN ANTIBODIES TO PD-L1
GTTGCATCC
>LX097333.1 JP 2017507650-A/47: HUMAN ANTIBODIES TO PD-L1
GTTGCATCC
>LX097325.1 JP 2017507650-A/39: HUMAN ANTIBODIES TO PD-L1
AAGATTTCT
>LX097317.1 JP 2017507650-A/31: HUMAN ANTIBODIES TO PD-L1
AAGGTTTCT
>LX097309.1 JP 2017507650-A/23: HUMAN ANTIBODIES TO PD-L1
GCTGCATCC
>LX097301.1 JP 2017507650-A/15: HUMAN ANTIBODIES TO PD-L1
ACTGCATCC
>LX097293.1 JP 2017507650-A/7: HUMAN ANTIBODIES TO PD-L1
AAGGCGTCT
>LX145443.1 JP 2017506067-A/77: ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
TGGGCCTCC
>LX145429.1 JP 2017506067-A/63: ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
TGGGCATCC
>LX145454.1 JP 2017506067-A/88: ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
TGGGCCTCT
>MS787063.1 Sequence 16 from Patent EP3135691
AGGGCTTCT
>MS792944.1 Sequence 1 from Patent EP3174985
CCATCTCCC
>MS791054.1 Sequence 142 from Patent WO2017025918
TGGGCCTCT
>MS791043.1 Sequence 131 from Patent WO2017025918
TGGGCCTCC
>MS791029.1 Sequence 117 from Patent WO2017025918
TGGGCATCC
>MS653939.1 Sequence 4 from Patent EP3099800
GATATACCA
>MS789491.1 Sequence 109 from Patent WO2017027316
AAGATTTCT
>MS789475.1 Sequence 93 from Patent WO2017027316
GCTGCATCC
>MS789459.1 Sequence 77 from Patent WO2017027316
TGGGCATCT
>MS789443.1 Sequence 61 from Patent WO2017027316
AAGATTTTT
>MS789427.1 Sequence 45 from Patent WO2017027316
GCTGCATCC
>MS789411.1 Sequence 29 from Patent WO2017027316
AAGGCGTCT
>MS789395.1 Sequence 13 from Patent WO2017027316
GCTGCATCC
>MS999743.1 Sequence 6 from Patent EP3147372
CGACAGCAA
>MS999670.1 Sequence 8 from Patent EP3147364
HGGGGGGGH
>MS999622.1 Sequence 3 from Patent EP3147297
TTTGATTAC
>MS995381.1 Sequence 3 from Patent EP3158089
AACNAACAA
>MS640157.1 Sequence 43 from Patent WO2017050853
AAGCTTAAA
>MS992611.1 Sequence 148 from Patent EP3107567
AAATTTTCC
>MS992587.1 Sequence 124 from Patent EP3107567
AAAGTTTCC
>MS992563.1 Sequence 100 from Patent EP3107567
GACACATCC
>MS992539.1 Sequence 76 from Patent EP3107567
GCTACATCC
>MS992515.1 Sequence 52 from Patent EP3107567
AAAGTTTCC
>MS992491.1 Sequence 28 from Patent EP3107567
CTGGTGTCT
>MS989005.1 Sequence 37 from Patent EP3107582
GGCACATCC
>MS638951.1 Sequence 165 from Patent WO2017053856
GCTGCATCC
>MS988981.1 Sequence 13 from Patent EP3107582
GCCACTTCC
>MS637875.1 Sequence 30 from Patent WO2017050848
GTGGCTCGG
>MS986262.1 Sequence 93 from Patent WO2017066204
GGTGCATCC
>MS952388.1 Sequence 62 from Patent WO2017036580
GGCCCGAAG
>MS946421.1 Sequence 5 from Patent WO2017035319
AGCACTTTG
>MS857346.1 Sequence 24 from Patent EP3173482
GCTCTGCCC
>MS857328.1 Sequence 6 from Patent EP3173482
GCTCTGACC
>MS843107.1 Sequence 596 from Patent WO2017070632
GGSGGSGGS
>MS926628.1 Sequence 326 from Patent EP3178845
AAGAATAAT
>MS926667.1 Sequence 365 from Patent EP3178845
GGCAACAAC
>MS926648.1 Sequence 346 from Patent EP3178845
GATGCATCC
>MS926590.1 Sequence 288 from Patent EP3178845
GGTAACAAC
>MS926574.1 Sequence 272 from Patent EP3178845
ACTACATCC
>MS926558.1 Sequence 256 from Patent EP3178845
GACGTCACT
>MS926528.1 Sequence 226 from Patent EP3178845
GCTGCATCC
>MS926500.1 Sequence 198 from Patent EP3178845
CAAGATACG
>MS926457.1 Sequence 155 from Patent EP3178845
GGTGCATCC
>MS926441.1 Sequence 139 from Patent EP3178845
GATGTCGAT
>MS926425.1 Sequence 123 from Patent EP3178845
CAAGATTCC
>MS926409.1 Sequence 107 from Patent EP3178845
GAGGTTTCT
>MS926393.1 Sequence 91 from Patent EP3178845
GATGGCAGT
>MS926377.1 Sequence 75 from Patent EP3178845
GATGTCAGT
>MS926361.1 Sequence 59 from Patent EP3178845
GACAATGAT
>MS926345.1 Sequence 43 from Patent EP3178845
AAAGACACT
>MS926329.1 Sequence 27 from Patent EP3178845
GATGATAGC
>MS926313.1 Sequence 11 from Patent EP3178845
AAGGCGTCT
>MS924701.1 Sequence 182 from Patent WO2017019894
TACACTAGC
>MS924690.1 Sequence 171 from Patent WO2017019894
TACACCTCC
>MS916483.1 Sequence 1645 from Patent WO2017023761
ACTGCATCC
>MS916291.1 Sequence 1453 from Patent WO2017023761
GGTGCATCC
>MS916275.1 Sequence 1437 from Patent WO2017023761
GGTGCATCC
>MS916259.1 Sequence 1421 from Patent WO2017023761
GGTGCATCC
>MS916243.1 Sequence 1405 from Patent WO2017023761
GGTGCATCC
>MS916227.1 Sequence 1389 from Patent WO2017023761
GCTGCATCC
>MS916027.1 Sequence 1189 from Patent WO2017023761
GTTGCATCC
>MS915915.1 Sequence 1077 from Patent WO2017023761
ACTGCATCC
>MS915899.1 Sequence 1061 from Patent WO2017023761
ACTGCATCC
>MS915883.1 Sequence 1045 from Patent WO2017023761
ACTGCATCC
>MS915867.1 Sequence 1029 from Patent WO2017023761
GGTGCATCC
>MS915851.1 Sequence 1013 from Patent WO2017023761
ACTGCATCC
>MS915835.1 Sequence 997 from Patent WO2017023761
TGGGCATCT
>MS915819.1 Sequence 981 from Patent WO2017023761
AAGGCGTCT
>MS915803.1 Sequence 965 from Patent WO2017023761
GGTGCGTCC
>MS915787.1 Sequence 949 from Patent WO2017023761
GGTGCGTCC
>MS915771.1 Sequence 933 from Patent WO2017023761
GGTGCATCC
>MS915755.1 Sequence 917 from Patent WO2017023761
GGTGCGTCC
>MS915739.1 Sequence 901 from Patent WO2017023761
GGTGCGTCC
>MS915723.1 Sequence 885 from Patent WO2017023761
GGTGCGTCC
>MS915707.1 Sequence 869 from Patent WO2017023761
GGTGCGTCC
>MS915691.1 Sequence 853 from Patent WO2017023761
GCTGCATCC
>MS915579.1 Sequence 741 from Patent WO2017023761
GATGCATCC
>MS915563.1 Sequence 725 from Patent WO2017023761
GCTGTATCC
>MS915547.1 Sequence 709 from Patent WO2017023761
GAAGCTTCT
>MS915531.1 Sequence 693 from Patent WO2017023761
GCTGCTTCC
>MS915515.1 Sequence 677 from Patent WO2017023761
GCTGCATCC
>MS915499.1 Sequence 661 from Patent WO2017023761
GCTGCATCC
>MS915483.1 Sequence 645 from Patent WO2017023761
GCTGCATCC
>MS915467.1 Sequence 629 from Patent WO2017023761
GCTGCATCC
>MS835674.1 Sequence 36 from Patent EP3112465
TNTCTGNTA
>MS915451.1 Sequence 613 from Patent WO2017023761
GCTGCATCC
>MS915435.1 Sequence 597 from Patent WO2017023761
GCTGCATCC
>MS915419.1 Sequence 581 from Patent WO2017023761
GGTGCAACC
>MS915403.1 Sequence 565 from Patent WO2017023761
GGTGCAACC
>MS915387.1 Sequence 549 from Patent WO2017023761
GGTGCATCC
>MS915371.1 Sequence 533 from Patent WO2017023761
GCTGCATCC
>MS915355.1 Sequence 517 from Patent WO2017023761
TGGGCATCT
>MS915339.1 Sequence 501 from Patent WO2017023761
GGTGCATCC
>MS915323.1 Sequence 485 from Patent WO2017023761
GGTGCATCC
>MS915307.1 Sequence 469 from Patent WO2017023761
GGTGCAACC
>MS915211.1 Sequence 373 from Patent WO2017023761
GGTGCATCC
>MS915195.1 Sequence 357 from Patent WO2017023761
GGTGCATCC
>MS915179.1 Sequence 341 from Patent WO2017023761
GGTGCATCC
>MS915163.1 Sequence 325 from Patent WO2017023761
GGTGCATCC
>MS915147.1 Sequence 309 from Patent WO2017023761
GGTGCATCC
>MS915131.1 Sequence 293 from Patent WO2017023761
GGTGCATCC
>MS915115.1 Sequence 277 from Patent WO2017023761
GGTGCATCC
>MS915099.1 Sequence 261 from Patent WO2017023761
GATGCATCC
>MS915083.1 Sequence 245 from Patent WO2017023761
GCTGCATCC
>MS915067.1 Sequence 229 from Patent WO2017023761
GCTGCATCC
>MS915051.1 Sequence 213 from Patent WO2017023761
GGTGCATCC
>MS915035.1 Sequence 197 from Patent WO2017023761
GCTGCATCC
>MS915019.1 Sequence 181 from Patent WO2017023761
GGTGCATCC
>MS915003.1 Sequence 165 from Patent WO2017023761
GGTGCATCC
>MS914987.1 Sequence 149 from Patent WO2017023761
ACTGCATCC
>MS914971.1 Sequence 133 from Patent WO2017023761
GGTGCATCC
>MS912596.1 Sequence 288 from Patent WO2017021541
AACCCCACT
>MS912618.1 Sequence 310 from Patent WO2017021541
ATTTTGCGC
>MS912582.1 Sequence 274 from Patent WO2017021541
TCCCTGGAG
>MS912611.1 Sequence 303 from Patent WO2017021541
CATATGCGC
>MS910270.1 Sequence 319 from Patent WO2017062456
TGGGCATCT
>MS910252.1 Sequence 301 from Patent WO2017062456
GCTGCATCA
>MS910236.1 Sequence 285 from Patent WO2017062456
GCTGCTTCC
>MS910220.1 Sequence 269 from Patent WO2017062456
GCTGCATCC
>MS910204.1 Sequence 253 from Patent WO2017062456
GTTGCATCC
>MS910188.1 Sequence 237 from Patent WO2017062456
GCTGCGTCC
>MS910172.1 Sequence 221 from Patent WO2017062456
GCTGCATCC
>MS910156.1 Sequence 205 from Patent WO2017062456
GCTGCATCC
>MS910140.1 Sequence 189 from Patent WO2017062456
GCTGCATCC
>MS910124.1 Sequence 173 from Patent WO2017062456
GCTGCGTCC
>MS910108.1 Sequence 157 from Patent WO2017062456
GCTGCAGCC
>MS910092.1 Sequence 141 from Patent WO2017062456
GCTGCATCC
>MS910076.1 Sequence 125 from Patent WO2017062456
GCTGCATCC
>MS910060.1 Sequence 109 from Patent WO2017062456
GCTGCATCC
>MS910044.1 Sequence 93 from Patent WO2017062456
GCTGCATCC
>MS910028.1 Sequence 77 from Patent WO2017062456
GCTGCATCC
>MS910012.1 Sequence 61 from Patent WO2017062456
GCTGCATCC
>MS909996.1 Sequence 45 from Patent WO2017062456
GGTGCATCC
>MS909980.1 Sequence 29 from Patent WO2017062456
GCTGCATCC
>MS909964.1 Sequence 13 from Patent WO2017062456
GCTGCATCC
>MS921477.1 Sequence 1 from Patent WO2017021963
TTCAAGAGA
>MS921478.1 Sequence 2 from Patent WO2017021963
TTTGTGTAG
>MS903417.1 Sequence 733 from Patent EP3156422
TTGGGTTTT
>MS903393.1 Sequence 709 from Patent EP3156422
GGTGCATCC
>MS903369.1 Sequence 685 from Patent EP3156422
AAGGTTTCT
>MS903345.1 Sequence 661 from Patent EP3156422
AAGGTTTCT
>MS903321.1 Sequence 637 from Patent EP3156422
AAGGTTTCT
>MS903297.1 Sequence 613 from Patent EP3156422
GGTGCATCC
>MS903273.1 Sequence 589 from Patent EP3156422
GATGCATCC
>MS903249.1 Sequence 565 from Patent EP3156422
GGTGCATCC
>MS903225.1 Sequence 541 from Patent EP3156422
GGTGCATCC
>MS903201.1 Sequence 517 from Patent EP3156422
TTGGGTTTT
>MS903177.1 Sequence 493 from Patent EP3156422
GGTGCATCC
>MS905932.1 Sequence 549 from Patent WO2017062888
GGTGCATCC
>MS905916.1 Sequence 533 from Patent WO2017062888
GGTGCATCC
>MS905908.1 Sequence 525 from Patent WO2017062888
GCTGCATCC
>MS905828.1 Sequence 445 from Patent WO2017062888
TTGGTTTCT
>MS905812.1 Sequence 429 from Patent WO2017062888
GATGCATCC
>MS905796.1 Sequence 413 from Patent WO2017062888
GGTGCATCC
>MS905780.1 Sequence 397 from Patent WO2017062888
GATGCATCC
>MS905764.1 Sequence 381 from Patent WO2017062888
AAGATTTCT
>MS905748.1 Sequence 365 from Patent WO2017062888
GCTGCATCA
>MS905732.1 Sequence 349 from Patent WO2017062888
GATGCATCC
>MS905716.1 Sequence 333 from Patent WO2017062888
TTGGTTTCT
>MS905620.1 Sequence 237 from Patent WO2017062888
GCTGCATCC
>MS905604.1 Sequence 221 from Patent WO2017062888
GCTACATCC
>MS905588.1 Sequence 205 from Patent WO2017062888
GGTTCATCC
>MS905572.1 Sequence 189 from Patent WO2017062888
GATGCATCC
>MS905556.1 Sequence 173 from Patent WO2017062888
GATGCATCC
>MS905540.1 Sequence 157 from Patent WO2017062888
GATGCATCC
>MS905524.1 Sequence 141 from Patent WO2017062888
GGTGCTTCC
>MS905508.1 Sequence 125 from Patent WO2017062888
AAGGTTTCT
>MS905492.1 Sequence 109 from Patent WO2017062888
GGTGCGTCC
>MS905476.1 Sequence 93 from Patent WO2017062888
GCTACATCC
>MS905460.1 Sequence 77 from Patent WO2017062888
GGTGCATCC
>MS905444.1 Sequence 61 from Patent WO2017062888
GCTGCATCC
>MS905428.1 Sequence 45 from Patent WO2017062888
GGTGCATCC
>MS905412.1 Sequence 29 from Patent WO2017062888
GCTGCATCC
>MS905396.1 Sequence 13 from Patent WO2017062888
GCTGCATCC
>MS904870.1 Sequence 93 from Patent EP3138917
AAGAAAAAG
>MS904869.1 Sequence 92 from Patent EP3138917
AAGAAGAAA
>MS904859.1 Sequence 82 from Patent EP3138917
GAGGAAGAG
>MS904858.1 Sequence 81 from Patent EP3138917
GAGGAGGAA
>MS904830.1 Sequence 53 from Patent EP3138917
TACTATTAC
>MS904829.1 Sequence 52 from Patent EP3138917
TACTACTAT
>MS904807.1 Sequence 30 from Patent EP3138917
ATCATTATC
>MS904806.1 Sequence 29 from Patent EP3138917
ATCATCATT
>MS904805.1 Sequence 28 from Patent EP3138917
CACCATCAC
>MS904804.1 Sequence 27 from Patent EP3138917
CACCACCAT
>MS904784.1 Sequence 7 from Patent EP3138917
CGTCGCCGT
>MS904783.1 Sequence 6 from Patent EP3138917
CGTCGTCGC
>MS903153.1 Sequence 469 from Patent EP3156422
AAGGCGTCT
>MS903129.1 Sequence 445 from Patent EP3156422
AAGGCGTCT
>MS903105.1 Sequence 421 from Patent EP3156422
AAGGCGTCT
>MS903081.1 Sequence 397 from Patent EP3156422
AAGGCGTCT
>MS903057.1 Sequence 373 from Patent EP3156422
GGTGCATCC
>MS903033.1 Sequence 349 from Patent EP3156422
AAGGCGTCT
>MS903009.1 Sequence 325 from Patent EP3156422
AAGGTTTCT
>MS902985.1 Sequence 301 from Patent EP3156422
TTGGGTTCT
>MS902961.1 Sequence 277 from Patent EP3156422
TTGGGTTTT
>MS902937.1 Sequence 253 from Patent EP3156422
TTGGGTTTT
>MS902913.1 Sequence 229 from Patent EP3156422
TTGGGTTCT
>MS902889.1 Sequence 205 from Patent EP3156422
TTGGGTTCT
>MS902865.1 Sequence 181 from Patent EP3156422
TTGGGTTCT
>MS902841.1 Sequence 157 from Patent EP3156422
AAGGTTTCT
>MS902817.1 Sequence 133 from Patent EP3156422
GCTGCATCC
>MS902793.1 Sequence 109 from Patent EP3156422
GCTGCATCC
>MS902769.1 Sequence 85 from Patent EP3156422
TGGGCATCT
>MS902745.1 Sequence 61 from Patent EP3156422
TGGGCCTCT
>MS902721.1 Sequence 37 from Patent EP3156422
AAGGCGTCT
>MS902697.1 Sequence 13 from Patent EP3156422
GGTGCATCC
>MS870366.1 Sequence 364 from Patent EP3173092
GGGTTTGGG
>MS870355.1 Sequence 353 from Patent EP3173092
GGTTTTTGG
>MS890223.1 Sequence 7 from Patent WO2017059122
GGGAGAGGG
>MS890222.1 Sequence 6 from Patent WO2017059122
GGGGAGAAA
>MS890218.1 Sequence 2 from Patent WO2017059122
CCCTCTCCC
>MS890217.1 Sequence 1 from Patent WO2017059122
TTTCTCCCC
>MS886362.1 Sequence 1 from Patent WO2017006318
ATCTGGATA
>MS897567.1 Sequence 965 from Patent EP3134131
CCRCCATGG
>MS999992.1 Sequence 4 from Patent WO2016207124
GGGACTTCC
>MS999533.1 Sequence 32 from Patent EP3126397
CTGACCTCC
>MS999545.1 Sequence 44 from Patent EP3126397
CTGACCAGC
>MS992467.1 Sequence 4 from Patent EP3107567
AAAGTTTCC
>MS986182.1 Sequence 13 from Patent WO2017066204
GCTGCATCC
>MS943638.1 Sequence 9 from Patent EP3177366
CTTTTAAAG
>MS924679.1 Sequence 160 from Patent WO2017019894
TATACATCC
>MS924668.1 Sequence 149 from Patent WO2017019894
TACACATCA
>MS915291.1 Sequence 453 from Patent WO2017023761
GGTGCAACC
>MS915275.1 Sequence 437 from Patent WO2017023761
GGTGCATCC
>MS915259.1 Sequence 421 from Patent WO2017023761
GGTGCATCC
>MS916307.1 Sequence 1469 from Patent WO2017023761
GGTGCATCC
>MS916011.1 Sequence 1173 from Patent WO2017023761
ACTGCATCC
>MS915995.1 Sequence 1157 from Patent WO2017023761
ACTGCATCC
>MS915979.1 Sequence 1141 from Patent WO2017023761
GTTGCATCC
>MS915963.1 Sequence 1125 from Patent WO2017023761
GCTGCATCC
>MS915947.1 Sequence 1109 from Patent WO2017023761
ACTGCATCC
>MS915931.1 Sequence 1093 from Patent WO2017023761
GTTGCATCC
>MS915675.1 Sequence 837 from Patent WO2017023761
GCTGCGTCC
>MS915659.1 Sequence 821 from Patent WO2017023761
GCTGCATCC
>MS915643.1 Sequence 805 from Patent WO2017023761
GCTGCATCC
>MS915627.1 Sequence 789 from Patent WO2017023761
GCTGCATCC
>MS915611.1 Sequence 773 from Patent WO2017023761
GCTGCATCC
>MS915595.1 Sequence 757 from Patent WO2017023761
GCTGCATCC
>MS915243.1 Sequence 405 from Patent WO2017023761
GGTGCATCC
>MS915227.1 Sequence 389 from Patent WO2017023761
GGTGCATCC
>MS912669.1 Sequence 361 from Patent WO2017021541
TCCGGGGAT
>MS912667.1 Sequence 359 from Patent WO2017021541
TCCCCGGAA
>MS912662.1 Sequence 354 from Patent WO2017021541
TACCCCACC
>MS912310.1 Sequence 2 from Patent WO2017021541
ATAAATGGA
>MS905948.1 Sequence 565 from Patent WO2017062888
GCTGCATCC
>MS905700.1 Sequence 317 from Patent WO2017062888
GCTGCATCC
>MS905684.1 Sequence 301 from Patent WO2017062888
TGGGCATCT
>MS905668.1 Sequence 285 from Patent WO2017062888
TGGGCATCT
>MS905652.1 Sequence 269 from Patent WO2017062888
TGGGCATCT
>MS905636.1 Sequence 253 from Patent WO2017062888
GGTGCATCC
>MS838535.1 Sequence 173 from Patent WO2017015472
GGTGCATCC
>MS838527.1 Sequence 165 from Patent WO2017015472
TGGGCATCT
>MS838519.1 Sequence 157 from Patent WO2017015472
GGTGCATCC
>MS838511.1 Sequence 149 from Patent WO2017015472
TGGGCATCT
>MS838503.1 Sequence 141 from Patent WO2017015472
GGTGCATCC
>MS838495.1 Sequence 133 from Patent WO2017015472
CAGGCGTCT
>MS838487.1 Sequence 125 from Patent WO2017015472
GGTGCATCC
>MS838479.1 Sequence 117 from Patent WO2017015472
AAGGCGTCT
>MS838471.1 Sequence 109 from Patent WO2017015472
GGTGCATCC
>MS838463.1 Sequence 101 from Patent WO2017015472
TGGGCATCT
>MS838455.1 Sequence 93 from Patent WO2017015472
GGTGCATCC
>MS838447.1 Sequence 85 from Patent WO2017015472
AAGGCGTCT
>MS838439.1 Sequence 77 from Patent WO2017015472
GGTGCATCC
>MS838431.1 Sequence 69 from Patent WO2017015472
CAGGCGTCT
>MS838423.1 Sequence 61 from Patent WO2017015472
GGTGCATCC
>MS838415.1 Sequence 53 from Patent WO2017015472
CAGGCGTCT
>MS838407.1 Sequence 45 from Patent WO2017015472
GGTGCATCC
>MS838399.1 Sequence 37 from Patent WO2017015472
AAGGCGTCT
>MS838391.1 Sequence 29 from Patent WO2017015472
GTTGCATCC
>MS838383.1 Sequence 21 from Patent WO2017015472
GGTGCATCC
>MS838375.1 Sequence 13 from Patent WO2017015472
GATGCATCC
>MS838367.1 Sequence 5 from Patent WO2017015472
AAGGCGTCT
>MS835661.1 Sequence 23 from Patent EP3112465
KTTGRTTCY
>MS816955.1 Sequence 3 from Patent EP3162889
CTAGGAAGT
>MS789635.1 Sequence 253 from Patent WO2017027316
GCTGCATCC
>MS789619.1 Sequence 237 from Patent WO2017027316
TTGGGTTCT
>MS789603.1 Sequence 221 from Patent WO2017027316
GATGCATCC
>MS789587.1 Sequence 205 from Patent WO2017027316
TGGGCATCT
>MS789571.1 Sequence 189 from Patent WO2017027316
GATGCTTCC
>MS789555.1 Sequence 173 from Patent WO2017027316
GATGCATCC
>MS789539.1 Sequence 157 from Patent WO2017027316
GCTGCATCC
>MS789523.1 Sequence 141 from Patent WO2017027316
TCTGCATCC
>MS789507.1 Sequence 125 from Patent WO2017027316
TTGGGTTCT
>LX080929.1 JP 2017504564-A/124: METHODS USING MONOVALENT ANTIGEN BINDING CONSTRUCTS TARGETING HER2
AGTGCATCA
>LX080915.1 JP 2017504564-A/110: METHODS USING MONOVALENT ANTIGEN BINDING CONSTRUCTS TARGETING HER2
TCTGCATCC
>LX080890.1 JP 2017504564-A/85: METHODS USING MONOVALENT ANTIGEN BINDING CONSTRUCTS TARGETING HER2
AGCGCCTCC
>LX080884.1 JP 2017504564-A/79: METHODS USING MONOVALENT ANTIGEN BINDING CONSTRUCTS TARGETING HER2
AGCGCCTCC
>LX080861.1 JP 2017504564-A/56: METHODS USING MONOVALENT ANTIGEN BINDING CONSTRUCTS TARGETING HER2
GACCACACA
>LX080851.1 JP 2017504564-A/46: METHODS USING MONOVALENT ANTIGEN BINDING CONSTRUCTS TARGETING HER2
AGCGCCTCC
>LX080662.1 JP 2017503480-A/163: BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2
TCTGCATCC
>LX080651.1 JP 2017503480-A/152: BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2
AGCGCTTCC
>LX080632.1 JP 2017503480-A/133: BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2
AGCGCCTCC
>LX080599.1 JP 2017503480-A/100: BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2
AGTGCATCA
>LX080588.1 JP 2017503480-A/89: BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2
TCTGCATCC
>LX080577.1 JP 2017503480-A/78: BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2
TCTGCATCC
>LX080560.1 JP 2017503480-A/61: BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2
AGCGCCTCC
>LX080538.1 JP 2017503480-A/39: BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2
AGCGCCTCC
>LX080532.1 JP 2017503480-A/33: BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2
AGTGCATCA
>LX080526.1 JP 2017503480-A/27: BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2
AGTGCATCA
>LX080520.1 JP 2017503480-A/21: BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2
AGCGCCTCC
>LX058230.1 JP 2013544816-A/69: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
TGTCGTTCT
>LX058225.1 JP 2013544816-A/64: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
TGACGTTCT
>LX058224.1 JP 2013544816-A/63: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
TGACGTTCT
>LX058220.1 JP 2013544816-A/59: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
TGACGTTCA
>LX058219.1 JP 2013544816-A/58: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
GACGTTCTT
>LX058216.1 JP 2013544816-A/55: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
TGACGTTCT
>LX058212.1 JP 2013544816-A/51: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
TGTCGTTCT
>LX058211.1 JP 2013544816-A/50: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
TGTCGTTCT
>LX058207.1 JP 2013544816-A/46: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
TGTCGTTCA
>LX058206.1 JP 2013544816-A/45: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
GTCGTTCTT
>LX058204.1 JP 2013544816-A/43: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
TGTCGTTCT
>LX058192.1 JP 2013544816-A/31: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
TCGTTCTTC
>LX058191.1 JP 2013544816-A/30: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
CTTGTCGTT
>LX058190.1 JP 2013544816-A/29: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
TTGTCGTTC
>LX058186.1 JP 2013544816-A/25: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
TGACGTTCT
>LX058185.1 JP 2013544816-A/24: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
TGTCGTTCT
>LX058184.1 JP 2013544816-A/23: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
TGTCGTTCT
>LX058183.1 JP 2013544816-A/22: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
TGTCGTTCT
>LX058182.1 JP 2013544816-A/21: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
TGTCGTTCT
>LX058181.1 JP 2013544816-A/20: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
TGACGTTCT
>LX058180.1 JP 2013544816-A/19: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
TGTCGACAT
>LX058179.1 JP 2013544816-A/18: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
TGTCGTTCT
>LX058178.1 JP 2013544816-A/17: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
TGTCGTTCT
>LX058177.1 JP 2013544816-A/16: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
TGTCGTTCT
>LX058175.1 JP 2013544816-A/14: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
TTGTCGTTA
>LX058172.1 JP 2013544816-A/11: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
TGTCGTTCA
>LX058170.1 JP 2013544816-A/9: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
TTGTCGTTC
>LX058168.1 JP 2013544816-A/7: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
TGTCGTTCT
>LX058166.1 JP 2013544816-A/5: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
TGTCGTTCT
>LX058165.1 JP 2013544816-A/4: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
GTCGTTCTT
>LX058162.1 JP 2013544816-A/1: Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response
TGTCGTTCT
>LX057242.1 JP 2015532097-A/68: HUMAN TOLL-LIKE RECEPTOR INHIBITORS AND METHODS OF USE THEREOF
TCCTTNANN
>LX057140.1 JP 2015528282-A/18: METHOD AND KIT FOR NUCLEIC ACID SEQUENCING
ACCTTGATG
>LX057130.1 JP 2015528282-A/8: METHOD AND KIT FOR NUCLEIC ACID SEQUENCING
TAGCCTTTG
>LX077610.1 WO 2017047707-A/77: Antisense Nucleic Acid
TGGAGTTCC
>LX056446.1 JP 2015524271-A/4: MVA VACCINE FOR DELIVERY OF A UL128 COMPLEX AND PREVENTING CMV INFECTION
GCCGCCACC
>LX056445.1 JP 2015524271-A/3: MVA VACCINE FOR DELIVERY OF A UL128 COMPLEX AND PREVENTING CMV INFECTION
GCCGCCGCC
>LX056444.1 JP 2015524271-A/2: MVA VACCINE FOR DELIVERY OF A UL128 COMPLEX AND PREVENTING CMV INFECTION
GCCACCACC
>LX073243.1 JP 2017051190-A/34: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GACAGCCTG
>LX073242.1 JP 2017051190-A/33: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
CAGGCTGTC
>LX073239.1 JP 2017051190-A/30: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GACACCGCA
>LX073238.1 JP 2017051190-A/29: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
TGCGGTGTC
>LX073233.1 JP 2017051190-A/24: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
CCTCCTCAG
>LX073232.1 JP 2017051190-A/23: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
CTGAGGAGG
>LX073225.1 JP 2017051190-A/16: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GTCCCATTA
>LX073224.1 JP 2017051190-A/15: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
TAATGGGAC
>LX073221.1 JP 2017051190-A/12: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GGTAGCGAA
>LX073220.1 JP 2017051190-A/11: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
TTCGCTACC
>LX073219.1 JP 2017051190-A/10: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GACCGTTAT
>LX073218.1 JP 2017051190-A/9: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
ATAACGGTC
>LX073217.1 JP 2017051190-A/8: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GACAGTTCC
>LX073216.1 JP 2017051190-A/7: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GGAACTGTC
>LX073215.1 JP 2017051190-A/6: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GACGTTCTG
>LX073214.1 JP 2017051190-A/5: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
CAGAACGTC
>LX073213.1 JP 2017051190-A/4: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GACGTTTTG
>LX073212.1 JP 2017051190-A/3: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
CAAAACGTC
>LX073211.1 JP 2017051190-A/2: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GACAGTTTC
>LX073210.1 JP 2017051190-A/1: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GAAACTGTC
>LX072277.1 JP 2017051188-A/2: Safe and Functional Humanized Antibodies
GGTGACTAC
>LX087007.1 JP 2017505125-A/103: Human Antibodies to PD-1
GCTGCATCC
>LX086999.1 JP 2017505125-A/95: Human Antibodies to PD-1
GGGGCAAGT
>LX086991.1 JP 2017505125-A/87: Human Antibodies to PD-1
GCTGCGTCC
>LX086983.1 JP 2017505125-A/79: Human Antibodies to PD-1
GCTGCATCC
>LX086975.1 JP 2017505125-A/71: Human Antibodies to PD-1
TCTGCATCC
>LX086967.1 JP 2017505125-A/63: Human Antibodies to PD-1
GGTGCATCC
>LX086959.1 JP 2017505125-A/55: Human Antibodies to PD-1
GCTGCATCC
>LX086951.1 JP 2017505125-A/47: Human Antibodies to PD-1
GCTGCATCC
>LX086943.1 JP 2017505125-A/39: Human Antibodies to PD-1
GCTGCATCC
>LX086935.1 JP 2017505125-A/31: Human Antibodies to PD-1
ACTGCATCC
>LX086927.1 JP 2017505125-A/23: Human Antibodies to PD-1
GGTGCATCC
>LX086919.1 JP 2017505125-A/15: Human Antibodies to PD-1
GGTGCATCC
>LX086911.1 JP 2017505125-A/7: Human Antibodies to PD-1
GCTGCATCC
>LX062489.1 JP 2015533510-A/34: RETROVIRAL VECTOR WITH MINI-PROMOTER CASSETTE
GGAGTTCCC
>LV582357.1 JP 2015227381-A/415: High Affinity Human Antibodies to Human Protease Activated Receptor-2
GGTGCATCC
>LV582345.1 JP 2015227381-A/403: High Affinity Human Antibodies to Human Protease Activated Receptor-2
GCTGCATCC
>LV582333.1 JP 2015227381-A/391: High Affinity Human Antibodies to Human Protease Activated Receptor-2
AAGATTTCT
>LV582321.1 JP 2015227381-A/379: High Affinity Human Antibodies to Human Protease Activated Receptor-2
AAGATTTCT
>LV582309.1 JP 2015227381-A/367: High Affinity Human Antibodies to Human Protease Activated Receptor-2
GCTGCATCC
>LV582297.1 JP 2015227381-A/355: High Affinity Human Antibodies to Human Protease Activated Receptor-2
AAGATTTCT
>LV582285.1 JP 2015227381-A/343: High Affinity Human Antibodies to Human Protease Activated Receptor-2
AAGATTTCT
>LV582273.1 JP 2015227381-A/331: High Affinity Human Antibodies to Human Protease Activated Receptor-2
AAGATTTCT
>LV582261.1 JP 2015227381-A/319: High Affinity Human Antibodies to Human Protease Activated Receptor-2
GCTGCATCC
>LV582249.1 JP 2015227381-A/307: High Affinity Human Antibodies to Human Protease Activated Receptor-2
AAGATTTCT
>LV582237.1 JP 2015227381-A/295: High Affinity Human Antibodies to Human Protease Activated Receptor-2
GCTGCATCC
>LV582225.1 JP 2015227381-A/283: High Affinity Human Antibodies to Human Protease Activated Receptor-2
GATGCATCC
>LV582213.1 JP 2015227381-A/271: High Affinity Human Antibodies to Human Protease Activated Receptor-2
GCTGCATCC
>LV582201.1 JP 2015227381-A/259: High Affinity Human Antibodies to Human Protease Activated Receptor-2
AAGATTTCT
>LV582189.1 JP 2015227381-A/247: High Affinity Human Antibodies to Human Protease Activated Receptor-2
GCTGCATCC
>LV582177.1 JP 2015227381-A/235: High Affinity Human Antibodies to Human Protease Activated Receptor-2
TCGGCGTCT
>LV582165.1 JP 2015227381-A/223: High Affinity Human Antibodies to Human Protease Activated Receptor-2
GGTGCATCC
>LV582153.1 JP 2015227381-A/211: High Affinity Human Antibodies to Human Protease Activated Receptor-2
GGTGCATCC
>LV582141.1 JP 2015227381-A/199: High Affinity Human Antibodies to Human Protease Activated Receptor-2
TGGGCATCT
>LV582129.1 JP 2015227381-A/187: High Affinity Human Antibodies to Human Protease Activated Receptor-2
AAGATTTCT
>LV582117.1 JP 2015227381-A/175: High Affinity Human Antibodies to Human Protease Activated Receptor-2
GCTACATCC
>LV582105.1 JP 2015227381-A/163: High Affinity Human Antibodies to Human Protease Activated Receptor-2
AAGATTTCT
>LV582093.1 JP 2015227381-A/151: High Affinity Human Antibodies to Human Protease Activated Receptor-2
GCTGCATCC
>LV582081.1 JP 2015227381-A/139: High Affinity Human Antibodies to Human Protease Activated Receptor-2
TTGGGTTCT
>LV582069.1 JP 2015227381-A/127: High Affinity Human Antibodies to Human Protease Activated Receptor-2
GGTGCATCC
>LV582057.1 JP 2015227381-A/115: High Affinity Human Antibodies to Human Protease Activated Receptor-2
AAGATTTCT
>LV582045.1 JP 2015227381-A/103: High Affinity Human Antibodies to Human Protease Activated Receptor-2
AAGATTTCT
>LV582033.1 JP 2015227381-A/91: High Affinity Human Antibodies to Human Protease Activated Receptor-2
AAGATTTCT
>LV582021.1 JP 2015227381-A/79: High Affinity Human Antibodies to Human Protease Activated Receptor-2
GCTGCATCC
>LV582009.1 JP 2015227381-A/67: High Affinity Human Antibodies to Human Protease Activated Receptor-2
GCTGCATCC
>LV581997.1 JP 2015227381-A/55: High Affinity Human Antibodies to Human Protease Activated Receptor-2
GCTGCATCC
>LV581985.1 JP 2015227381-A/43: High Affinity Human Antibodies to Human Protease Activated Receptor-2
AAGATTTCT
>LV581973.1 JP 2015227381-A/31: High Affinity Human Antibodies to Human Protease Activated Receptor-2
AAAATTTCT
>LV581961.1 JP 2015227381-A/19: High Affinity Human Antibodies to Human Protease Activated Receptor-2
AAGATTTCT
>LV581949.1 JP 2015227381-A/7: High Affinity Human Antibodies to Human Protease Activated Receptor-2
AAGATTTCT
>LV580751.1 JP 2015231387-A/73: COMPOSITIONS FOR DETECTING HUMAN INTERFERON-ALPHA SUBTYPES AND METHODS OF USE
GAAGGCAGA
>LV580750.1 JP 2015231387-A/72: COMPOSITIONS FOR DETECTING HUMAN INTERFERON-ALPHA SUBTYPES AND METHODS OF USE
CTGGTTGCC
>LV709061.1 JP 2016027825-A/117: Identification of Clonal Cells by Repeats in T-Cell Receptor V/D/J Genes
GTAGAGATG
>LV709057.1 JP 2016027825-A/113: Identification of Clonal Cells by Repeats in T-Cell Receptor V/D/J Genes
GTGGATACA
>LV709028.1 JP 2016027825-A/84: Identification of Clonal Cells by Repeats in T-Cell Receptor V/D/J Genes
GGTATAACC
>LV709024.1 JP 2016027825-A/80: Identification of Clonal Cells by Repeats in T-Cell Receptor V/D/J Genes
GGTACAACT
>LV747688.1 JP 2015524810-A/1: ENGINEERING T-CELL RECEPTORS
TCTGCTAGC
>LV746552.1 JP 2015521629-A/191: Anti-EGFR Antibodies and Uses Thereof
GCTGCATCC
>LV746544.1 JP 2015521629-A/183: Anti-EGFR Antibodies and Uses Thereof
TTTGCTTCC
>LV746536.1 JP 2015521629-A/175: Anti-EGFR Antibodies and Uses Thereof
GCGGCATCC
>LV746528.1 JP 2015521629-A/167: Anti-EGFR Antibodies and Uses Thereof
GCTGCATCC
>LV746520.1 JP 2015521629-A/159: Anti-EGFR Antibodies and Uses Thereof
TTTGCTTCC
>LV746512.1 JP 2015521629-A/151: Anti-EGFR Antibodies and Uses Thereof
GCTGCTTCC
>LV746504.1 JP 2015521629-A/143: Anti-EGFR Antibodies and Uses Thereof
GCTGCATCC
>LV746496.1 JP 2015521629-A/135: Anti-EGFR Antibodies and Uses Thereof
GCTGCATCC
>LV746488.1 JP 2015521629-A/127: Anti-EGFR Antibodies and Uses Thereof
GCTGCATCC
>LV746480.1 JP 2015521629-A/119: Anti-EGFR Antibodies and Uses Thereof
GATGCGTCT
>LV746472.1 JP 2015521629-A/111: Anti-EGFR Antibodies and Uses Thereof
GATGCATCC
>LV746464.1 JP 2015521629-A/103: Anti-EGFR Antibodies and Uses Thereof
AAGGCGTCT
>LV746456.1 JP 2015521629-A/95: Anti-EGFR Antibodies and Uses Thereof
GATGCATCC
>LV746448.1 JP 2015521629-A/87: Anti-EGFR Antibodies and Uses Thereof
GATGCATCC
>LV746440.1 JP 2015521629-A/79: Anti-EGFR Antibodies and Uses Thereof
GATGCATCC
>LV746432.1 JP 2015521629-A/71: Anti-EGFR Antibodies and Uses Thereof
GATGCATCC
>LV746424.1 JP 2015521629-A/63: Anti-EGFR Antibodies and Uses Thereof
AAGGCGTCT
>LV746416.1 JP 2015521629-A/55: Anti-EGFR Antibodies and Uses Thereof
AAGGCGTCT
>LV746408.1 JP 2015521629-A/47: Anti-EGFR Antibodies and Uses Thereof
GATGCATCT
>LV746400.1 JP 2015521629-A/39: Anti-EGFR Antibodies and Uses Thereof
TTGGTCTCT
>LV746392.1 JP 2015521629-A/31: Anti-EGFR Antibodies and Uses Thereof
GATGCATCC
>LV746384.1 JP 2015521629-A/23: Anti-EGFR Antibodies and Uses Thereof
TTGGTTTCT
>LV746376.1 JP 2015521629-A/15: Anti-EGFR Antibodies and Uses Thereof
TTGGTTTCT
>LV746368.1 JP 2015521629-A/7: Anti-EGFR Antibodies and Uses Thereof
TTGGTTTCT
>LV618422.1 JP 2016000059-A/53: OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
CAGGCAGGC
>LV618416.1 JP 2016000059-A/47: OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
GCAGCAGCA
>LV618412.1 JP 2016000059-A/43: OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
AGCAGCAGC
>LV618408.1 JP 2016000059-A/39: OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
CAGCAGCAG
>LV578513.1 JP 2017501723-A/5: NOVEL ANTI ADAM17 ANTIBODY AND ITS USE FOR THE TREATMENT OF CANCER
TACACATCA
>LV576169.1 JP 2017500018-A/111: APLNR MODULATORS AND USES THEREOF
GCTGCATCC
>LV576161.1 JP 2017500018-A/103: APLNR MODULATORS AND USES THEREOF
ACTGCATCC
>LV576153.1 JP 2017500018-A/95: APLNR MODULATORS AND USES THEREOF
GCTGCATCC
>LV576145.1 JP 2017500018-A/87: APLNR MODULATORS AND USES THEREOF
GCAGCATCC
>LV576137.1 JP 2017500018-A/79: APLNR MODULATORS AND USES THEREOF
GCTGCATCC
>LV576129.1 JP 2017500018-A/71: APLNR MODULATORS AND USES THEREOF
TGGGCATCT
>LV576121.1 JP 2017500018-A/63: APLNR MODULATORS AND USES THEREOF
TGGGCATCT
>LV576113.1 JP 2017500018-A/55: APLNR MODULATORS AND USES THEREOF
GGTGCATCC
>LV576105.1 JP 2017500018-A/47: APLNR MODULATORS AND USES THEREOF
GCTGCATCC
>LV576097.1 JP 2017500018-A/39: APLNR MODULATORS AND USES THEREOF
GCTGCATCC
>LV576089.1 JP 2017500018-A/31: APLNR MODULATORS AND USES THEREOF
GCTACATCC
>LV576081.1 JP 2017500018-A/23: APLNR MODULATORS AND USES THEREOF
GCTGCATCC
>LV576073.1 JP 2017500018-A/15: APLNR MODULATORS AND USES THEREOF
GCTACATCC
>LV576065.1 JP 2017500018-A/7: APLNR MODULATORS AND USES THEREOF
GCTGCATCC
>LV573196.1 JP 2017500020-A/84: NUCLEIC ACID AMPLIFICATION
GTTTCCCAA
>LV573195.1 JP 2017500020-A/83: NUCLEIC ACID AMPLIFICATION
TTGGGAAAC
>LV572233.1 WO 2017026497-A/7: Antibody
CGGATGTCC
>LV571076.1 JP 2017029156-A/37: Bispecific T cell activating antigen binding molecules
TTTGACTAC
>LV571849.1 WO 2017026331-A/7: Antibody
GCCACATCC
>LV571646.1 WO 2017018360-A/4: Artificial Nucleoside, Artificial Nucleotide and Artificial Oligonucleotide
TTTTTTTTT
>LV571643.1 WO 2017018360-A/1: Artificial Nucleoside, Artificial Nucleotide and Artificial Oligonucleotide
TTTTTTTTT
>LV571157.1 JP 2017029156-A/118: Bispecific T cell activating antigen binding molecules
TTCGACTAC
>LV501740.1 JP 2017012171-A/4: METHOD OF DNA SEQUENCING BY HYBRIDISATION
ACAGCCAGC
>LV539547.1 JP 2016539950-A/39: Immunogenic Compositions and Vaccines Derived From Bacterial Surface Receptor Proteins
ATTGATGGG
>LV533908.1 JP 2016539639-A/55: KITS-OF-PARTS COMPRISING NUCLEIC ACIDS ABLE TO FORM A KISSING COMPLEX AND THEIR USES THEREOF
AGACCGGCA
>LV533892.1 JP 2016539639-A/39: KITS-OF-PARTS COMPRISING NUCLEIC ACIDS ABLE TO FORM A KISSING COMPLEX AND THEIR USES THEREOF
GAGGCGGAA
>LV533856.1 JP 2016539639-A/3: KITS-OF-PARTS COMPRISING NUCLEIC ACIDS ABLE TO FORM A KISSING COMPLEX AND THEIR USES THEREOF
ACGCTGAGT
>LV533858.1 JP 2016539639-A/5: KITS-OF-PARTS COMPRISING NUCLEIC ACIDS ABLE TO FORM A KISSING COMPLEX AND THEIR USES THEREOF
TCCCCTGCA
>LV533962.1 JP 2016539639-A/109: KITS-OF-PARTS COMPRISING NUCLEIC ACIDS ABLE TO FORM A KISSING COMPLEX AND THEIR USES THEREOF
GGTTATACT
>LV533859.1 JP 2016539639-A/6: KITS-OF-PARTS COMPRISING NUCLEIC ACIDS ABLE TO FORM A KISSING COMPLEX AND THEIR USES THEREOF
ACGCGTCCT
>LV514478.1 WO 2017010568-A/51: RNA-Protein Complex and use thereof
GCCCGACAC
>LV514476.1 WO 2017010568-A/49: RNA-Protein Complex and use thereof
CCCGACTAC
>LV514474.1 WO 2017010568-A/47: RNA-Protein Complex and use thereof
CCCGACTCC
>LV514457.1 WO 2017010568-A/30: RNA-Protein Complex and use thereof
TCAGTGACA
>LV514455.1 WO 2017010568-A/28: RNA-Protein Complex and use thereof
GCACTGACT
>LV514453.1 WO 2017010568-A/26: RNA-Protein Complex and use thereof
ATGGTGACC
>LV514451.1 WO 2017010568-A/24: RNA-Protein Complex and use thereof
GAACTGACT
>LV514449.1 WO 2017010568-A/22: RNA-Protein Complex and use thereof
GGTGTGACT
>LV514447.1 WO 2017010568-A/20: RNA-Protein Complex and use thereof
TACCTGACG
>LV514445.1 WO 2017010568-A/18: RNA-Protein Complex and use thereof
TGTCTGACA
>LV514443.1 WO 2017010568-A/16: RNA-Protein Complex and use thereof
GTTGTGACC
>LV514441.1 WO 2017010568-A/14: RNA-Protein Complex and use thereof
CGAGTGACA
>LV514439.1 WO 2017010568-A/12: RNA-Protein Complex and use thereof
AAGCTGACA
>LV514437.1 WO 2017010568-A/10: RNA-Protein Complex and use thereof
TCTGTGACG
>LV514435.1 WO 2017010568-A/8: RNA-Protein Complex and use thereof
ATCGTGACT
>LV514433.1 WO 2017010568-A/6: RNA-Protein Complex and use thereof
GTTCTGACC
>LV514429.1 WO 2017010568-A/2: RNA-Protein Complex and use thereof
GCTCTGACC
>LV473527.1 JP 2016535595-A/9: Vectors for Transgene Expression
AATTCAGAG
>LV473526.1 JP 2016535595-A/8: Vectors for Transgene Expression
TCGACTCTG
>LF951844.1 WO 2016189628-A/3: Method for detecting a light emission
TCTAAGCTG
>LF947889.1 JP 2016211882-A/2: Method for treating electrode surface of microelectrode, method for making surface-treated microelectrode and surface-treated microelectrode
CAGTGACCG
>LF954391.1 JP 2016533749-A/6: COMPOSITIONS FEATURING AN ATTENUATED NEWCASTLE DISEASE VIRUS AND METHODS OF USE FOR TREATING NEOPLASIA
ACGGGTAGA
>LF856385.1 JP 2015145424-A/223: HUMAN ANTIBODIES TO HUMAN ANGIOPOIETIN-LIKE PROTEIN 4
GCTGCATCC
>LF856373.1 JP 2015145424-A/211: HUMAN ANTIBODIES TO HUMAN ANGIOPOIETIN-LIKE PROTEIN 4
GCTGCATCC
>LF856361.1 JP 2015145424-A/199: HUMAN ANTIBODIES TO HUMAN ANGIOPOIETIN-LIKE PROTEIN 4
GGTGCATCC
>LF856349.1 JP 2015145424-A/187: HUMAN ANTIBODIES TO HUMAN ANGIOPOIETIN-LIKE PROTEIN 4
AAGGCGTCT
>LF856337.1 JP 2015145424-A/175: HUMAN ANTIBODIES TO HUMAN ANGIOPOIETIN-LIKE PROTEIN 4
GCTGCATTC
>LF856325.1 JP 2015145424-A/163: HUMAN ANTIBODIES TO HUMAN ANGIOPOIETIN-LIKE PROTEIN 4
GGTACATCC
>LF856313.1 JP 2015145424-A/151: HUMAN ANTIBODIES TO HUMAN ANGIOPOIETIN-LIKE PROTEIN 4
TTTGCATCC
>LF856301.1 JP 2015145424-A/139: HUMAN ANTIBODIES TO HUMAN ANGIOPOIETIN-LIKE PROTEIN 4
AAGGCGTCT
>LF856289.1 JP 2015145424-A/127: HUMAN ANTIBODIES TO HUMAN ANGIOPOIETIN-LIKE PROTEIN 4
AAGGCGTCT
>LF856277.1 JP 2015145424-A/115: HUMAN ANTIBODIES TO HUMAN ANGIOPOIETIN-LIKE PROTEIN 4
AAGGCGTCT
>LF856265.1 JP 2015145424-A/103: HUMAN ANTIBODIES TO HUMAN ANGIOPOIETIN-LIKE PROTEIN 4
GCTGCATCC
>LF856253.1 JP 2015145424-A/91: HUMAN ANTIBODIES TO HUMAN ANGIOPOIETIN-LIKE PROTEIN 4
AAGGCGTCT
>LF856241.1 JP 2015145424-A/79: HUMAN ANTIBODIES TO HUMAN ANGIOPOIETIN-LIKE PROTEIN 4
AAGGCGTCT
>LF856229.1 JP 2015145424-A/67: HUMAN ANTIBODIES TO HUMAN ANGIOPOIETIN-LIKE PROTEIN 4
AAGGCGTCT
>LF856217.1 JP 2015145424-A/55: HUMAN ANTIBODIES TO HUMAN ANGIOPOIETIN-LIKE PROTEIN 4
GAGGCGTCT
>LF856205.1 JP 2015145424-A/43: HUMAN ANTIBODIES TO HUMAN ANGIOPOIETIN-LIKE PROTEIN 4
GCTGCATCC
>LF856193.1 JP 2015145424-A/31: HUMAN ANTIBODIES TO HUMAN ANGIOPOIETIN-LIKE PROTEIN 4
AAGGCGTCT
>LF856181.1 JP 2015145424-A/19: HUMAN ANTIBODIES TO HUMAN ANGIOPOIETIN-LIKE PROTEIN 4
GCTGCGTCC
>LF856169.1 JP 2015145424-A/7: HUMAN ANTIBODIES TO HUMAN ANGIOPOIETIN-LIKE PROTEIN 4
CAGGCGTCC
>LF855164.1 JP 2015145412-A/77: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
GGTGCATCC
>LF855156.1 JP 2015145412-A/69: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
GATGTCGAT
>LF855148.1 JP 2015145412-A/61: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
CAAGATTCC
>LF855140.1 JP 2015145412-A/53: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
GAGGTTTCT
>LF855132.1 JP 2015145412-A/45: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
GATGGCAGT
>LF855124.1 JP 2015145412-A/37: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
GATGTCAGT
>LF855273.1 JP 2015145412-A/186: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
GGCAACAAC
>LF855260.1 JP 2015145412-A/173: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
GATGCATCC
>LF855250.1 JP 2015145412-A/163: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
AAGAATAAT
>LF855231.1 JP 2015145412-A/144: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
GGTAACAAC
>LF855223.1 JP 2015145412-A/136: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
ACTACATCC
>LF855215.1 JP 2015145412-A/128: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
GACGTCACT
>LF855200.1 JP 2015145412-A/113: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
GCTGCATCC
>LF855186.1 JP 2015145412-A/99: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
CAAGATACG
>LF855116.1 JP 2015145412-A/29: HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
GACAATGAT
